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Cutaneous melanoma (CM), is a malignant tumor of the skin, which originates 
from pigment producing cells, the melanocytes by neoplastic transformation 
(Gilchrest et al., 1999, Owens and Watt, 2003). It has developed from a rather 
rare tumor in the past to a tumor with growing medical importance. The 
incidence of CM has steadily increased over the past 50 years, predominantly in 
fair-skinned populations (Erdmann et al., 2013, Garbe and Leiter, 2009, 
Nikolaou and Stratigos, 2014). According to global estimates for 2012, there 
were over 230,000 new cases of melanoma, of which 100,000 occurred within 
Europe, and an estimated 55,000 related deaths. Melanoma burden is highest 
in Australia and New Zealand, where incidence rates (IR) are between 40 and 
60 cases/100,000 per year, followed by North America and Northern Europe 
with rates over 20 cases/100,000 per year (Ferlay et al., 2015, Greinert et al., 
2015, Karimkhani et al., 2017).  
The major causal risk factor for melanoma development is exposure to 
ultraviolet radiation (UVR), (IARC Working Group on the Evaluation of 
Carcinogenic Risks to Humans, 1992). About 80% of diagnosed melanoma are 
found on body sites exposed to intermittent UVR. Changes in lifestyle, namely 
from sun avoidance to sun-seeking behavior, have largely contributed to the 
steep increase in incidence of CM observed over the past decades (de Vries et 
al., 2003, Garbe and Leiter, 2009). In most European countries, melanoma 
rates continue to rise, particularly in higher age groups. First signs of 
stabilization or declining rates, however have been reported from younger birth 
cohorts in Australia/New Zealand, North America, and in Scandinavia (Arnold et 
al., 2014, Erdmann et al., 2013, Whiteman et al., 2016). These more favorable 
trends are attributed to primary prevention campaigns aimed to reduce harmful 
UVR exposure. In contrast to other malignant diseases, which develop 
predominantly at an advanced age (i.e. the sixth or seventh decade of life), 
melanoma can also occur at a younger age (median age at diagnosis is 55 
years).  
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Nevertheless, as with other tumors, the risk of being diagnosed with melanoma 
increases with age. The highest incidence rates are recorded in men and 
women aged 65 years or older (Garbe and Leiter, 2009, Robert Koch Institut 
Berlin, 2017). 
Since the early 1970s, increased life expectancy and low birth rates have 
caused a phenomenon known as demographic aging. It is characterized by a 
significant shift in the age distribution in the population towards an increased 
proportion of older people (Christensen et al., 2009). Both, high incidence rates 
among older cohorts and their growing presence in the population, imply an 
ongoing increase of melanoma for the foreseeable future. 
The predicted increase in melanoma burden represents a major challenge for 
future health care provision and indicates the need for targeted melanoma 
control measures. Health care officials need detailed information about the 
expected disease burden in order to set research priorities and to plan the 
allocation of limited resources for core elements of cancer control. These 
include: primary prevention, screening and early diagnosis, treatment, 
rehabilitation and palliative care. An understanding of the forces that might 
affect future trends is essential in translating cancer predictions to decision 
making processes. Main determinants of cancer development are exposure to 
risk factors (in melanoma mainly UVR exposure) and demographic changes 
(population size and age distribution). In order to achieve effective melanoma 
control, it is crucial to estimate the number of new melanoma cases due to 
changes in exposure to UVR and demographics (Bashir and Esteve, 2000, Bray 
and Moller, 2006).  
The following literature review (chapters 1.2-1.4) has a dual purpose. First, it will 
provide insights into the epidemiology of melanoma (chapter 1.2) with a focus 
on incidence trends and the role of UVR exposure in the pathogenesis of 
melanoma. Another part (chapter 1.3) will be devoted to demographic changes, 
in particular, the phenomenon of demographic aging and its impact on public 
health care systems in the future. Chapter 1.4 summarizes recent scientific 
research on future melanoma burden attributed to UVR exposure and 
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demographic changes. Secondly, this literature review aims to identify gaps in 
research in order to position the present project within its field. 
1.2 Epidemiology of cutaneous melanoma 
Since the early 1970s, incidence rates, and to a lesser extent also mortality 
rates, of melanoma have steadily increased (Arnold et al., 2014, de Vries and 
Coebergh, 2004, Erdmann et al., 2013, Forsea et al., 2012, Leiter et al., 2014, 
Nikolaou and Stratigos, 2014). While mortality rates remained roughly stable or 
declined since the 1990s (Autier et al., 2015, Barbaric et al., 2016, de Vries et 
al., 2003, Severi et al., 2000), melanoma incidence continued to rise. Although 
accounting for less than 5% of all skin cancers, melanoma is the major cause of 
death from skin cancer (Garbe and Leiter, 2009). Given steep increases in 
incidence and high risk of mortality, this type of skin cancer poses an enormous 
burden on society and public health. As the main focus of the present project 
was to investigate melanoma incidence trends over time and the impact of UVR 
exposure and demographic changes, mortality trends of melanoma will not be 
covered in this project. 
1.2.1 Incidence trends 
Geographical variations 
The frequency of the occurrence of cutaneous melanoma is closely related with 
the constitutive color of the skin and the geographical region (de Vries et al., 
2003, Leiter et al., 2014). It occurs nearly exclusively in white populations (of 
European origin). In dark pigmented populations such as Africa, Asia and partly 
Southern and Eastern Europe, the incidence of malignant melanoma (MM) is 
relatively low. Overall, the lifetime risk of developing melanoma is about 2.4% in 
Caucasians, 0.1% in Blacks, and 0.5% in Hispanics (de Vries and Coebergh, 
2004, Erdmann et al., 2013, Gloster and Neal, 2006). 
The highest age-standardized incidence rates (ASIR) for 2012 in both males 
and females were reported from Australia and New Zealand (about 35/100,000 
per year; according to the World Standard Population), where incidence rates 
tend to be two to three times higher than anywhere else in the world. The 
second highest rates were found in North America, followed by Northern and 
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Western Europe (rates over 10/100,000 per year in both sexes). Very low 
incidence rates (below 0.5/100,000 per year in both sexes) were estimated for 
South-Eastern Asia and South-Central Asia (Ferlay et al., 2015), Table 1. 
Incidence rates within Europe show great variation. Generally, melanoma 
incidence increases with proximity to the equator (‘latitude gradient’). In 
Western Europe, however the inverse pattern is observed, with 3- to 6-fold 
higher incidence rates in Northern countries (i.e. Scandinavia) than in Southern 
Europe (de Vries et al., 2004, de Vries and Coebergh, 2004). Exceptions are 
Switzerland and the Netherlands which exhibit high incidence rates about 
20/100,000 per year (also age-standardized according to the World Standard 
Population) compared with the surrounding countries. The lowest incidence 
rates in Europe were found in the Mediterranean and Eastern countries (4-
8/100,000 per year) which are less than half of that of Western Europe (12-
20/100,000 per year). Darker skin type (type III-IV according to Fitzpatrick) in 
the Mediterranean populations and different attitudes to recreational activities 
are responsible for this Nord-South gradient (de Vries et al., 2004, Erdmann et 
al., 2013, Garbe and Leiter, 2009, Nikolaou and Stratigos, 2014). 
Table 1 and Figure 1 provide an overview about global melanoma incidence 
rates for 2012. 
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Table 1: Age-standardized, crude incidence rates and cumulative risk for 










    
Australia/New Zealand 35.1 53.8 3.75 
Northern America 13.8 21.3 1.50 
Europe 8.6 13.5 0.89 
Northern Europe 14.6 23.2 1.51 
Denmark 19.2 28.5 1.91 
Norway 18.8 30.4 2.02 
Sweden 18.0 30.7 1.90 
Western Europe 12.1 19.7 1.24 
Germany 11.4 20.6 1.20 
The Netherlands 19.4 28.7 1.95 
Switzerland 20.3 32.1 2.05 
Southern Europe 8.1 12.2 0.81 
Central and Eastern Europe 4.5 7.0 0.49 
Africa 1.1 0.6 0.13 
Asia 0.5 0.5 0.05 
    1
 ASIR: Age-standardized incidence rates (Segi World Standard Population) per 100,000 
2
 CIR: Crude incidence rates per 100,000  
3
 Cumulative risk [0-74 years] (in %) 
Source: Globocan 2012 (IARC, 2012) 
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Source: Globocan 2012 (IARC, 2012) 
Figure 1: Age-standardized incidence rates (World Standard Population) from 




The incidence of CM has steadily increased in fair-skinned populations over the 
past 50 years. The annual increase varied between different populations, but 
has been estimated to be 3-7% (Arnold et al., 2014, de Vries and Coebergh, 
2004, Leiter and Garbe, 2008).  
Steep increases were mainly reported from industrial countries with Caucasian 
populations (Northern America, Northern Europe, Australia and New Zealand) 
(Aitken et al., 2018, Fuglede et al., 2011, Glazer et al., 2016, Helvind et al., 
2015, Holman et al., 2018, Richardson et al., 2008, Whiteman et al., 2008), 
whereas in populations with greater pigmentation (Asia and Africa) melanoma 
incidence has remained largely unchanged (Erdmann et al., 2013, Ferlay et al., 
2015). Rising incidence rates were observed across all age groups, most 
obvious however in subjects older than 60 years (Jemal et al., 2011, MacKie et 
al., 2009). A variety of behavioral changes in lifestyle (i.e. increased outdoor 
recreational activities, desire to tan, more frequent holidays spent in tropical 
climates), associated with increasing exposure to UVR, have largely contributed 
to the observed increase in melanoma incidence in the past (de Vries et al., 
2003, Eggermont et al., 2014, Erdmann et al., 2013). While incidence rates of 
melanoma continue to rise in most European countries (i.e. in Southern and 
Eastern Europe), particularly in higher age groups, there have been recent 
reports from several Northern and Western European countries, Australia, New 
Zealand, Canada and the United States of declining incidence rates within 
younger birth cohorts (Aitken et al., 2018, Arnold et al., 2014, Bulliard et al., 
1999, de Vries et al., 2003, Erdmann et al., 2013, Hall et al., 1999, Iannacone et 
al., 2015, Richardson et al., 2008, Watson et al., 2016, Whiteman et al., 2016). 
The following section describes global melanoma incidence trends of different 
populations with different susceptibility to melanoma due to their geographical 
location and genetic predisposition. 
Global data were assembled from the Cancer Incidence in Five Continents 
(CI5), Volume I-XI (IARC, 2018), as well as from the online database Globocan 
2012 (IARC, 2012), both released from the International Agency for Research 
on Cancer (IARC). To increase the time period of data (the last year of 
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diagnosis available in Volume XI is 2012), melanoma incidence rates were 
additionally obtained from national population-based cancer registries of 
Autralia (AIHW, 2018), the United States (SEER, 2018) and Europe (ECIS, 
2018). Melanoma incidence data for Scandinavian countries were sourced from 
the NORDCAN data base (NORDCAN, 2018). 
In order to compare global melanoma trends, incidence rates are age-
standardized according to the World Standard Population (Segi) and are 
expressed as incidence per 100,000 persons per year. 
Australia 
Between 1982 and 2014, age-standardized incidence rates increased for men 
and women by +70% from 20.6/100,000 per year (20.8 for males and 20.7 for 
females) to 34.9/100,000 per year (41.0 for males and 29.4 for females). During 
the observation period, the melanoma incidence went through three different 
phases characterized as rapid increase (+6.9% p.a.) at the beginning (1982-
1987), a moderate increase (+1.7% p.a.) until 2005 (with a peak in 2005 at 
36.8/100,000 per year), and declining rates (-0.7% p.a.) thereafter (AIHW, 2018, 
IARC, 2012, Whiteman et al., 2016).  
Uniformly, increasing trends of incidence were seen across all age groups. The 
highest increase in melanoma rates without signs of stabilization or leveling off 
was observed in older men and women (≥65 years), while declining rates were 
reported for younger age groups (-1.2% p.a. for men and -1.8% p.a. for women) 
from the end of the 1990s onwards, especially for those aged 25-44 years 
(Whiteman et al., 2016), 
United States (White population) 
In US whites, age-standardized incidence rates increased between 1975 and 
2012 by +135% for females (from 7.3 to 17.1/100,000 per year) and by +176% 
for males (from 7.9 to 21.8/100,000 per year), respectively. Strong increases 
(+3.4% p.a.) for both sexes were seen between 1975 and 2007, followed by 
slower increases thereafter. From the 2000s onwards, rates in US males aged 
25-44 years appear rather stable (+0.1% p.a.), whereas rates in older men and 
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in US Caucasian women, irrespective of age, continued to rise (Glazer et al., 
2016, Holman et al., 2018, IARC, 2012, SEER, 2018, Weir et al., 2011). 
Europe 
Incidence trends in Europe are greatly varying. In all European countries 
incidence rates of CM have steadily increased since the 1950s. Between 1990-
2007 incidence rates have risen by an average of +3.8% p.a. for women and by 
+4.2% for men (Arnold et al., 2014). 
The strongest increases were observed in Northern Europe, followed by 
Western and later also in Eastern and Southern Europe (de Vries et al., 2003, 
Greinert et al., 2015). While a deceleration in the trends could be observed in 
some Western and more notably in Northern European countries from the 
1990s onwards, rates continue to climb in other regions of Europe, particularly 
in Southern and Eastern Europe (Arnold et al., 2014, de Vries et al., 2003, 
Erdmann et al., 2013, Forsea et al., 2012). 
Northern Europe (Norway, Sweden, Finland, Denmark and Iceland) 
Scandinavia has the longest period of cancer registration. Each of the Nordic 
countries has a population-based cancer registry. The Danish Registry is the 
oldest and was founded in 1942. The Norwegian, Finnish and Icelandic 
registries were founded in 1952-1954 and the Swedish Registry in 1958 
(Engholm et al., 2010, Gjerstorff, 2011, Moller et al., 2002). 
While melanoma incidence rates were low in the 1950s/1960s (in the range 
between 1 and 3 cases/100,000 per year), incidence rates grew rapidly over the 
last 5-6 decades. Of all Northern European countries, the highest incidence 
rates for 2013 were reported from Denmark, ranging between 21 and 28 
cases/100,000 per year for men and women, respectively. Incidence rates 
between 8 (Iceland), 14 (Finland) and ≥20 cases/100,000 per year (Sweden 
and Norway) were observed in the other Scandinavian countries. 
The greatest increase in incidence between 1990 and 2008 was observed for 
men in Iceland (+6.1% p.a.), and was most pronounced in higher age groups 
(70+ years: +13.7% p.a.). While incidence rates slightly increased in the 
youngest age group (25-44 years) in Finland (men:+1.5% p.a., women: +1.9% 
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p.a.) and in Icelandic men (+3.1% p.a.), between 1990 and 2008, it significantly 
decreased in Norwegian males (-2.8% p.a.) and remained rather stable in 
Norwegian females (-0.7% p.a.) and Swedish males (+0.5% p.a.) and females 
(+0.9% p.a.). Incidence rates in Icelandic females aged 25-44 years increased 
initially (1992-2001: +13.5% p.a.) and then declined (2001-2008: -7.3% p.a.). 
Over the entire period (1990-2008) an overall increase of +6.8% p.a. has been 
estimated. In more recent years (2008-2013), however, reversing trends with 
slightly increasing incidence rates were observed among young women (25-44 
years) in Norway and more pronounced in Sweden, rates among Icelandic 
women continued to decline. Between 1990 and 2007 melanoma incidence 
rates in Denmark increased uniformly across all age groups. While among men, 
the highest increase was observed in the age group ≥70 years (+4.0% pea), the 
strongest increases were seen among women younger than 45 years (+2.5% 
p.a.) (Arnold et al., 2014, NORDPRED, 2016, Whiteman et al., 2016). 
Western Europe (The Netherlands, Switzerland) 
In the Netherlands, age-standardized incidence rates have continuously 
increased between 1990 and 2013. While incidence rates of melanoma were 
less than 10 cases per 100,000 in 1990, melanoma rates grew up to around 20 
cases per 100,000 in 2013 for both sexes. Between 1990 and 2007, the annual 
increase ranged between +3.5% p.a. (females) and +4.2% p.a. (males), 
respectively (Arnold et al., 2014, de Vries et al., 2005, ECIS, 2018, Holterhues 
et al., 2013). 
Similar trends were observed for Switzerland. For men and women, age-
standardized incidence rates doubled from 10 cases per 100,000 in 1990 to 
around 20 cases per 100,000 in 2013, corresponding to an annual increase of 
about +3%. For men, a minor deceleration in the trend was observed from 1995 
onwards, however this was not statistically significant. 
In both countries, trends of increasing melanoma rates were observed across 
all age groups. In the Netherlands, the strongest increase in incidence (+5-6% 
p.a.) was found in the highest age group (70+ years), while in Switzerland men 
and women aged between 25 and 44 years experienced the largest increases 
(approximately +3% p.a.) (Arnold et al., 2014, ECIS, 2018). 
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Eastern Europe (Czech Republic, Slovakia) 
Since 1990, the incidence of melanoma has increased significantly in both 
countries, across all ages. Incidence rates in the Czech Republic have risen for 
both sexes from 7-8 cases per 100,000 in 1990 to around 13 cases per 100,000 
in 2013 and were higher than reported rates in Slovakia, where the rates 
increased from 4-5 cases per 100,000 in 1990 to 8-10 cases per 100,000 in 
2013. Slovakia recorded a stronger increase between 1997 and 2004 (+7.1% 
p.a.) after initially a moderate growth (1990-1997: +2.7% p.a.), while rates in the 
Czech Republic continued to evenly increase throughout the observation period 
(Arnold et al., 2014, ECIS, 2018) 
Southern Europe (Portugal Slovenia) 
In Southern Europe, the lowest melanoma incidence rates have been reported 
from the cancer registry of Northern Portugal. During the study period (1996-
2010), melanoma incidence rates rised for men and women from 1-2 
cases/100,000 per year to around 5 cases/100,000 per year. Significantly 
higher incidence rates, climbing from 5 cases/100,000 in 1990 to 15 
cases/100,000 in 2012 were observed in Slovenia. Increasing rates of 
melanoma were seen in all age groups, the greatest increases occurred in the 
oldest age group (70+ years). For both countries, the estimated annual increase 
ranged between +5% p.a. (females) and +6% p.a. (males) (Arnold et al., 2014, 
ECIS, 2018). 
Asia and South America 
Melanoma incidence rates in Asian (<1 cases/100,000 per year) and South 
American countries (2-4 cases/100,000 per year) are low, and in contrast to 
other countries rather stable over time. An exception is Israel, where incidence 
rates between 9 (females) and 11 (males) cases per 100,000 have been 
reported for the period 2000-2002. As in other countries, incidence rates have 
largely stabilized since the mid-1990s (Erdmann et al., 2013, IARC, 2012, 
2018).  
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Clinical epidemiology (Sex and age distribution)  
The male/female ratio of melanoma varies among different countries. A male 
predominance has been recorded in countries with a high melanoma incidence, 
such as Australia, New Zealand and the United States (Geller et al., 2002, 
Marks, 2002). Conversely, melanoma incidence is higher among females in 
lower-incidence countries (i.e. Scotland or Great Britain) (Erdmann et al., 2013, 
MacKie et al., 2002). Increases in melanoma incidence among men however 
have changed the predominance of women in high-latitude, lower-incidence 
populations, resulting in a more balanced male/female ratio (Garbe and Leiter, 
2009). Up to age 50, melanoma is more common in females, while melanoma 
incidence beyond this age is higher in males than in females (Erdmann et al., 
2013, Nikolaou and Stratigos, 2014).  
Melanoma is diagnosed at a median age of 55, which is earlier than other skin 
cancers are diagnosed (Robert Koch Institut Berlin, 2017). It affects a 
disproportionally large number of young adults and is one of the most common 
cancers diagnosed among adolescents and young adults (Baade et al., 2011, 
Lange et al., 2007, Watson et al., 2016). The risk of developing melanoma 
increases with age. In most high-risk populations (i.e. Australia, New Zealand, 
Northern Europe) incidence rates peak at the seventh and eighth decades of 
life, with rates ranging between 50 cases/100,000 per year in females and 100 
cases/100,000 per year in males (MacKie et al., 2002, Robert Koch Institut 
Berlin, 2017). 
1.2.2 Risk factor: Ultraviolet radiation  
The role of sunlight in the pathogenesis of melanoma 
The malignant melanoma is a malignant tumor originating from pigment 
producing cells, the melanocytes by neoplastic transformation (Gilchrest et al., 
1999, Jhappan et al., 2003). It mainly occurs on the skin, rarely on mucous 
membranes and other organs. Its predominant location on the outer skin makes 
it particularly susceptible to damaging UVR. In white-skinned populations, 
intermittent sun exposure has been identified as the main risk factor for 
melanoma. Eighty percent of melanomas develop on anatomical sites exposed 
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to intermittent sun exposure (i.e. trunks or legs) (de Vries and Coebergh, 2004, 
Elwood and Jopson, 1997, Garbe and Leiter, 2009).  
UVR is part of the electromagnetic spectrum with wavelengths 100–400 nm; it is 
emitted by the sun and by artificial sources (e.g. sunbeds). This wavelength 
band has been further subdivided into three wavelength regions: UVC (100–280 
nm), UVB (280–315 nm) and UVA (315–400 nm). The UV components to 
reaching the earth's surface consist of about 95% UVA and only 5% UVB. Solar 
UVC is absorbed by the stratospheric ozone layer and hardly reaches the 
earth's surface (Greinert et al., 2015). 
The role of UVR as a leading environmental cause of melanoma is supported 
by a series of epidemiological evidence, including a high prevalence of 
melanoma in populations that migrated from a low to a high ambient UVR 
environment, a higher incidence in fair-skinned compared with darker-skinned 
individuals, and a latitude-dependent rise in melanoma incidence among white 
populations with proximity to the equator (Garbe and Leiter, 2009, Nikolaou and 
Stratigos, 2014). Case-control studies on the risk for melanoma development 
have also shown that the risk for CM was associated with the number of 
melanocytic nevi and the occurrence of sunburns in childhood, both elevating 
the risk for melanoma development (de Vries and Coebergh, 2004, Leiter and 
Garbe, 2008, Whiteman et al., 2001). 
The epidemiological evidence implicating the causal role of UVR in the 
pathogenesis of melanocytic nevi and melanoma is confirmed by biological 
studies. The damaging effect of UVR on the skin can be caused by three 
different mechanisms. It directly damages DNA leading to mutations, it 
produces activated oxygen molecules which in turn damage DNA and other 
cellular structures, and it leads to a localized immuno-suppression that blocks 
the body’s natural anti-cancer defence (de Vries and Coebergh, 2004, Ichihashi 
et al., 2003). UVR exposure during childhood seems to be the main factor to 
induce mutations in the melanocytic system associated with an increased 
induction of melanocytic nevi and later on an increased risk for the development 
of malignant melanoma (Garbe and Leiter, 2009, Whiteman et al., 2001). 
Whether nevi, especially clinically atypical nevi, are precursors for melanoma 
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however remains a matter of debate. Pathology-based studies have found that 
only 20 to 30% of melanoma contain nevus cells, suggesting a direct 
transformation of a nevus into melanoma. The majority of melanomas (70-80%), 
arise de novo, with no associated nevus (Cymerman et al., 2016, Haenssle et 
al., 2016, Shain et al., 2015).  
Moreover, several clinical and epidemiological features give rise to question a 
straightforward dose relationship between melanoma risk and UVR exposure. 
Anatomical site distribution of CM does not correspond to body areas of 
greatest UVR exposure. Only 10-15% of CMs are found on continuously 
exposed sites, like the head or the neck, while the majority of melanomas are 
localized on less frequently exposed body sites (i.e. trunk and limbs). In contrast 
to non-melanoma skin cancer (NMSC), melanoma already occurs in younger 
years of life, where it can be assumed that the highest cumulative sun exposure 
has not yet been reached. Finally, an increased risk of melanoma after high 
cumulative sun exposure in adulthood and after sunburns during this time could 
not be found in most case-control studies (Garbe and Leiter, 2009, Nikolaou 
and Stratigos, 2014). This suggests a more complex association between 
melanoma and UVR, supporting the hypothesis that melanomas may arise 
through different causal pathways (Siskind et al., 2005, Whiteman et al., 2006, 
Whiteman et al., 2003). Different case-control studies have shown melanomas 
developing at different body sites are associated with distinct patterns and 
amount of sun exposure. Intermittent sun exposure and sunburns in childhood 
were strong predictors of melanoma occurring on less frequently exposed body 
sites, whereas chronic patterns of exposure were more likely to be associated 
with melanomas localized on continuously exposed sites. Both, patterns of sun 
exposure and anatomical location of melanocytic nevi seem to play a central 
role in the suggested pathways (Caini et al., 2009, Chang et al., 2009a, Green, 
1992, Olsen et al., 2009). Green et al. proposed the theory of a site-dependent 
susceptibility of melanocytes to malignant transformation. People with a low 
propensity for melanocytic proliferation and low numbers of nevi require chronic 
sun exposure to initiate melanocytes to malignant transformation, thus this 
occurs on continually exposed body sites, while people with a high propensity 
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for melanocytic proliferation and a high number of nevi, will tend to develop 
melanomas on intermittently and less frequently exposed sites (Green, 1992). 
The theory of different pathways has been strengthened by observations that 
BRAF gene mutations are more likely in melanoma of younger subjects with 
larger numbers of nevi, exposed to intermittent UVR than in melanomas 
localized on continually sun-exposed sites of older patients with few nevi 
(Greinert et al., 2015, Poynter et al., 2006, Thomas et al., 2007). 
The population attributable fraction (PAF) 
Rationale and calculation 
The population attributable fraction (PAF) provides a valuable appraisal of the 
impact of a risk factor in cancer causation (Parkin et al., 2011b). It quantifies the 
proportion and the numbers of cancer cases that can be attributed to a risk 
factor and that could potentially be avoided by complete elimination of the 
causative factor. It is helpful in prioritizing cancer control strategies and for the 
evaluation of the potential impact of interventions seeking to reduce exposure to 
a risk factor (Shield et al., 2016).  
Risk assessment studies require evidence of a causal relationship between a 
risk factor and disease. Meanwhile there is sufficient epidemiological and 
biological evidence for the causal role of UVR exposure in melanoma 
development. In 1992, the International Agency for Research on Cancer (IARC) 
declared that UVR was carcinogenic to humans (IARC Working Group on the 
Evaluation of Carcinogenic Risks to Humans, 1992). The subsequent IARC 
monograph from 2009 confirmed ‘There is sufficient evidence that UVR causes 
CM as well as keratinocyte cancers (squamous cell carcinoma (SCC) and basal 
cell carcinoma (BCC))’ (El Ghissassi et al., 2009, IARC Working Group on the 
Evaluation of Carcinogenic Risks to Humans, 2012). 
The population attributable fraction is estimated by comparing the observed 
incidence rates in an ‘exposed‘ population with those of an 
‘unexposed‘ reference population, and attributing the differences in incidence 
rates to corresponding differences in exposure to the risk factor between 
reference and study population (Armstrong and Kricker, 1993, de Vries et al., 
2017). Defining an unexposed reference population is challenging because 
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there are no unexposed populations (all human are to a certain degree exposed 
to UVR). As solution, Parkin et al. proposed to apply incidence rates from a 
‘minimal exposed population’ as approximation for the incidence rates in an 
‘unexposed’ population (Parkin et al., 2011b). More details referring the 
calculation of the PAF and the selection of the reference population are 
provided in chapter 2.2.4. 
Global estimates 
The proportion of melanoma cases caused by UVR exposure varies greatly 
across different regions, ranging from less than 1% to ≥95%, with the lowest 
and highest PAF observed in East Asia and Oceania (Armstrong and Kricker, 
1993, Arnold et al., 2018a, de Vries et al., 2017, Lucas et al., 2008, Olsen et al., 
2015). Most recent estimates for 2012, revealed that around 168,000 cases of 
melanoma were attributed to excess exposure to UVR, representing 75.7% of 
all melanoma cases worldwide (Arnold et al., 2018a). The burden was higher in 
men (81.3% attributable cases) than in women (69.4% attributable cases). The 
vast majority (around 89%, 149,340 of 168,000 cases) of UVR-attributable 
melanoma cases occurred in countries with a very high human development 
index (HDI), where 86.6% of all melanoma cases (91% among men and 81.4% 
among women) were due to high UVR exposure. This was most pronounced in 
Australia and New Zealand, where 97.4% of all melanomas in men and 93.4% 
in women, respectively were attributable to UVR. Similarly high values were 
also estimated for the White US population, with a PAF ranging between 85-
92% in females and between 94-96% in males (Armstrong and Kricker, 1993, 
Arnold et al., 2018a, Islami et al., 2018). Within Europe, the proportion of 
melanomas attributed to excess sun exposure shows a great variation. The 
highest values for the PAF were reported from Northern (90-95%) and Western 
Europe (86%), lower PAFs were estimated for Eastern (68%) and Southern 
(78%) European countries (Armstrong and Kricker, 1993, Arnold et al., 2018a, 
Arnold et al., 2018b, Parkin et al., 2011a, Parkin et al., 2011b, Winther et al., 
1997). Figure 2 displays the estimated PAFs for different countries.  
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Table 2 provides an overview of studies estimating the proportion of melanoma 
cases attributable to UVR for different regions, using different reference 





Figure 2: Population attributable fraction (PAF%) of melanoma cases worldwide in 2012, among men and women all ages 
(30+ yrs), attributable to UVR exposure, by country. 
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Asia 1985 Black US population Males and females: 8%  Calculation see above 
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1980 Danish Cohort (1940) 83% 87% Calculation see above 
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United Kingdom 2010 South Thames Cohort (1903) 89.8% 82.4% Calculation see above 
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De Vries et 
al. (2017) 
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Islami et al. 
(2018) 
US Whites 2014 US Blacks (2010-2014) 96.0% 93.7% Calculation see above 
Abbreviations: HDI: Human development index, ALM: acral lentiginous melanoma 
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1.2.3 Other risk factors 
In addition to UVR exposure, genetic predisposition and individual host risk 
factors are also causally linked to melanoma development. 
Genetic risk factors 
Heritable factors play an important role in melanoma predisposition. A family 
history of melanoma is associated with a 2-fold increased risk of melanoma. 
Around 5-12% of patients with melanoma have a family history of CM in one or 
more first-degree relatives. A large proportion of these patients (30-40%) have 
inherited mutations in highly penetrant susceptibility genes which are 
associated with a significantly increased risk of melanoma. Constitutional 
mutations have been identified in two melanoma susceptibility genes: CDKN2 
and CDK4, which play an important role in cell-cycle control (de Vries and 
Coebergh, 2004, Eggermont et al., 2014, Gandini et al., 2005c, MacKie et al., 
2009, Nikolaou and Stratigos, 2014, Olsen et al., 2010c). 
Further high- and low risk melanoma genes have been identified, whose 
variants are linked to phenotypic traits (i.e. red hair, freckling, and sun 
sensitivity). Among the low-penetrance genes, the strongest association was 
found for the melanocortin 1 receptor gene (MC1R) (Eggermont et al., 2014, 
MacKie et al., 2009, Raimondi et al., 2008). A loss in MC1R functions induced 
by single nucleotide polymorphisms, cause a shift of photoprotective eumelanin 
to pheomelanin, resulting in red hair, pale skin and freckles. A pooled meta-
analysis of different MC1R variants showed a relative risk (RR) of 2.44 (95% CI: 
1.72-3.45) for CM in patients carrying the ‘red hair variants‘ compared with a RR 
of 1.1 (95% CI: 1.1-1.51) for those with ‘non-red hair’ MC1R variants (Williams 
et al., 2011). 
Further hereditary disorders associated with an increased risk of melanoma 
development, are the dysplastic nevus syndrome, also known as familial 
atypical multiple-mole melanoma syndrome (Azoury and Lange, 2014, Greene 
et al., 1985, Rigel et al., 1988) and xeroderma pigmentosum (XP) (Cleaver, 
2005, de Vries and Coebergh, 2004, Paszkowska-Szczur et al., 2013). 
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Phenotypic risk factors 
The major constitutional risk factors for melanoma include fair pigmentation, 
poor tanning ability, multiple nevi, clinically atypical or dysplastic nevi and 
freckling (Davies et al., 2015, Gandini et al., 2005b, Nikolaou and Stratigos, 
2014). A majority of observational studies reported a significant increased risk 
for melanoma development in patients with multiple or clinically atypical nevi 
(Chang et al., 2009b, Gandini et al., 2005a, Gandini et al., 2016, Goldstein and 
Tucker, 2013, MacKie et al., 2009, Olsen et al., 2010a). A meta-analysis has 
shown a gradual increased risk of melanoma, proportional to the number of 
common or dysplastic nevi (Gandini et al., 2005a). The relative risk for patients 
with one dysplastic nevi was 1.45 (95% CI: 1.31-1.60), increased to 3.03 (95% 
CI: 2.23-4.06) for patients with three dysplastic nevi and were highest for those 
with five dysplastic nevi (RR=6.36; 95% CI: 3.80-10.33). Patients with a high 
number of common nevi (>100) showed a 7-fold increased (RR=6.89; 95% CI: 
4.63-10.25) risk for melanoma compared with those with low numbers (0-15) of 
common nevi. A 60% higher risk (RR=1.62: 95% CI 1.44-1.81) for melanoma 
was reported for individuals having ‘fair eye color’ (including blue, green and 
hazel eye color) compared to individuals with ‘dark eye color’ (Gandini et al., 
2005c). With respect to hair color, the RR for melanoma for ‘light hair color’ 
(blond, red, and light brown) was 1.87 (95% CI: 1.63-1.95) compared with 
‘medium dark, brown hair color’. The strongest association (RR=3.64; 95% CI: 
2.56-5.37) was found in individuals with red hair color (Gandini et al., 2005c). In 
a pooled analysis of 15 case-control studies (Olsen et al., 2010b) the RR for 
melanoma was 1.66 (95% CI: 1.36-2.01) for individuals with skin type I/II 
compared to subjects with skin type III/IV. 
Further risk factors 
Artificial ultraviolet radiation exposure: tanning beds  
Indoor tanning is an artificial source of intermittent UVR, emitting significant 
amounts of UVA and/or UVB radiation (de Vries and Coebergh, 2004, Young, 
2004). It became popular in the early 1980s among white populations, 
particularly in the Northern countries and, since then, a substantial proportion of 
young people use sunbeds (Nikolaou and Stratigos, 2014, Young, 2004). To 
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date, there is strong evidence that sunbed users are at an increased risk for 
melanoma development, even after adjustment for outdoor sun exposure 
(Boniol et al., 2012, Gandini S. et al., 2011, Gandini et al., 2014, Veierod et al., 
2010, Westerdahl et al., 2000). The risk increases with the number of sunbed 
sessions and with initial usage at a young age (Boniol et al., 2012). Findings 
from a meta-analyses, including 27 studies, showed an overall summary 
relative risk of 1.20 (95% CI: 1.08-1.34) of melanoma development in ‘ever 
users‘ of sunbeds and a 1.8% increase of risk for each additional session of 
sunbed use per year. First use of sunbeds before age 35 years was associated 
with a summary relative risk of 1.87 (95% CI: 1.41-2.48) (Boniol et al., 2012).  
A substantial burden of melanoma can be attributed to artificial UVR. It has 
been estimated that 5.4% of all new melanoma cases (7% in females), 
diagnosed every year in European countries, could be attributed to sunbed use 
(Zhang et al., 2012). 
Additional risk factors, increasing the risk for melanoma, include a personal 
history of skin cancer or other malignancies (Abern et al., 2013, Li et al., 2013), 
immunosuppression related to organ transplantation (Krynitz et al., 2013, 
Mudigonda et al., 2013), lympho-proliferative diseases or human 
immunodeficiency virus infection/AIDS (Eggermont et al., 2014, van Leeuwen et 
al., 2010). 
Other possible associations or factors influencing melanoma risk have been 
discussed, evidence for a causal relationship with risk of melanoma however 
remains inconclusive. One study, reviewing long-term use of an immunotherapy 
with tumor necrosis factor α, reported a 4-fold (OR=3.94) increased risk in 
patients with inflammatory bowel disease (Long et al., 2012). A potential 
protective effect of nonsteroidal anti-inflammatory drug use (RR=0.87; 95% 
CI=0.80-0.95), with regard to developing melanoma has been described 
(Johannesdottir et al., 2012). There have been no conclusive data so far on the 
role of female sex hormones (Gandini Sara et al., 2011), the influence of 
overweight (Sergentanis et al., 2013), or levels of vitamin D (Asgari et al., 2009) 
in the risk of melanoma carcinogenesis. An association between Parkinson's 
28 
disease and an increased risk of melanoma is also controversially discussed 
(Liu et al., 2011, Olsen et al., 2006, Pan et al., 2011). 
1.3 Demographic trends 
1.3.1 Demographic aging  
Demographic aging is a global phenomenon, occurring primarily in developed 
countries, most advanced in European countries and in East Asia (Christensen 
et al., 2009). It describes a process, which is characterized by a shift in the age 
structure of a population towards an increased proportion of older people and at 
the same time a sharp decline in younger people (Nowossadeck et al., 2013, 
Peters et al., 2010, Pritzkuleit et al., 2010). 
The age structure of a population is mainly determined by changes in birth rates 
and life expectancy. Data from Germany are used to illustrate these changes 
(Grünheid and Sulak, 2016, Statistisches Bundesamt Wiesbaden, 2016). 
Low birth rates 
In order for one generation to remain numerically stable, a constant birth rate of 
2.1 children per woman is required. However, if this falls below the so-called 
replacement level of 2.1, which is necessary for a generation to replace itself in 
terms of numbers, this will lead to a decline in the population, especially the 
younger generation (Pritzkuleit et al., 2010, Statistisches Bundesamt 
Wiesbaden, 2015a, 2015b). 
Between 1955 and 1970, the birth rate was between 2 and 2.5 children per 
woman. For more than four decades now, the birth rate has been far below the 
level of 2.1 children per woman. This value was attained in the territory of the 
Federal Republic of Germany for the last time in 1969 (in the German 
Democratic Republic in 1971). Since then, the birth rates have been 
consistently lower. In 2008, the average number of children per woman was 
1.38 children (Pritzkuleit et al., 2010). Forecasts by the Federal Statistical Office 
assume that there will be a constant birth rate for Germany, so that an average 
number of 1.4 children per woman will continue to be assumed in the future 
(Statistisches Bundesamt Wiesbaden, 2015a, 2015b). 
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Life expectancy 
In the last 40 years, the life expectancy of female newborns has risen by 9.3 
years (from 74.1 years in 1971/1973 to 83.4 years in 2013/2015) and that of 
male newborns by more than 10 years (from 67.6 years to 78.4 years for the 
same time period). The gap between the life expectancy of female and male 
newborn babies, which had been widening since the mid-20th century, has 
therefore been closing slowly since the 1980s (Nowossadeck, 2012, Peters et 
al., 2010). The Federal Statistical Office estimates that the average life 
expectancy in Germany in 2050 is 88.0 years for women and 83.5 years for 
men (Statistisches Bundesamt Wiesbaden, 2015a, 2015b). But not only the life 
expectancy at birth has increased, but also the long distance life expectancy, i. 
e. the life expectancy that a person still has at a certain age. 65-year-old men 
today have on average an additional 17.7 years of life to expect and women 
20.9 years; these are 5.7 and 6.0 years, respectively more than in 1970. Both, 
rising life expectancy at birth and at long distance life expectancy will increase 
the number and proportion of elderly people in the population (Peters et al., 
2010, Pritzkuleit et al., 2010). 
Special features of the current age structure (‘Baby boomer generation’) 
Large changes in the birth rate over a short period of time have a particular 
influence on the current age structure of a population. After the two world wars, 
which contributed to great cuts in the age structure due to large numbers of war 
victims and sharply declining birth rates, the birth rates rose sharply again in the 
1960s. The generation born between 1955 and 1970, also known as ‘baby 
boomer generation’, is the most populated age group at present. By 2025, this 
cohort will be 65 years and older, having an increased risk of age-related 
diseases, such as tumors or other chronic diseases (Nowossadeck, 2012, 
Pritzkuleit et al., 2010). 
Net migration 
In contrast to low birth rates, continuously rising life expectancy and cohort-
specific peculiarities (‘baby boomer generation’), migration from abroad, 
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especially by younger migrants, may attenuate the process of demographic 
aging that has been observed (Nowossadeck, 2012). 
1.3.2 Demographic aging and its impact on health care systems 
Demographic changes and the aging population will lead to two major changes 
that health care systems will have to account for in the future (Haberland et al., 
2006, Nowossadeck, 2012). The aging population will both increase the number 
of diseases for which the risk increases with age (such as cancers and chronic 
diseases) and change the age structure of patients towards a higher proportion 
of older patients. Further, multimorbidity will increase in importance, as will the 
number of patients requiring geriatric care. The resources, both, financial (direct 
costs of transport, infrastructure) and human resources (medical and nursing 
staff) needed for patient care are expected to increase in the future. The 
situation becomes worse when the declining employment potential is 
considered. As a result of the aging population, there will be more people who 
need to be cared for by the health care system, and fewer people to take care 
of them (Bray and Moller, 2006, Noethern, 2011, Nowossadeck, 2012). 
1.3.3 Demographic trends in Germany and in Denmark 
Germany 
In Germany, the process of demographic aging already began in the 1970s, and 
will continue in the coming years. This process is predicted to accelerate from 
2025 onwards and continue until around 2040 (Nowossadeck, 2012). 
Population forecasts, based on the 13th coordinated population projection, 
assume that by 2060, the total German population will shrink by -16.3% from 
80.8 million (2013) to 68.7 million inhabitants (in case of weaker immigration - 
variant 1) and to 73.1 million inhabitants (in case of stronger immigration - 
variant 2), respectively (Statistisches Bundesamt Wiesbaden, 2015a, 2015b). 
Particularly sharp declines in population are expected in the working age 
citizens. The number of 20- to 64- year-olds (2013: 49 million) will fall sharply 
from 2020 onwards and, depending on the size of net immigration, will be 
around 34 (-30%) and 38 million (-23%), by 2060. Their proportion in the total 
population will fall from 61% in 2013 to around 51-52% in 2060. Similarly, the 
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young population under 20 years of age will decrease from 15 million to 11 (-
26%) and 12 million (-18%) in 2060, suggesting that their proportion of the total 
population will decrease to 18% and 16%, respectively. On the other hand, by 
2060, the number of people aged 65 years and over will rise to 22-23 million. 
While one in five people currently belongs to this age group (2013: 21%), by 
2060 it is estimated to become one in three (2060: 32-33%). Four out of ten 
people aged 65 and over will even be 80 years and older, so that their 
proportion of the total population will increase from the current 5% (2013: 4.4 
million) to 12% or 13% in 2060 (9 million) (Statistisches Bundesamt Wiesbaden, 
2015a, 2015b). 
Denmark 
In contrast to population forecasts for Germany, recent projections released 
from the Statistics Denmark (Statistics Denmark, 2018b), assume that by 2060, 
the total Danish population will rise by +4.4% from 5.0 million (2013) to 5.2 
million inhabitants in 2060. Strong increases are expected for people aged 65 
years and over. Their number (2013: 956,200) will rise to around 1.3 million by 
2060 (+39%), so that their proportion in the total population will increase from 
19.1% in 2013 to 25.4% in 2060. Even stronger increases (+115%) are 
expected for the elderly (80+ yrs). Their proportion will rise from 4.5% (224,320) 
in 2013 to 11% (572,430) in 2060. On the other hand, a decline of -7.5% is 
expected for people aged between 20 and 64 years. Their numbers will fall from 
currently 2.84 million (57% of the total population) to around 2.63 million 
(50.5%) in 2060. Other trends are proposed for the young population (<20 
years). In contrast to population forecasts for Germany, their number will 
increase by +5.2% from 1.19 million (2013) to 1.26 million (2060). Their 
proportion within the total population however will remain almost stable (23.9% 
in 2013 vs. 24.1% in 2060) (Statistics Denmark, 2018b). 
Observed and projected demographic trends for both countries for three time 





   
   
Figure 3: Observed and projected demographic trends in Germany and Denmark for three time points 
(1960, 2010 and 2060). 
Source: United Nations (UN), Population Division (United Nations, 2017) 
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1.4 Future perspectives - Impact of UVR exposure and 
demographics 
Incidence predictions, including the forces that might affect future trends 
(exposure to UVR and demographic changes), play a key role in cancer control 
programs. They assist health care providers in planning the best possible 
allocation of limited resources for effective cancer control.  
In this chapter, the results of different studies on the future incidence 
development of melanoma will be presented, in particular those that have also 
investigated the impact of UVR (risk exposure) and demographic changes on 
future trends. Incidence predictions are naturally subject to great uncertainty 
and depend largely on the method and their underlying assumptions (Bray and 
Moller, 2006, Moller et al., 2002). For this reason, estimates presented in this 
chapter will be focused on one study in Australia, which mostly resembled the 
approach of the present study to predict future incidence rates for Germany and 
Denmark. 
The Australian study projected melanoma incidence rates and numbers of 
cases for six susceptible populations from Australia/New Zealand, the United 
States and Europe at the same time. Incidence predictions were all based on 
the same method and the same assumptions, using identical time periods for 
observation and future periods (Whiteman et al., 2016). By applying modified 
age-period-cohort models, melanoma incidence rates were projected for four 5-
year time periods from 2012/2016 through 2027/2031, based on observed rates 
between 1982/1986 and 2007/2011.  
Results of this study are summarized in Table 3. The information provided in 
this chapter is supplemented by results from other studies, which have applied 
the same prediction method (Guy et al., 2015, Mistry et al., 2011, Moller et al., 
2002, Moller et al., 2007, Weir et al., 2015). 
Australia and New Zealand  
Age-standardized incidence rates (US Standard Population 2000) in Australia 
have already peaked in 2002/2006 (49/100,000 per year) and are projected to 
continue declining until 2027/2031 (41/100,000 per year). The proposed decline 
is primarily anticipated for younger age groups (<60 years), whereas rates in 
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the elderly (>80 years) are expected to continue to increase. At the same time, 
the numbers of melanoma cases have steadily increased since 1982/1986 and 
are believed to continue on this trajectory. Between 1982/1986 and 2027/2031, 
the number of Australians diagnosed with melanoma is expected to rise by 
+291% from around 4,100 cases to 16,075. Almost equal proportions of the 
suggested increase will be attributed to changes in UVR exposure (49%) and to 
changes in demographics (51%) (Whiteman et al., 2016). 
Similar trends are expected for New Zealand. Age-standardized incidence rates 
will peak in 2012/2016 (51/100,000 per year), and then decline slowly 
thereafter. Incidence rates in persons >80 years will continue to rise, while 
younger age groups (<60 years) can expect further declines. The numbers of 
melanoma cases is expected to rise by +363% from about 720 per year in 
1982/1986 to 3,300 per year in 2027/2031. Two-thirds (67%) of the projected 
increase will be due to changes in UVR exposure and only one-third (33%) due 
to changes in population growth and aging (Whiteman et al., 2016). 
In both countries, crude incidence rates (CIR) are projected to continue to rise, 
signs of stabilization or leveling off in increase might not be expected for the 
foreseeable future.  
United States 
Projections suggest that age-standardized incidence rates in US Caucasians 
will continue to rise at least until 2022/2026 (32/100,000 per year), followed by a 
slight decline thereafter. An ongoing increase was supposed for the crude 
incidence rates. Melanoma rates for subjects younger than 60 years are 
projected to stabilize in 2017/2021, whereas no signs of stabilization or leveling 
off in increase will be expected for the elderly (>80 years). The numbers of 
melanoma patients will rise from about 25,000 per year in 1982/1986 to more 
than 116,000 per year in 2027/2031 (corresponding to a relative increase of 
+368%). 79% of the predicted increase will be attributed to increasing exposure 
to UVR (Whiteman et al., 2016). 
Similar trends for white males and females in the US were reported by Guy et 
al. (Guy et al., 2015). Based on observed incidence rates between 1982 and 
2011, sourced from the National Program of Cancer Registries and the 
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Surveillance, Epidemiology, and End Results (SEER) program, this study 
projected melanoma incidence rates and numbers of cases through 2030. Age-
standardized incidence rates (US Standard Population, 2000) are projected to 
rise at least until 2020, followed by a stabilization thereafter. From 2020 
onwards, incidence rates will peak at around 40/100,000 per year in men and 
between 25 and 30/100,000 per year in females. A steady increase is projected 
for the numbers of melanoma cases. By 2030, more than 100,000 US males 
and females are expected to be diagnosed with melanoma. 
Another approach to predict future melanoma incidence rates for Caucasians in 
the US was made by Weir at al. (Weir et al., 2015). Melanoma incidence rates 
have continuously increased since 1975 and are expected to keep so in future. 
Until 2020, age-standardized incidence rates (US Standard Population, 2000) 
will climb up to 30/100,000 per year for women and 40/100,000 per year for 
men, respectively. Signs of a leveling off or stabilization might be visible in later 
periods. 
United Kingdom 
An ongoing increase in age-standardized incidence rates is also projected for 
the UK. By 2022/2026, incidence rates will peak at around 25/100,000 per year 
for both, men and women, followed by a possible stabilization (Whiteman et al., 
2016). First signs of stabilization or even declining melanoma rates are 
projected for subjects younger than 60 years from 2026 onwards, while 
incidence rates in the elderly (80+ years) will continue to rise. No leveling off is 
expected for the crude rates. Strong increases are suggested for the numbers 
of patients diagnosed with melanoma, which are expected to rise by +585% 
from 3,275 cases per year in 1982/1986 to almost 22,500 per year in 
2027/2031. Most of the increase (around 90%) in numbers of persons 
diagnosed with melanoma will be attributable to increasing UVR exposure, 
rather than to population growth or aging (Whiteman et al., 2016).  
Same conclusion are drawn by Moller at al., who estimated future burden of 
cancer in England up to the year 2020 (Moller et al., 2007). Incidence 
projections for melanoma suggest an ongoing increase of age-standardized 
rates until 2020. Thereafter, future rates will reach a plateau with around 20 
36 
cases/100,000 per year for males and females. Particularly strong increases are 
supposed for the absolute numbers of melanoma cases, climbing from 2,630 in 
2001 to 4,940 (+88%) in 2020 for males and from 3,380 to 5,600 (+66%) for 
females, respectively. As in the Whiteman study, for both sexes more than three 
thirds (66% for males and 75% for females) of the corresponding increase in 
melanoma cases will be due to changes in risk (Moller et al., 2007). 
In a more recent study, Mistry et al. conducted a study on incidence predictions 
for different types of cancer in the UK up to the year 2030, including melanoma 
(Mistry et al., 2011). While for several sites, such as stomach, bladder or larynx, 
age-standardized incidence rates are projected to decrease, age-standardized 
incidence rates for other sites are expected to increase at rates of 1% or more 
annually. Melanoma is one of the tumor entities that is expected to show the 
greatest increase in the coming years (around +1.8% p.a. between 1984 and 
2030). Incidence rates will reach more than 20 cases/100,000 per year (22.3 for 
females and 23.4 for males, respectively) in 2030. Like other studies, age-
specific incidence rates will further rise for persons aged 75 years or older, 
while a leveling off can be expected for younger age groups (Mistry et al., 
2011). 
Scandinavia (Norway, Sweden) 
Incidence predictions performed by Whiteman et al. are restricted to two 
Scandinavian countries, Norway and Sweden. In both countries, age-
standardized incidence rates are projected to peak at around 36/100,000 per 
year from 2022/2026 onwards. An ongoing increase in incidence rates is 
estimated for the age group >80 years, while incidence rates in subjects 
younger than 60 years are projected to stabilize from 2022/2026 onwards. No 
leveling off of incidence is expected for the crude rates and for the numbers of 
persons diagnosed with melanoma. In Norway the numbers of melanoma will 
rise by +333% from 619 cases in 1982/1986 to 2,683 in 2027/2031 and in 
Sweden by +388% from 1,081 to 5,270. In both countries, more than 80% of the 
increase will be attributable to increasing UVR exposure (Whiteman et al., 
2016). 
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Incidence predictions for all Nordic countries (Sweden, Norway, Finland, 
Denmark and Iceland) were already carried out by Moller et al. in the early 
2000s (Moller et al., 2007). Based on observed incidence data, future 
melanoma rates were projected up to the years 2018/2022. Age-standardized 
incidence rates (World Standard Population) among males in Denmark, Finland, 
Norway and Sweden were predicted to peak in 2008/2012, whereas the future 
rates for females did not display a similar downward trend. The largest 
increases between 1993/1997 and 2018/2022 were estimated for females in 
Denmark (+36%) and in Iceland (+40%), while only the half of the projected 
growth was suggested for males (Denmark: +16% and Iceland: +19%). An 
ongoing increase without any signs of leveling off was proposed for crude 
incidence rates and for the absolute numbers of melanoma diagnoses. When 
apportioning the increase in melanoma cases into contribution from changes in 
risk and changes in demographics, the proportion attributable to changes in risk 
was particularly high among females. This was evident in Iceland and more 
notably in Denmark, where about 70% and 75% of the proposed increase in 
melanoma cases were attributable to changes in UVR exposure (Moller et al., 
2002). 
Three major findings can be retrieved from the Australian study, supported by 
trends proposed from other studies: (1) Age-standardized incidence rates will 
initially rise, but are expected to stabilize or even decline (in Australia already 
visible since 2005) in future time periods. Signs of stabilizing or even declining 
rates will be particularly expected for age groups younger than 60 years, while 
rates in the elderly (>80 years) are projected to continue rising for the next two 
or three decades; (2) No declines in crude rates and absolute numbers of 
melanoma cases are anticipated for the foreseeable future, because of high 
incidence rates in age groups >60 years and demographic aging in the 
population; (3) In European countries the expected increase in melanoma cases 
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1.5 Summary and research question 
Increasing exposure to UVR, the major environmental risk factor for melanoma 
has largely contributed to the steep increase in the incidence of melanoma, 
which has been observed in many parts of the world, particularly among white-
skinned populations since the mid-1950s (Arnold et al., 2014, de Vries et al., 
2003, de Vries and Coebergh, 2004, Erdmann et al., 2013, Forsea et al., 2012, 
Garbe and Leiter, 2009, Nikolaou and Stratigos, 2014). Although melanoma 
also affects younger age groups, it is diagnosed more often in elderly people 
(Hoejberg et al., 2016). While incidence rates continue to rise in most European 
countries, more favorable trends with stabilizising or even declining rates 
among younger birth cohorts have been observed in Australia/New Zealand, 
Northern America and in some Northern European countries in recent years. 
(Coory et al., 2006, de Vries et al., 2003, Erdmann et al., 2013, Fuglede et al., 
2011, Holman et al., 2018, Moller et al., 2002, Weir et al., 2011). Still increasing 
rates among men and women aged 60 years or older, coupled with 
demographic aging, imply an ongoing increase of melanoma incidence in the 
future. The expected growing burden of melanoma poses major challenges for 
future health care systems. Estimating the future burden of melanoma and the 
forces that might affect future trends, are necessary for setting heath care 
priorities and to achieve effective melanoma control. 
While much effort has been done so far to analyze past and present trends of 
melanoma incidence (Arnold et al., 2014, de Vries et al., 2003, Erdmann et al., 
2013, Garbe and Leiter, 2009, Nikolaou and Stratigos, 2014), there are only a 
few studies that have attempted to estimate future melanoma burden 
attributable to changes in UVR exposure and demographics (Moller et al., 2002, 
Moller et al., 2007, Weir et al., 2015, Whiteman et al., 2016). A comprehensive 
study in this field has been conducted in Australia (chapter 1.4). This study 
analyzed recent trends and estimated future melanoma burden in six 
susceptible populations of mainly European heritage with different patterns of 
UVR exposure (Australia, New Zealand, US Whites, and populations of the UK, 
Sweden, and Norway) and varying approaches for melanoma control 
(Whiteman et al., 2016).  
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Another study predicting future melanoma burden in all Nordic countries, 
including Denmark, has been carried out by Moller et al. in the early 2000s 
(Moller et al., 2002). Based on observed incidence rates (1958-1997), the 
researchers predicted future melanoma trends up to the year 2020 and 
apportioned the expected increases in melanoma cases into contribution from 
changes in population risk (UVR exposure) and population size and age 
distribution.  
Growing melanoma burden in future can also be assumed for Germany and in 
particular for Denmark, where melanoma incidence rates are currently the 
second highest in Europe (31.5 per 100,000/year, European Standard 
Population, WHO 1976), (ECIS, 2018). In both countries, melanoma incidence 
rates have steeply increased in the past and unlike other countries, there have 
been no signs of a leveling off so far, neither in Germany (Garbe et al., 2018, 
Leiter and Garbe, 2008), nor in Denmark (Bay et al., 2015, Helvind et al., 2015). 
For both populations, there are no recent studies investigating melanoma 
incidence trends attributable to changes in UVR exposure and demographics. 
The only studies that could be identified for Germany were those published by 
Prizkuleit and Quante. However, these studies only examined demographic 
aspects and did not analyse the effects of changes in risk behaviour (UVR 
exposure) on the development of melanoma incidence (Pritzkuleit et al., 2010, 
Quante et al., 2016). For Demark, the study carried out by Moller et al. at the 
beginning of the 2000s has not been updated since then (Moller et al., 2002). 
The present research project sought to address these gaps and raised the 
question: to what extent have previous trends in melanoma incidence in 
Germany and Denmark been influenced by UVR exposure and demographic 
changes and what impact will they have on future trends? Denmark was chosen 
as a further country, because it has the longest cancer registration in Europe 
that allows for long-term incidence trend analyses, based on high-quality data 
with a high degree of completeness (Engholm et al., 2010, Gjerstorff, 2011).  
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1.6 Aims and objectives 
Aim 
The aim of the present research project was to investigate the impact of 
changes in sun exposure and demographics on past and present melanoma 
burden in Germany (1995-2013) and in Denmark (1943-2013) and to project 
incidence rates and numbers of melanoma cases according to these changes 
for the period 2014-2033.  
Objectives 
1. To describe observed (1995-2013, Germany and 1943-2013, Denmark) and 
to estimate future (2014-2033) age-standardized, crude and age-specific 
incidence rates of melanoma, and to identify significant changes in trends, 
stratified by sex. 
2. To describe observed (1995-2013, Germany and 1980-2013, Denmark) and 
to estimate future (2014-2033) numbers of melanoma cases, and to 
calculate the relative change from baseline (1995/1998, Germany and 
1980/1983, Denmark), stratified by age (<40 yrs, 40-59 yrs, 60-79 yrs, and 
80+ yrs) and sex. 
3. To estimate the change in the total numbers of new melanoma cases from 
baseline (1995/1998, Germany and 1980/1983, Denmark) attributable to 
changes in UVR exposure and to changes in demographics. 
4. To estimate the number and proportion of melanoma cases attributed to 
UVR exposure at baseline (1995/1998, Germany and 1980/1983, Denmark) 
and in the further course (1999/2003-2029/2033, Germany and 1984/1988-
2029/2033, Denmark), stratified by sex. 
5. To estimate the number and proportion of melanoma cases attributed to 
demographic changes at baseline (1995/1998, Germany and 1980/1983, 
Denmark) and in the further course (1999/2003-2029/2033, Germany and 
1984/1988-2029/2033, Denmark), stratified by sex. 
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2 Materials and Methods 
This chapter is divided into four sections. The first two sections provide general 
information of the data used in the analyses (2.1) and of the basic statistical 
concepts (2.2). Country-specific details on data source and parameters included 
in the models are provided in section 2.3 for Germany, and in section 2.4 for 
Denmark, respectively. 
2.1 Data 
2.1.1 Data Source 
Trend analyses were based on observed incidence rates of CM (ICD-10 code: 
C43), which were retrieved by database query from population-based cancer 
registries covering the periods 1995-2013 for Germany, and 1943-2013 for 
Denmark (Engholm et al., 2010, Robert Koch Institut Berlin, 2016), respectively. 
Historical and projected population data (1980-2033) were obtained from 
national statistics agencies from Germany (Statistisches Bundesamt 
Wiesbaden, 2015a, 2015b) and Denmark (Statistics Denmark, 2018b). 
2.1.2 Measures 
The present analyses were based on different measures of disease burden, 
including incidence rates (age-standardized, crude and age-specific rates) as 
well as absolute numbers of melanoma cases. This was done in order to 
separately investigate the impact of changes in population risk (UVR exposure) 
and demographics (population size and age structure) on melanoma burden. 
Age-standardized incidence rates are usually used to describe epidemiological 
trends. They approximate the population’s risk of being diagnosed with cancer 
and are useful to compare cancer burden between populations with different 
age structure or to compare rates over time within a population. Age-
standardized rates however do not fully convey the extent of cancer burden, 
because they remove the effect of demographic aging in a population. To 
overcome this shortcoming, crude rates, accounting for the additional effect of 
an aging population, were additionally analyzed. In order to fully describe 
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demographic effects, including changes in population size, all investigations 
were extended by calculating absolute numbers of melanoma cases. 
Table 4 provides an overview of measures of disease burden used to describe 
temporal trends of melanoma incidence attributed to changes in UVR exposure 
and demographics (population size and age distribution). 















    
ASIR or age-specific IRs x   
CIR x x  
Number 
of melanoma cases 
x x x 
    
ASIR: Age-standardized incidence rate, CIR: Crude incidence rate, IR: incidence rate 
Age-standardized incidence rates were standardized using the European 
Standard Population (WHO, 1976). Age-specific rates were grouped into four 
age groups (<40 yrs, 40-59 yrs, 50-79 yrs, and 80+ yrs). All rates were reported 
as 100,000 per year and stratified by sex. 
2.2 Statistical analyses 
2.2.1 Incidence trends (Joinpoint Regression) 
Regression analysis is a widely applied technique to model time trends in 
incidence and mortality in epidemiological studies. (Kim et al., 2000). 
Regression analysis provides valuable information for health authorities and 
physicians to develop cancer control strategies and to answer the following 
questions: 
(1) What is the average change in incidence rates per calendar year? 
(2) Is there a constant trend over time or are there any significant changes 
(in direction and/or magnitude) in trends? 
Thus, in modeling trends over time, it is important to be able to detect when 
statistically significant changes in trends occur. Joinpoint analysis is usually 
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used to detect these change points (joinpoints) and to determine the trends 
between joinpoints (Kim et al., 2000, Kim et al., 2004, Kim et al., 2009). 
Joinpoint Regression model 
A joinpoint regression model, also known as piecewise or segmented 
regression, describes changing trends over successive segments of time and 
the amount of change within each segment. Trends are characterized by joined 
linear segments; a joinpoint is created where two segments meet, representing 
a statistically significant change in trend. The model assumes continuity at the 
joinpoints. For each time segment, the annual percentage change (EAPC) and 
its 95% confidence intervals (CI) were estimated by fitting linear regression lines 
to the natural logarithm of the incidence rates (dependent variable) using 
calendar year as independent regressor variable. To summarize the trend in 
incidence for the entire period of observation, the average annual percentage 
rate change (AAPC) is calculated as a weighted average of the EAPCs of each 
joinpoint segment, with the weights equal to the lengths of the EAPC intervals 
(Clegg et al., 2009). 
The joinpoint regression model has the same underlying assumptions as single 
regression models (homogeneous error variance, independent observations 
and normally distributed error term). When analyzing time trends, however, the 
assumption of independence and constant variance is usually not valid. 
Joinpoint regression models may incorporate estimated variance at each point 
(i.e. when the response variables are age-standardized rates) or use a Poisson 
model of variation (i.e. when the response variables are rates or counts), 
allowing for two kinds of probabilistic models: Normal and Poisson (Kim et al., 
2000). 
Model fitting 
Joinpoint regression takes trend data (e.g. cancer rates) and fits the simplest 
joinpoint model, that the data allow. The minimum and the maximum number of 
joinpoints are selected by the user. The program starts with the minimum 
number of joinpoints (i.e. 0 joinpoints, which is a straight line) and tests whether 
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adding further joinpoints (up to the maximum number) would significantly 
improve the fit and must be added to the model. 
The default value for the maximum number of joinpoints depends on the 
number of observed data points (at least seven data points should be observed 
in order to consider allowing a joinpoint) and is based on two pre-set rules (Kim 
et al., 2009): 
 To reduce model over-fitting, there should be at least four observations 
between two joinpoints. 
 To keep joinpoints from being placed too close to the end points, there 
should be at least three observations from a joinpoint to either end of the 
data. 
These algorithmic recommendations lead to the following default maximum 
number of joinpoints, Table 5: 
Table 5: Number of observed data points and recommended maximum 
number of joinpoints 
Number of data points Max. number of Joinpoints 
(Default) 













The next step in the modeling process involves the search for the localization of 
the joinpoints. Two different methods may be applied to determine the best fit of 
each model: 
 The Grid Search Method (default setting) tests a discrete number of 
locations, allowing the joinpoints only to occur exactly at the 
observations. To find a better fit, the ‘number of joinpoints to place 
between adjacent observed x values’ can be set >0 (maximum=9) 
(Lerman, 1980). 
 The Hudson’s Method does a continuous fitting between observed 
values to find the best fit (Hudson, 1966). The method provides the best 
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fit, but is computationally more intensive than the Grid Search Method. 
A maximum of four joinpoints are allowed when continuous fitting is 
applied. 
The last step is to find the final model, i.e. with the optimal number of joinpoints, 
and the optimal locations of related joinpoints. Stepwise selection procedures 
based on hypothesis testing are a common approach to determine the optimal 
model. All of the resulting combinations of possible trend lines are sequentially 
compared using a series of Monte Carlo permutation tests, with Bonferoni 
correction for multiple testing. The option with the fewest joinpoints that provide 
the best fit to the observed data is chosen as final model (Kim et al., 2000). 
The analysis of time trends has been carried out with the Joinpoint Regression 
Program (Version 4.3.1.0), a statistical software package developed by the 
Statistical Research and Applications Branch of the National Cancer Institute 
(NCI) in the United States (National Cancer Institute, 2016). 
2.2.2 Incidence predictions (Age-Period-Cohort Model) 
Historically, generalized linear regression models have widely been used to 
predict future incidence rates (Holford, 1983). The rates are modeled as a 
function of age, calendar period and birth cohort, assuming that the number of 
incident cases in a specific age group and period is a random variable with a 
Poisson distribution (Moller et al., 2002, Osmond, 1985). 
The classical age-period-cohort model can be written as: 
Rap = exp (Aa + D*p + Pp + Cc), 
where Rap is the incidence rate in age group a and in calendar period p, Aa is 
the age component for age group a, D is the common drift parameter 
accounting for the linear component of the trend in period p and cohort c, Pp is 
the non-linear period component of period p and Cc is the non-linear cohort 
component of cohort c. 
However, two disadvantages may arise from the above described model: 
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(1) The multiplicative relationship between the rate and the covariates in 
the standard Poisson regression model produces predictions in which 
the rates may grow exponentially with time.  
(2) A constant drift parameter over a long period of time may not be 
appropriate, as it can be assumed that more distant periods are less 
directly affected by current trends than previous periods. 
To improve model accuracy, two modifications have therefore been 
implemented into the classical age-period-cohort model (Moller et al., 2002): 
(1) To level off the exponential growth in the multiplicative model, a power 
link function was used instead of the log link. 
(2) To allow for a dampening of the impact of current trends in future time 
periods, a gradual reduction in the drift parameter of 25%, 50% and 
75% in the second, third and fourth 5-year prediction period, 
respectively was used. 
An empirical evaluation has shown that both modifications improved the 
predictions (Moller et al., 2003). The modified age-period-cohort model has 
therefore been used for the present predictions:  
Rap = (Aa + D*p + Pp + Cc)
5, 
where Rap, Aa, Pp and Cc are defined as in the multiplicative model. 
Incidence predictions are based on observed number of cancer cases, 
observed population figures and on forecasts of population size and age 
structure. Cancer cases and population data are aggregated into 5-year time 
periods and 5-year age groups (0-4, to 85+), stratified by sex. Incidence rates 
are projected for 5-year time periods.  
The first age group for which the number of cases exceeds 20 in each of the 5-
year observation periods will be included in the regression model. Projections 
for age groups below this limit are based on average rates in the last 10 years. 
The number of periods used in the prediction base will be determined by the 
goodness-of-fit test (5% level). 
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In order to prevent the projected trend from being influenced by older, less 
relevant trends, the trends of crude rates were analyzed. When crude rates 
displayed a significant curvature in the prediction base, the trend in the last 10 
years instead of the average change over the entire period was used as drift 
component D to be projected (Moller et al., 2002).  
Incidence predictions were carried out with NORDPRED, a software package in 
R, available at https://www.kreftregisteret.no/en/Research/Projects/Nordpred/ 
(NORDPRED, 2016). 
2.2.3 Number of new melanomas attributed to changes in UVR exposure 
and demographics 
The numbers of new melanoma cases (2014-2033) were predicted by 
multiplying the projected incidence rates (chapter 2.2.2) according to sex and 5-
year age group (0-4, 5-9,…., 80-84, 85+) by the corresponding population 
forecasts. The total number of projected melanomas is the sum of melanoma 
cases in each age group. Observed melanoma cases (Denmark: 1984-2013; 
Germany: 1999-2015) were sourced directly from the cancer registry databases 
(NORDCAN, 2018, Robert Koch Institut Berlin, 2016). 
The changes in the annual numbers of melanoma cases between baseline and 
future time periods are influenced both by changes in the risk for cancer (i.e. 
increase in UVR exposure) and by changes in demographics (population size 
and age structure). The number of cancer cases can be described as NRAS, 
with cancer risk ‘R’, population age distribution ‘A’ and population size ‘S’ 
(Moller et al., 2002), Figure 4: 
 













‘R’, ‘A’ and ‘S’ are levels for the observed/baseline period (B) or for future 
periods (F). NBBB is then the observed number of cases at baseline, when 
present rates are applied to present population size and age structure. Similarly, 
NFFF is the predicted number of cases in future, based on projected incidence 
rates and population forecasts (size and age distribution).  
NFFF – NBBB is the total change in the annual number of cases between 
baseline and future periods and according to Engeland et al. this change can be 
divided into two components (Engeland et al., 1993): 
(1) Changes due to increased risk of being diagnosed with cancer 
(changes of age-standardized or age-specific incidence rates):  Risk 
(2) Changes due to demographic variations (population size and age): 
 Population 
 Total = NFFF – NBBB = (NFFF – NBFF) + (NBFF – NBBB) 
 =   Risk +  Population, 
NBFF is the expected number of new melanoma cases in future, applying 
baseline rates (B) to future population size (F) and age structure (F). The 
number of new cancer cases attributed to change in risk ( Risk) is therefore the 
difference between the number of cases in the future using the predicted (NFFF) 
or observed (NBFF) rates, while the change due to population structure ( 
Population) is the difference between the number of cases obtained when baseline 
rates are applied to baseline (NBBB) or future age distribution and population 
size (NBFF).  
To evaluate the impact of demographic aging, the population component ( 
Population) can be divided into two sub-components, changes due to age 
distribution ( Age) and changes due to population size ( Size):   
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 Population  =  Age +  Size (absolute change) or 
 Population/NBBB  =  Age/NBBB +  Size/NBBB (relative change) 
The relative change in the number of new cases due to population size 
(Size/NBBB) is equal to the relative increase or decrease in population size. 
The relative change due to age structure is therefore given by:  
 Age/NBBB =  Population/NBBB -  Size/NBBB 
 Age/NBBB = (NBFF- NBBB)/NBBB -  Size/NBBB 
The supplementary tables (S1 and S3) illustrate how the calculations were 
carried out in detail. 
2.2.4 Proportions of melanoma attributable to UVR exposure 
(background level) 
This chapter describes the method used to estimate the population attributable 
fraction (PAF%) of melanoma cases that can be attributed to high background 
levels of UVR (the so-called ‘baseline risk’ for CM). 
The traditional approach to estimate the population attributable fraction, using 
population prevalence of exposure as compared to prevalence in unexposed 
populations, cannot be applied as there are neither unexposed populations nor 
reliable exposure data (Arnold et al., 2018a, de Vries et al., 2017, Winther et al., 
1997). 
Therefore an approach proposed by Parkin et al. was used which compares 
currently observed melanoma incidence rates in the study population with those 
of a ‘minimal-exposed’ or ‘low-incidence’ reference population (as 
approximation of an ‘unexposed’ population) (Parkin et al., 2011b).  
The difference in rates or numbers of cases is then attributed to corresponding 
differences in solar UVR exposure between the study and the reference 
population.  
The PAF% is calculated according to the following formula: 
PAF% = (IS – IR)/IS, 
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where IS is the observed incidence of melanoma in the study population and IR is 
the incidence in the reference population.  
To get the numbers of melanoma cases that would have been expected with a 
theoretical-minimum-exposure distribution, age-specific incidence rates of the 
reference population IR are multiplied by the age- and sex-specific population 
sizes of the study population. The expected numbers of melanoma cases NE 
are then compared with the observed numbers of the study population NO and 
the PAF% is calculated as follows: 
PAF% = (NO – NE)/NO 
The supplementary tables (S2 and S4) illustrate how the calculations for 
Germany and Denmark have been carried out in detail. 
To approximate incidence rates for an ‘unexposed population’ a series of 
different low-risk populations, selected according to time, geography/genetic 
susceptibility or anatomical site, has been described (Armstrong and Kricker, 
1993, Parkin et al., 2011b, Winther et al., 1997). Table 6 provides an overview 





Table 6: Characteristics of commonly used reference populations 
Criteria Reference population Melanoma IRs Rationale Author (Year) 
     
Time South Thames birth cohort 
from 1903 (UK) 
 1.0-1.9/100,000/yr 
 
 Historical cohort which is minimally exposed to UVR due to 
cultural habits (clothing style, recreational activities); 
Long series of high quality data, included in the ‘Cancer 
Incidence in Five Continents (CI5) 
Parkin et al (2005) 
     
 Danish Cohort from 1940s  See above Winther et al (1997) 
     
Geography Ethnically similar population 




 (in 1983-1988) 
Populations, less exposed to UVR, living in areas of low 
solar irradiance compared to study population (exposed to 
high solar irradiance); 
Commonly used to estimate the PAF% for the Australian 
population having their ancestry in low solar areas (i.e. UK) 
Armstrong et al 
(1993) 
     
 Migration from an area of 
low to high solar irradiance 
during adulthood 
- Population living in an area of lower risk for melanoma 
during childhood (time of highest risk for melanoma); 
Commonly used to estimate the PAF% for native-born 
Australians, living in an area of high solar irradiance 
Armstrong et al 
(1993) 
     
Genetics Non-Caucasian, darker-




Dark-pigmented populations, less susceptible to UVR; 
lesions occurring on sites (plantar surfaces of feet/hands) 
which are unlikely to be related to UVR 
Armstrong et al 
(1993) 
 
     





See above Arnold et al (2018) 
     
Anatomical 
site 
Unexposed body sites 
(scalp or buttocks) 
Weighted average: 
1.1/100,000/yr 
Occurrence of melanoma on non-sun exposed sites, 
melanoma is unlikely to be related to UVR 
Armstrong et al 
(1993) 
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2.3 Germany: Data and statistical analyses 
2.3.1 Data  
Cancer registry data 
Incidence data of CM, covering the period 1995-2013, were obtained from the 
Robert Koch-Institute (RKI) in Berlin, which collects data on cancer diseases 
from all 16 population-based cancer registries in Germany (Robert Koch Institut 
Berlin, 2016). Within the Robert Koch-Institute, the Centre for Cancer Registry 
Data (CCRD) is responsible for pooling and quality assurance of the data, 
including checks for completeness and plausibility. Based on these data, the 
CCRD regularly estimates and analyses the number of new cancer cases that 
occur each year. 
Initial cancer registration in Germany is based on notifications from hospitals, 
practicing physicians as well as reports from pathology departments. Case 
ascertainment is supplemented by death certificates only (DCO-cases) provided 
by health authorities. In 11 federal states (Saarland, Hamburg, Bremen, 
Schleswig-Holstein, Lower Saxony, Bavaria, Brandenburg, Mecklenburg-
Vorpommern, Saxony, Thuringia, and for the government district of Muenster 
(North Rhine Westphalia)), the estimated coverage rate was over 90% for the 
year 2012. Reliable data on new cancer cases are therefore available for a 
population of around 55 million inhabitants (~70% of the entire German 
population). According to estimates from the Robert Koch-Institute, only 2% of 
melanoma cases, reported to the CCRD between 2012 and 2013, were notified 
by death certificate only (DCO). Both, high coverage rate and low proportion of 
DCO cases are indicators for the high quality of the data (Robert Koch Institut 
Berlin, 2016). 
Population data  
Historical (1995-2013) and forecast (2014-2033) population size and structure, 
stratified by sex and 5-year age intervals (0-4, 5-9, …, 85+), were retrieved from 
the Federal Statistical Office in Germany (Statistisches Bundesamt Wiesbaden, 
2015a, 2016). Population forecasts were based on data of the 13th coordinated 
population projection, which was released in April 2015 and which consists of 
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eight different variants. For the present analyses, variant 4 (G1-L2-W2) was 
chosen, assuming a birth rate of 1.4 children per women, life expectancy at birth 
in 2060 of 86.7 years for men and 90.4 years for women, as well as net 
migration of 200,000 individuals per year (Statistisches Bundesamt Wiesbaden, 
2015b). 
The observation period covered the years 1995-2013, the first four years (1995-
1998) were defined as baseline period with which subsequent rates and 
melanoma cases were compared. Incidence projections were performed for a 
time period of 20 years from 2014 until 2033. Except of the baseline period, all 
measures are given as 5-year average rates or numbers (1999/2003, 
2004/2008,…..2024/2028, 2029/2033). 
2.3.2 Statistical analyses and parameter setting 
Joinpoint regression (Observed incidence trends) 
To determine whether incidence rates changed significantly during the period of 
observed data (1995-2013), the estimated annual percentage change (EAPC) 
with 95% confidence intervals was calculated using joinpoint regression (Kim et 
al., 2000). Trend analyses were performed for age-standardized, crude and 
age-specific incidence rates, separately for men and women.  
Joinpoint regression models are sensitive to parameter setting. In order to be 
able to compare geographical and temporal incidence trends of melanoma, a 
number of parameters have been predefined. For the analyses of age-
standardized incidence rates, constant error variance was assumed, while a 
Poisson model with heteroscedastic error option was chosen for the analyses of 
crude and age-specific incidence rates. Permutation testing with an overall 
significance level of 0.05 and a Grid Search algorithm was used to define the 
final regression model. Details on parameter selection and model fitting are 
given in Table 7. 
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Model (linear vs. log-linear) Log-linear Log-linear 
Data distribution of dependent variable 
(Normal vs. Poisson) 
Normal Poisson 
Variance (constant vs. non-constant) constant non-constant 
Number of joinpoints (min; max) 0; 3 0; 3 
Minimum numbers of observations from a 
joinpoint to either end of the data 
4 4 
Minimum numbers of observations between 
2 joinpoints 
4 4 
Searching method (Grid or Hudson) Grid Grid 
Model selection method: Permutation Permutation 
 Number of permutations n=4499 n=4499 
 Overall significance level 0.05 0.05 
Age-Period-Cohort Model (Projected incidence trends) 
Modified age-period-cohort models with a power link function were used to 
project incidence rates for four 5-year time periods from 2014/2018 through to 
2029/2033. The calculations were based on new cancer cases, diagnosed 
between 1999 and 2013, on population numbers for 1999-2013 and forecasts of 
population size and age structure for 2014-2033. Incident cancer cases were 
aggregated into 5-year periods (from 1999/2003 through to 2009/2013) and 5-
year age groups (0-4, to 85+) by sex (Moller et al., 2002). 
For both, males and females, the first age group for which the number of 
melanoma exceeded 20 in each 5-year observation period, and which was 
therefore included in the regression model, was the age group 15-19 years. As 
crude rates showed a significant departure from the linear trend for both sexes 
in the prediction base, only the trend in last 10 years was used as a drift 
component to be projected. Incidence predictions were performed for age-
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standardized, crude and age-specific incidence rates, separately for men and 
women. Final parameter setting is given in Table 8. 
Table 8: Age-period-cohort models – parameter setting (for males and 
females) 
Parameter Value 
Number of 5-yr. periods used in estimate  
(prediction base) 
3 
 Prediction base 1999-2003; 2004-2008; 2009-2013 
Number of 5-yr. periods predicted 4 
 Projected periods 2014-2018; 2019-2023; 2024-2028; 2029-2033 
Trend used in predictions (cuttrend) 0; 0.25; 0.5; 0.75 
Link function Power 
P-value for goodness of fit NA* 
Used trend (average or recent) Recent  
P-value for recent <0.001 (both sexes) 
First age group estimated (lower age 
limit) 
15-19 yrs (both sexes) 
* NA: not applicable as the prediction base is fixed on the minimum of three required 5-year 
time intervals 
Numbers of new melanoma attributed to changes in risk and demographics 
The number of melanoma cases between 1999/2003 and 2029/2033 were 
compared with the number of melanomas diagnosed at baseline period 
(1995/1998). The total change in the annual number of melanoma ( Total) was 
divided into two components: changes in UVR exposure (population risk) and 
changes in demographics (population size and age distribution) (Engeland et 
al., 1993, Moller et al., 2002): 
 Total  = NFFF – NBBB = (NFFF – NBFF) + (NBFF – NBBB) 
 =   Risk +  Population 
58 
The risk component ( Risk) is calculated as the difference between the 
numbers of melanoma cases in 1999/2003-2029/2033 using incidence rates of 
1999/2003-2029/2033 (NFFF) and baseline rates of 1995/1998 (NBFF). The 
demographic component ( Population) is the difference of melanoma cases 
obtained when baseline rates (1995/1998) are applied to population size and 
age structure of 1995/1998 (NBBB) or to population data of 1999/2003-
2029/2033 (NBFF). 
A detailed description of the calculations is given in the supplementary tables 
(Table S1). 
Proportions of melanoma attributable to UVR exposure (background level) 
The population attributable fractions and the numbers of melanoma cases due 
to UVR at baseline (1995/1998) were estimated as the proportional difference 
between observed melanoma cases in 1995/1998 by 5-year age groups (0-4 
yrs, ......, 85+ yrs) and sex and the expected number of cases applying 
incidence rates from a historical Danish cohort (1943/1947) (IARC, 2018). This 
cohort was chosen as reference population given its minimal exposure to UVR, 
living in an era when clothing styles almost completely covered the skin. 5-year 
averages of the age-standardized incidences rates (European Standard 
population, WHO 1976) in 1943/1947 were 1.3/100,000 per year for males and 
1.5/100,000 per year for females, respectively. Incidence data from this cohort 
have been included in the ‘Cancer Incidence in Five Continents (CI5)’ (IARC, 
2018), an indicator of high quality data having high comparability, completeness 
and validity. Supplementary table (Table S2) describes the details of the 
calculations.  
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2.4 Denmark: Data and statistical analyses 
2.4.1 Data  
Cancer registry data 
Melanoma incidence data for Denmark (1943-2013) were sourced from the 
NORDCAN database (NORDCAN, 2018). The NORDCAN database includes 
detailed information and results on cancer incidence, mortality and prevalence 
in each of the Nordic countries over five and more decades (Engholm et al., 
2010). The data originates from the national cancer registries and causes of 
death registries in Denmark, Finland, Iceland, Norway, Sweden, and the Faroe 
Island. 
The Danish Cancer Registry is the oldest, founded in 1942 (Gjerstorff, 2011). 
First complete year of cancer registration exists since 1943. In Denmark, cancer 
is reported from multiple sources, including public hospitals, private 
clinicians/dentists, inpatient hospital registries and pathological laboratories, 
supplemented by death certificates. Only 0.3% of all cancer cases between 
2009 and 2013 were notified by death certificate only (DCO cases). As cancer 
notification has become mandatory in all of the Nordic countries, close to 100% 
coverage of incident cases has been reported in each of the Nordic cancer 
registries (Engholm et al., 2010, Larsen et al., 2009, Storm et al., 1997, Teppo 
et al., 1994). Each of the five Nordic cancer registries has been included in the 
Cancer Incidence in Five Continents (CI5), indicating to have high quality data. 
Population data  
In contrast to the melanoma data, which are recorded since the mid-1940s, 
population data are not available until 1980. Historical (1980-2013) and forecast 
(2014-2033) population size and structure, stratified by sex and 5-year age 
intervals (0-4, 5-9, …, 85+), were obtained from the Statistics Denmark 
(Statistics Denmark, 2018b). Population projections for Denmark include only 
one scenario for future developments, assuming a birth rate of 1.9 children per 
women, life expectancy at birth of 87.1 years for men and 89.5 years for women 
in 2060, as well as net migration of 45,000 individuals per year (Statistics 
Denmark, 2018a). 
60 
1980 is the first year for which both cancer and population data are available. 
The years 1980-1983 were defined as baseline period. Subsequent time 
periods were divided into 5-year intervals (1984/1988, 1989/1993,…., 
2024/2028, 2029/2033). Rates and numbers of melanoma cases are presented 
as 5-year averages. 
2.4.2 Statistical analyses and parameter setting 
Joinpoint regression (Observed incidence trends) 
Joinpoint regression models (Kim et al., 2000) were used to analyze incidence 
trends between 1980 and 2013. Changes in trends were quantified by 
calculating the estimated annual percentage change (EAPC) and its 95% 
confidence intervals. Trend analyses were performed for age-standardized, 
crude and age-specific incidence rates, and were stratified by sex.  
For the analyses of age-standardized incidence rates, constant error variance 
was assumed, while a Poisson model with heteroscedastic error option was 
chosen for the analyses of crude and age-specific incidence rates. Permutation 
testing with an overall significance level of 0.05 and a Grid Search algorithm 
was used to define the final regression model. Details on parameter selection 
and model fitting are given in Table 9. 
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Table 9: Joinpoint regression analyses - parameter setting (for males and 
females) 
Parameter ASIR CIR  
Age-specific 
IRs 
Model (linear vs. log-linear) Log-linear Log-linear Log-linear 
Data distribution of dependent variable 
(Normal vs. Poisson) 
Normal Poisson Poisson 
Variance (constant vs. non-constant) constant non-constant non-constant 
Number of joinpoints (min; max) 0; 5 0; 5 0; 3 
Minimum numbers of observations from 
a joinpoint to either end of the data 
5 5 5 
Minimum numbers of observations 
between 2 joinpoints 
5 5 5 
Searching method (Grid or Hudson) Grid Grid Grid 
Model selection method: Permutation Permutation Permutation 
 Number of permutations n=4499 n=4499 n=4499 
 Overall significance level 0.05 0.05 0.05 
Age-Period-Cohort Model (Projected incidence trends) 
Modified age-period-cohort models were used to project incidence rates from 
2014/2018 through to 2029/2033 (Moller et al., 2002). Incidence predictions 
were based on melanoma cases, diagnosed between 1984 and 2013, on 
population data covering the same time period, and on forecasts of population 
size and age structure for 2014 until 2033. Incident cases of CM were 
aggregated into 5-year periods (from 1984/1988 through to 2009/2013) and 5-
year age groups (0-4, to 85+) by sex. 
For both, males and females, the first age group for which the number of 
melanoma exceeded 20 in each 5-year observation period, and which was 
therefore included in the regression model, was the age group 20-24 years. The 
predictions were based on the last three observation periods (1999/2003-
2009/2013) for males and on the last six observation periods (1984/1988-
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2009/2013) for females, as determined by the goodness-of-fit test (5% level). As 
crude rates for females showed a significant departure from the linear trend in 
the prediction base, only the trend in last 10 years was used as drift component 
to be projected. For males, the average linear trend over the entire period of 
observation was used as drift component. Incidence predictions were performed 
for age-standardized, crude and age-specific incidence rates, stratified by sex. 
Final parameter setting is given in Table 10. 
Table 10: Age-period-cohort models - parameter setting (for males and 
females) 
Parameter Males Females 
 
Number of 5-yr. periods used 
in estimate  
(prediction base) 
3 6 
   
 Prediction base 1999-2003; 2004-2008  1984-1988; 1989-1993;  
 2009-2013 1994-1998; 1999-2003; 
  2004-2008; 2009-2013 
Number of 5-yr. periods 
predicted 
4 4 





 2028; 2029-2033 2028; 2029-2033 
Trend used in predictions 
(cuttrend) 
0; 0.25; 0.5; 0.75 0; 0.25; 0.5; 0.75 
Link function Power Power 
P-value for goodness of fit 0.0941 0.4686 
Used trend (average or 
recent) 
Average  Recent  
P-value for recent 0.1389  < 0.001  
First age group estimated 
(lower age limit) 
20-24 yrs 20-24 yrs  
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Numbers of new melanoma attributed to changes in UVR exposure and 
demographics 
The number of observed (1984/1988-2009/2013) and projected (2014/2018-
2029/2033) melanoma cases were compared with the number of melanomas 
diagnosed at baseline period (1980/1983). The total change in the annual 
number of melanoma ( Total) was divided into changes due to UVR exposure 
and into changes due to population structure (size and age distribution) 
(Engeland et al., 1993, Moller et al., 2002): 
 Total  = NFFF – NBBB = (NFFF – NBFF) + (NBFF – NBBB) 
 =   Risk + Population 
Changes due to risk ( Risk) are calculated as the difference between the 
number of melanoma cases in 1984/1988-2029/2033 using incidence rates of 
1984/1988-2029/2033 (NFFF) and baseline rates of 1980/1983 (NBFF). Changes 
due to population ( Population) is the difference of melanoma cases obtained 
when baseline rates (1980/1983) are applied to population size and age 
structure of 1980/1983 (NBBB) or to population data of 1984/1988-2029/2033 
(NBFF). 
A detailed description of the calculations is given in the supplementary tables 
(S3). 
Proportions of melanoma attributable to UVR exposure (background level) 
To calculate the numbers and proportion of melanoma cases attributed to UVR 
at baseline (1980/1983), the same reference population (Danish cohort from 
1943/1947) was chosen as for Germany (IARC, 2018). Details of the 




3.1.1 Trends in incidence rates 
The results of the Joinpoint regression analysis with estimates of the annual 
percentage change of observed incidence trends (1995-2013) are summarized 
and illustrated in Table 12 and in Figure 5, 6 and 7. Projected incidence rates 
for 2014/2018 until 2029/2033, based on age-period-cohort models, are 
presented in Table 11 and Figure 8, 9 and 10. 
Age-standardized and crude incidence rates 
For both sexes, age-standardized incidence rates have almost doubled during 
the observation period. In men, they climbed by +95.0% from 10.1/100,000 per 
year in 1995/1998 to 19.7/100,000 per year in 2009/2013, with an average 
annual increase of +4.4% (95% CI=2.8; 6.1), Figure 5a. Similar increases were 
observed for females, rising by +96.0% from 9.9/100,000 per year in 1995/1998 
to 19.4/100,000 per year in 2009/2013, with an average annual increase of 
+4.3% (95% CI=1.3; 7.4), Figure 5b. Steepest increases of +11.1% p.a. for 
both, males and females, were observed between 2006 and 2009, followed by a 
leveling off in increase thereafter. 
The increase in incidence was more pronounced in crude incidence rates. In 
men, CIRs have risen by +145% from 11.0 in 1995/1998 to 26.9/100,000 per 
year in 2009/2013, which corresponds to an annual increase of +6.0% (95% 
CI=4.4; 7.6), Figure 6a. For the same time period, CIRs increased by +111% in 
females, climbing from 12.1 in 1995/1998 to 25.5/100,000 per year in 
2009/2013, with an annual increase of +4.9% (95% CI=2.7; 7.1), Figure 6b. 
Again, the strongest increases of +13.2% p.a. for males and of +11.7% p.a. for 
females, respectively, were observed between 2006 and 2009. 
Projections, based on age-period-cohort models, suggest further increases in 
incidence for the next 20 years. In men, ASIRs will rise from 19.7/100,000 per 
year in 2009/2013 to 29.9/100,000 per year in 2029/2033, with first signs of 
stabilization from the mid-2020s onwards. In females, ASIRs will climb from 
65 
19.4 in 2009/2013 up to 33.6/100,000 per year in 2029/2033, Figure 8a/b, Table 
11. 
Even higher increases are projected for CIRs. In contrast to ASIRs, no 
stabilization or leveling off in increase is expected to occur in both sexes. In 
2029/2033, CIRs will reach 50.1/100,000 per year in men and 47.3/100,000 per 
year in women, Figure 9a/b, Table 11. 
Age-specific incidence rates 
IRs of melanoma increased exponentially with age. Melanoma was rare in 
adults younger than 40, with IRs of 3.0/100,000 per year for males and of 
5.0/100,000 per year for females in 1995/1998. IRs peaked in the elderly (80+ 
yrs) with IRs of about 30.0 for females and 45.0/100,000 per year for males, 
respectively, Figure 7a/b, Table 11. Until age 60, melanoma was more common 
in females than in males (apart from one exception for the age group 40-59 yrs), 
while the opposite was true for age groups ≥60 years. At the end of the 
observation period (2009/2013), IRs in men aged 80+ years were almost 90% 
higher compared to females of same age (89.3/100,000 per year vs. 
47.4/100,000 per year), Figure 7a/b, Table 11. 
Between 1995/1998 and 2009/2013 melanoma incidence rates increased in all 
age groups, most obvious in age groups ≥60 years, Table 11, Figure 7a/b. The 
steepest increase in incidence was observed in the age group 60-79 years, with 
an average annual increase of +6.2% (95% CI=3.3; 9.2) for males and of +4.8% 
(95% CI=2.8; 6.8) for females, Table 12, Figure 7a/b. Lower, but also significant 
increases, ranging between +3.1% p.a. (0-39 yrs) and +4.3% p.a. (80+ yrs) for 
males and between +3.4% p.a. (80+ yrs) and +4.2% p.a. (40-59 yrs) for 
females, respectively, were found in the other age groups. 
Within the observation period, trends varied across the age groups. Strong 
increases in incidence were found between 2005/2006 and 2009. Among men, 
the annual increases ranged between +9.6% (0-39 yrs) and +13.4% (60-79 yrs) 
and in women between +9.1% (60-79 yrs) and +10.8% (40-59 yrs). Slightly 
declining incidence rates in the following time period were found for younger 
age groups. From 2009 onwards, melanoma incidence decreased by -4.4% p.a. 
66 
for men (0-39 yrs) and by -3.3% p.a. for women (0-39 yrs), however this was 
not statistically significant, Table 12. 
Trends of increasing incidence rates are anticipated for all age groups in future. 
Strong and persistent increasing rates are projected for age groups ≥60 years, 
while for younger age groups first signs of a leveling-off in increase or even 
declining incidence rates are expected from the mid-2020s onwards, Figure 
10a/b, Table 11. For men aged 80+ years, IRs will double from 89.3/100,000 
per year in 2009/2013 to almost 180/100,000 per year in 2029/2033. Lower 
increases are suggested for men between 60 and 79 years of age, rising from 
69.2/100,000 per year in 2009/2013 to 102.2/100,000 per year in 2029/2033. 
For women, the highest increase is projected for the age group 60-79 years. IRs 
will climb by +82% from 41.7 in 2009/2013 up to 75.8/100,000 per year in 
2029/2033. An increase of about +70%, rising from 47.4 in 2009/2013 to 
80.1/100,000 per year in 2029/2033, is anticipated for elderly (80+ yrs) women, 
Figure 10a/b, Table 11. For men and women aged 40-59 years, IRs are 
predicted to continue to rise at least until the mid-2020s. Incidence rates will 
peak in 2024/2028 (men: 36.1/100,000 per year and women: 53.5/100,000 per 
year), thereafter a decline in IRs is expected to occur, Figure 10a/b, Table 11. 
Trends of increasing IRs are also expected for the youngest age group (<40 
yrs), with first signs of stabilization from 2024/2028 onwards. In men, IRs will 
rise about +65% from 4.6 in 2009/2013 to 7.6/100,000 per year in 2029/2033 









Abbreviations: APC, annual percentage change: AAPC, average annual percentage change 
* APC, AAPC are significantly different from zero at α=0.05 
Figure 5: Trends of age-standardized incidence rates (European Standard 
Population, WHO 1976) of cutaneous melanoma, Germany (1995-2013): 






Abbreviations: APC, annual percentage change: AAPC, average annual percentage change 
* APC, AAPC are significantly different from zero at α=0.05 
Figure 6: Trends of crude incidence rates of cutaneous melanoma, Germany 






Abbreviations: APC, annual percentage change: AAPC, average annual percentage change 
* APC, AAPC are significantly different from zero at α=0.05 
Figure 7: Trends of age-specific incidence rates of cutaneous melanoma, 






Figure 8: Projections of age-standardized incidence rates of cutaneous 






Figure 9: Projections of crude incidence rates of cutaneous melanoma, 






Figure 10: Projections of age-specific incidence rates of cutaneous melanoma, 





Table 11: Observed (1995/1998-2009/2013) and projected (2014/2018-2029/2033) age-standardized, crude and age-
specific incidence rates of cutaneous melanoma by sex, Germany* 
  Observed Data Projected Data** 
 
  1995-1998 1999-2003 2004-2008 2009-2013  2014-2018 2019-2023 2024-2028 2029-2033  
  
 
   
 





   
 





10.1 13.4 15.4 19.7  24.2 27.7 29.6 29.9 
 
  
          
CIR  11.0 15.4 19.3 26.9  34.7 41.7 47.2 50.1  
 
   
   
 
    
 
0-39 yrs 3.0 4.0 4.1 4.6  5.6 6.7 7.2 7.6  
40-59 yrs 15.3 17.5 18.1 23.3  30.5 35.4 36.1 32.5  
60-79 yrs 27.0 41.3 51.6 69.2  84.8 92.2 96.6 102.2  
80+ yrs 45.0 45.5 66.1 89.3  114.5 145.9 174.9 179.4  
            
Females            
  
ASIR  9.9 13.5 15.2 19.4  24.4 28.7 31.9 33.6 
 
            
CIR  12.1 16.8 19.4 25.5  32.2 38.5 43.9 47.3  
 
   
   
 
    
 
0-39 yrs 5.0 7.5 8.1 9.4  11.6 13.4 14.2 14.6  
40-59 yrs 14.8 19.0 22.3 29.9  40.3 49.1 53.5 52.2  
60-79 yrs 21.3 30.0 32.5 41.7  50.5 58.3 67.0 75.8  
80+ yrs 29.6 35.3 39.5 47.4  55.6 65.5 76.9 80.1  
Abbreviations: ASIR, age-standardized incidence rate (European Standard Population, WHO 1976); CIR, crude incidence rate 
* All rates are expressed as number per 100,000 per year 




Table 12: Trends and annual percentage change of age-standardized, crude and age-specific incidence rates of cutaneous 
melanoma by sex, Germany (1995-2013)** 
  Line segment 1 Line segment 2 Line segment 3 Line segment 4  
  








1995-2000 7.92* 2000-2006 1.42 2006-2009 11.13* 2009-2013 -0.03 1995-2013 4.4* (2.8; 6.1) 
  
          
CIR  1995-2000 9.23* 2000-2006 3.03* 2006-2009 13.17* 2009-2013 1.38 1995-2013 6.0*( 4.4; 7.6) 
 
   
       
  
0-39 yrs 1995-1999 12.92* 1999-2006 -0.48 2006-2009 9.62 2009-2013 -4.36 1995-2013 3.1* (1.6; 5.7) 
40-59 yrs 1995-1999 6.23* 1999-2006 -0.84 2006-2009 10.38 2009-2013 2.20 1995-2013 3.2* (1.3; 5.2) 
60-79 yrs 1995-2000 11.23* 2000-2006 3.37 2006-2009 13.35 2009-2013 -0.48 1995-2013 6.2* (3.3; 9.2) 
80+ yrs 1995-2000 -1.31 2000-2013 6.58* 
 
   1995-2013 4.3* (2.5; 6.2) 
            
Females            
  
ASIR  1995-2001 7.60* 2001-2006 0.49 2006-2009 11.11 2009-2013 -0.37 1995-2013 4.3* (1.3; 7.4) 
            
CIR  1995-2001 8.10* 2001-2006 0.79 2006-2009 11.72 2009-2013 0.38 1995-2013 4.9* (2.7; 7.1) 
 
   
       
  
0-39 yrs 1995-2001 9.88* 2001-2006 -0.34 2006-2009 9.52 2009-2013 -3.31 1995-2013 3.9* (1.1; 6.8) 
40-59 yrs 1995-2006 3.47* 2006-2009 10.82 2009-2013 1.24   1995-2013 4.2* (1.8; 6.6) 
60-79 yrs 1995-2000 10.93* 2000-2005 -0.97 2005-2009 9.06* 2009-2013 0.65 1995-2013 4.8* (2.8; 6.8) 
80+ yrs 1995-1998 9.89* 1998-2007 1.51* 2007-2010 7.63 2010-2013 -0.97 1995-2013 3.4* (1.9; 5.0) 
Abbreviations: ASIR, age-standardized incidence rate (European Standard Population, WHO 1976); CIR, crude incidence rate 
* Annual percentage change (APC) and average annual percentage change (AAPC) are significantly different from zero at α=0.05 
** All rates are expressed as number per 100,000 per year 
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3.1.2 Trends in incident melanoma cases 
Observed (1995/1998-2009/2013) and projected (2014/2018-2029/2033) 
numbers of melanoma cases, which were calculated by applying projected 
incidence rates to population forecasts, are summarized in Table 13. The 
percentage change from baseline (1995/1998) by age group is illustrated in 
Figure 11a/b.  
Trends in the total population 
For both sexes, the number of persons diagnosed with melanoma increased 
between 1995/1998 and 2009/2013, for males from 4,372 to 10,567 cases p.a. 
(+141.7%) and for females from 5,085 to 10,475 cases p.a. (+106%), 
respectively, Table 13. During the forecast period (2014/2018-2029/2033), an 
ongoing increase is expected. The number of melanoma cases will climb up to 
20,161 new melanoma cases p.a. for males (+361.1% from 1995/1998-
2029/2033) and up to 19,397 new cases p.a. in females (+281.5% from 
1995/1998-2029/2033), respectively, Table 13. 
Trends by age group 
Between 1995/1998 and 2009/2013, the number of melanoma cases increased 
in all age groups. For males, the largest increase was observed in the age 
groups ≥60 years (60-79 yrs: +235.5%; 80+ yrs: +228.6%). For females, the 
strongest increases were found in the age groups 40-59 years (+132.2%) and 
60-79 years (+116.7%), Table 13, Figure 11a/b. 
For the next 20 years, a further increase in melanoma cases is expected for all 
age groups. The largest increase is projected for subjects aged ≥60 years, 
particularly for males. In men ≥80 years, the number of melanoma cases will 
almost quadruple from 1,239 cases p.a. in 2009/2013 to 4,676 cases p.a. in 
2029/2033. Relative to baseline period (1995/1998), the number of melanoma 
cases will rise by +1,140.4% (80+ yrs), while only about half of the increase 
(+549.3%) is expected for men aged 60-79 years, climbing from 1,660 cases 
p.a. in 1995/1998 to 10,778 cases p.a. in 2029/2033. A doubling of melanoma 
cases is also proposed for young and middle-aged men, with relative increases 
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ranging between +92.2% (0-39 yrs) and +105.1% (40-59 yrs), Table 13, Figure 
11a. 
For women, a further doubling in melanoma cases is projected for age groups 
≥60 years, climbing from 3,809 cases p.a. in 2009/2013 to 8,616 cases p.a. in 
2029/2033 (60-79 yrs) and from 1,354 cases p.a. to 3,201 cases p.a. for women 
aged ≥80 years. In contrast to men, both age groups (60-79 yrs: +390.1% and 
≥80 yrs: +366.7%) are expected to experience the largest increase relative to 
baseline period (1995/1998). Lower increases, but still higher than for men, are 
proposed for women aged <60 years, ranging between +115.9% (<40 yrs) and 
+233.2% (40-59 yrs), Table 13, Figure 11b. 
While the increase in the 60+ age groups is expected to continue at least until 
2029/2033, a leveling off or even a decline is to be expected for younger age 
groups from 2020 onwards, Table 13, Figure 11a/b. For men aged 40-59 years, 
the peak will be reached in 2019/2023 (+143.9%), after which an attenuation of 
the growth can be expected. First signs of stabilization are also becoming 
apparent for the age group <40 years from 2024/2028 onwards, with relative 
increases of around 90%, Table 13, Figure 11a. Similar trends are projected for 
young (<40 yrs) and middle-aged (40-59 yrs) women. The peak will be reached 
in 2024/2028, ranging between +119.4% (<40 yrs) and +253.6% (40-59 yrs), 





Table 13: Number of melanoma cases and percentage change from baseline (1995/1998) by age and sex, Germany 
(1999/2003-2029/2033) 







1999-2003 2004-2008 2009-2013 2014-2018 2019-2023 2024-2028 2029-2033 
Males                
Total 4372 6188 (+41.5%) 7760 (+77.5%) 10567 (+141.7%) 13905 (+218.0%) 16893 (+286.4%) 19054 (+335.8%) 20161 (+361.1%) 
0-39 yrs 646 825 (+27.7%) 785 (+21.5%) 812 (+25.7%) 988 (+52.9%) 1178 (+82.3%) 1238 (+91.6%) 1242 (+92.2%) 
40-59 yrs 1689 1957 (+15.9%) 2218 (+31.3%) 2946 (+74.4%) 3734 (+121.1%) 4119 (+143.9%) 3936 (+133.0%) 3465 (+105.1%) 
60-79 yrs 1660 3021 (+82.0%) 4040 (+143.4%) 5570 (+235.5%) 7126 (+329.3%) 8188 (+393.2%) 9640 (+480.7%) 10778 (+549.3%) 
80+ yrs 377 385 (+2.1%) 717 (+90.2%) 1239 (+228.6%) 2057 (+445.6%) 3408 (+804.2%) 4240 (+1024.7%) 4676 (+1140.4%) 
Females                
Total 5085 7097 (+39.6%) 8146 (+60.2%) 10475 (+106.0%) 13341 (+162.4%) 15987 (+214.4%) 18134 (+256.6%) 19397 (+281.5%) 
0-39 yrs 1040 1482 (+42.5%) 1488 (+43.1%) 1594 (+53.3%) 1954 (+87.9%) 2227 (+114.1%) 2282 (+119.4%) 2245 (+115.9%) 
40-59 yrs 1601 2087 (+30.4%) 2671 (+66.8%) 3718 (+132.2%) 4854 (+203.2%) 5599 (+249.7%) 5661 (+253.6%) 5335 (+233.2%) 
60-79 yrs 1758 2710 (+54.1%) 2937 (+67.1%) 3809 (+116.7%) 4779 (+171.8%) 5711 (+224.9%) 7262 (+313.1%) 8616 (+390.1%) 
80+ yrs 686 818 (+19.2%) 1050 (+53.1%) 1354 (+97.4%) 1754 (+155.7%) 2450 (+257.1%) 2929 (+327.0%) 3201 (+366.7%) 







Abbreviation: MM, malignant melanoma 
Figure 11: Relative change of melanoma cases from baseline (1995/1998) by 






































































3.1.3 Shift in the age distribution of melanoma patients 
The percentage change in the age distribution of melanoma patients between 
1995/1998 and 2029/2033 towards higher proportions of older patients is 
graphically shown in Figure 13a/b. Corresponding estimates for the absolute 
numbers of melanoma cases are illustrated in Figure 12a/b. 
At the beginning of the observation period (1995/1998), for both sexes the 
proportion of melanoma patients was almost equally distributed across the age 
groups (<60 yrs vs. ≥60 yrs), with slightly higher percentages for subjects 
younger than 60 years (males: 53.4%; females: 51.9%). In the further course a 
trend towards higher proportion of older patients was observed, which will 
continue into future, Figure 12 and 13. 
Particularly, men are expected to see a significant increase in the proportion of 
people diagnosed with melanoma in the age groups ≥60 years. While less than 
half of the melanoma patients (46.6%) were ≥60 years in the mid-1990s, their 
proportion grew up to 64.4% in 2009/2013, with a sharp rise in the age group 
60-79 years (from 38.0% in 1995/1998 to 52.7% in 2009/2013). A further 
significant increase is expected by 2029/2033. 76.7% of male melanoma 
patients will then be 60 years and older, almost a quarter (23.2%) even 80 
years and older, Figure 12a and 13a. At the same time, the proportion of 
melanoma patients aged ≤60 years will significantly decrease from 53.4% in 
1995/1998 to less than a quarter (22.3%) in 2029/2033, with equal contribution 
of both age groups (<40 yrs and 40-59 yrs). For women, the situation will be 
somewhat different. The proportion of female patients aged ≥60 years will 
remain fairly constant until 2014/2018 (1995/98: 48.1% and 2014/18: 49.0%). 
From 2019/2023 onwards, a shift in the age structure will also become apparent 
among females. The proportion of women with melanoma in the over 60-year-
olds will rise from 51.1% in 2019/2023 to 60.9% in 2029/2033, mainly 
attributable to a high increase in the age group 60-79 years (from 35.7% to 
44.4%), Figure 12b and 13b. Simultaneously decreasing proportions of young 
patients, especially in the youngest age group (<40 years), where the proportion 
will be reduced by almost half from 20.4% in 1995/1998 to 11.6% in 2029/2033, 
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will lead to a shift in the age ratio (≥60 years vs. <60 years) from 48.1%:51.9% 






Abbreviation: MM, malignant melanoma 
Figure 12: Number of melanoma cases by age group and sex, Germany 




























































Abbreviation: MM, malignant melanoma 
Figure 13: Age distribution (%) of melanoma cases by sex, Germany 
(1995/1998-2029/2033): (a) Males, (b) Females 
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3.1.4 Numbers of new melanoma attributed to changes in UVR exposure 
and demographics 
The excess numbers of observed (1999/2003-2009/2013) and projected 
(2014/2018-2029/2033) melanoma cases compared to baseline (1995/1998), 
which were estimated according to the method described by Moller et. al., are 
summarized in Table 14a/b and graphically illustrated in Figure 14a/b.  
Since 1995/1998, the number of melanoma cases has steadily increased in 
both sexes. In 2009/2013, 6,195 additional melanoma cases were diagnosed 
among men, representing a total increase of +141.7% (123.5% due to changes 
in risk and 18.2% due to changes in population structure), Table 14a, Figure 
14a. Among women, the corresponding increase was +106% (98.4% due to 
changes in risk and 7.6% due to changes in population structure), with 5,390 
additional melanoma cases in 2009/2013, Table 14b, Figure 14b. Most of the 
increase in new melanoma diagnoses was attributed to changes in age-specific 
melanoma risk rather than in population size and aging, most evident among 
females (92.8% for females and 87.2% for males), Table 14a/b. 
For the foreseeable future, the numbers of melanomas diagnosed will continue 
to rise. Compared to baseline period, almost 15,800 additional melanoma cases 
are expected to be diagnosed in men in 2029/2033, which corresponds to a 
relative increase of +361.1% (+322.5% due to changes in risk and +38.6% due 
to changes in population structure), Table 14a, Figure 14a. For women, 14,312 
additional melanoma cases are expected by 2029/2033, an increase of 
+281.5% (+267% due to changes in risk and +14.5% due to changes in 
population structure) compared to baseline period, Table 14b, Figure 14b. 
Again, increasing risk (+89.3% for men and +94.8% for women) rather than 
changes in population size and age distribution are responsible for the expected 
increase. 
Observed and projected trends differed only slightly between men and women. 
However, the increase in melanoma due to changes in risk was higher in 
women than in men (90.7-94.9% in women vs. 83.2-89.3% in men). The 
opposite applies to the demographic component, which was on average two 
times higher for men than for women (10.7-16.8% in men vs. 5.1-9.3% in 
women), Table 14a/b. 
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Due to only small changes in population size expected between 1995/1998 and 
2029/2033 (between -0.7% and +1.3% for men between -2.5% and +0.2% for 
women), changes in demographics will be mainly attributed to changes in the 





Table 14a: Excess number of melanoma cases (1999/2003-2029/2033) attributed to changes in UVR exposure and 
demographics (population size and age distribution) from baseline (1995/1998), Germany, Males 






1999-2003 2004-2008 2009-2013 2014-2018 2019-2023 2024-2028 2029-2033 
MM cases 4372 6188 7760 10567 13905 16893 19054 20161 




















































(size)  33 (1.8%) 39 (1.2%) -31 (-0.5%) 18 (0.2%) 56 (0.4%) 52 (0.4%) 28 (0.2%) 
(age)  209 (11.5%) 530 (15.6%) 826 (13.3%) 1078 (11.3%) 1367 (11.0%) 1515 (10.3%) 1659 (10.5%) 




- 0.8% 0.9% -0.7% 0.4% 1.3% 1.2% 0.7% 
Excess MM from 
baseline (total) 
- 41.5% 77.5% 141.7% 218.0% 286.4% 335.8% 361.1% 
due to risk   36.0% 64.5% 123.5% 193.0% 253.8% 300.0% 322.5% 
due to 
population 
 5.5% 13.0% 18.2% 25.0% 32.6% 35.8% 38.6% 
(size)  0.75% 0.9% -0.7%  0.4% 1.3% 1.2% 0.7% 
(age)  4.75% 12.1% 18.9% 24.6% 31.3% 34.6% 37.9% 
Abbreviation: MM, malignant melanoma 




Table 14b: Excess number of melanoma cases (1999/2003-2029/2033) attributed to changes in UVR exposure and 
demographics (population size and age distribution) from baseline (1995/1998), Germany, Females 






1999-2003 2004-2008 2009-2013 2014-2018 2019-2023 2024-2028 2029-2033 
MM cases 5085 7097 8146 10475 13341 15987 18134 19397 




















































(size)  12 (0.6%) -4 (-0.1%) -82 (-1.5%) -72 (-0.9%) -62 (-0.6%) -86 (-0.6%) -127 (-0.9%) 
(age)  98 (4.9%) 290 (9.4%) 468 (8.7%) 580 (7.1%) 691 (6.4%) 748 (5.7%) 867 (6.1%) 




- 0.2% -0.1% -1.6% -1.4% -1.2% -1.7% -2.5% 
Excess MM from 
baseline (total) 
- 39.6% 60.2% 106.0% 162.4% 214.4% 256.6% 281.5% 
due to risk   37.4% 54.6% 98.4% 152.4% 202.0% 243.6% 267.0% 
due to 
population  
 2.2% 5.6% 7.6% 10.0% 12.4% 13.0% 14.5% 
(size)  0.25% -0.08% -1.6%  -1.4% -1.2% -1.7% -2.5% 
(age)  1.95% 5.68% 9.2% 11.4% 13.6% 14.7% 17.0% 
Abbreviation: MM, malignant melanoma 






Abbreviation: MM, malignant melanoma 
Figure 14: Number of excess melanoma cases from baseline (1995/1998), 
attributed to changes in population risk and demographics, Germany 



































































3.1.5 Proportions of melanoma attributable to UVR exposure 
(background level) 
Table 15 shows the number and proportion of melanoma cases attributable to 
UVR by 5-year age groups and sex at baseline (1995/1998), which were 
calculated by comparing the observed numbers of melanoma (1995/1998) in 
the German population with those of a historical Danish cohort from 1943/1947. 
An estimated 8,106 (3,816 in males and 4,290 in females) melanoma cases p.a. 
were attributable to ambient UVR exposure, representing 85.7% of all 
melanomas diagnosed in 1995/1998. The proportion attributable fraction 
(PAF%) was higher in men (3,816 attributable cases; 87.3% of all melanomas) 
than in women (4,290; 84.4%). 
The situation is different when age is taken into account. In age groups younger 
than 40 years the proportion of melanoma caused by UVR is higher in women 
(86.3%) than in men (80.2%). In age groups >40 years the opposite is true, with 
larger proportions of UVR-induced melanoma among men compared to women 
(40-59 yrs: 89% (men) vs. 84.5% (women) and for 60+ yrs: 88.1% (men) vs. 
83.4% (women), respectively). In women, a trend towards increasing 
proportions of UVR-induced melanoma with decreasing age is apparent (60+ 





Table 15: Number and proportion of melanoma cases attributed to UVR at baseline (1995/1998) by age and sex, Germany 

















         
0-4  2 0 -2  4 0 -4   
5-9 5 0 -5  2 0 -2   
10-14 7 1 -6  11 0 -11   
15-19 0 18 18 100.0 0 27 27 100.0 
20--24 5 52 47 90.4 22 98 76 77.6 
25-29 26 122 96 78.7 30 281 251 89.3 
30-34 52 205 153 74.6 24 343 319 93.0 
35-39  31 248 217 87.5 49 291 242 83.2 
40-44 42 282 240 85.1 35 330 295 89.4 
45-49 57 312 255 81.7 48 402 354 88.1 
50-54 31 405 374 92.3 44 397 353 88.9 
55-59 56 690 634 91.9 121 472 351 74.4 
60-64 47 577 530 91.9 52 451 399 88.5 
65-69 44 526 482 91.6 73 441 368 83.4 
70-74 62 350 288 82.3 116 494 378 76.5 
75-79 50 207 157 75.8 40 372 332 89.2 
80-84 27 214 187 87.4 67 382 315 82.5 
85+ 12 163 151 92.6 57 304 247 81.3 
Total 556 4372 3816 87.3 795 5085 4290 84.4 
Abbreviations: UVR, ultraviolet radiation, PAF, population attributable fraction 
* Incidence rates of a historical Danish cohort (1943/1947) were used as reference population 
 
90 
3.1.6 Proportions of melanoma attributable to UVR exposure and 
demographics at baseline and in the further course 
The numbers and fraction of melanoma cases attributable to UVR and 
demographics at baseline (1995/1998), and in the further course (1999/2003-
2029/2033) are summarized in Table 16a/b. Figure 15a/b illustrate the increase 
in melanoma cases between baseline and future periods that can be attributed 
to changes in risk and demographics. 
For both sexes, the numbers and proportions of melanomas caused by UVR 
have increased between 1995/1998 and 2009/2013 and are projected to keep 
on doing so in future. At baseline, higher proportions of UVR-induced 
melanomas were observed among males (87.3% in men vs. 84.4% in women), 
while the opposite is expected for later periods. Among women, the proportion 
of UVR attributable melanoma will strongly increase, so that by 2029/2033 
about 92% of all diagnosed melanoma cases will be attributable to high 
exposure to UVR, Table 16b, Figure 15b; smaller proportions (89%) are 
proposed for men, Table 16a, Figure 15a. Reverse patterns are expected for 
the proportion of melanoma cases attributable to demographic changes, 
particularly among women. While at the beginning a considerable proportion 
(>15%) of melanoma diagnosis could be attributed to demographics, their 
proportion will be reduced by a half from 15.6% in 1995/1998 to 7.9% in 
2029/2033. Similar trends, although to a lesser extent, are supposed for males, 
where demographic changes will count for ≥11% of all melanoma cases over 





Table 16a: Number and proportion of melanoma cases attributed to UVR and demographic changes at baseline (1995/1998) 
and following time periods (1999/2003-2029/33), Germany, Males 
 Time Period 
Number 
of cases 
Changes in cases (from baseline)** 






due to change 
in UVR 
due to change  
in demographics 
UVR demographics UVR demographics 
1995/1998 
(baseline)* 
4372 - - - 3816 556 87.3% 12.7% 
1999/2003 6188 1816 1574 242 5390 798 87.1% 12.9% 
2004/2008 7760 3388 2819 569 6635 1125 85.5% 14.5% 
2009/2013 10567 6195 5400 795 9216 1351 87.2% 12.8% 
2014/2018 13905 9533 8437 1096 12253 1652 88.1% 11.9% 
2019/2023 16893 12521 11098 1423 14914 1979 88.3% 11.7% 
2024/2028 19054 14682 13115 1567 16931 2123 88.9% 11.1% 
2029/2033 20161 15789 14102 1687 17918 2243 88.9% 11.1% 
Abbreviation: UVR, ultraviolet radiation 
* The number of melanoma cases attributable to population risk and demographics at baseline (1995/1998) is given in Table 15 
** The excess number of melanoma cases attributed to changes in population risk (UVR) and demographics (population size and age distribution) in 




Table 16b: Number and proportion of melanoma cases attributed to UVR and demographic changes at baseline (1995/1998) 
and following time periods (1999/2003-2029/33), Germany, Females 
 Time Period 
Number of 
cases 
Changes in cases (from baseline)** 
Number of cases  
attributed to  




due to change 
in UVR 
due to change  
in demographics 
UVR demographics UVR demographics 
1995/1998 
(baseline)* 
5085 - - - 4290 795 84.4% 15.6% 
1999/2003 7097 2012 1902 110 6192 905 87.2% 12.8% 
2004/2008 8146 3061 2775 286 7065 1081 86.7% 13.3% 
2009/2013 10475 5390 5004 386 9294 1181 88.7% 11.3% 
2014/2018 13341 8256 7748 508 12038 1303 90.2% 9.8% 
2019/2023 15987 10902 10273 629 14563 1424 91.1% 8.9% 
2024/2028 18134 13049 12387 662 16677 1457 92.0% 8.0% 
2029/2033 19397 14312 13572 740 17862 1535 92.1% 7.9% 
Abbreviation: UVR, ultraviolet radiation 
* The number of melanoma cases attributable to population risk and demographics at baseline (1995/1998) is given in Table 15 
** The excess number of melanoma cases attributed to changes in population risk (UVR) and demographics (population size and age distribution) in 







Abbreviation: MM, malignant melanoma 
Figure 15: Baseline (1995/1998) and excess number of melanoma cases 
(1999/2003-2029/2033) attributed to changes in UV exposure and 































































3.2.1 Trends in incidence rates 
The results of the Joinpoint regression analysis for observed incidence trends 
and incidence predictions, based on age-period-cohort models, are summarized 
in Table 17a/b and in Table 18. 
Age-standardized and crude incidence rates 
Between 1979/1983 and 2009/2013, age-standardized incidence rates have 
tripled in both sexes. For males, they climbed from 8.6/100,000 per year in 
1979/1983 to 29.8/100,000 per year in 2009/2013, with an average annual 
increase of +3.9% (95% CI=2.9, 4.9), Table 17a and 18. In females, ASIRs 
increased by an average of +3.9% p.a. (95% CI=3.3, 4.5), from 11.3/100,000 
per year in 1979/1983 to 34.3/100,000 per year in 2009/2013, Table 17b and 
18. For males, steepest increases (+8.5% p.a.) were observed between 2004 
and 2009, followed by a leveling off in increase thereafter (+1.9% p.a.). For 
women, age-standardized incidence rates have been rising steadily since 2002 
(+6.1% p.a.), without any signs of leveling off. Over the entire period 
(1944/1948-2009/2013), ASIRs displayed an increase of +4.7% p.a. (95% 
CI=4.6, 4.9) for males, and by +4.6% p.a. (95% CI=4.6, 4.9) for females, Figure 
19a/b. 
Stronger increases in incidence were observed for crude incidence rates, 
particularly among males. In men, CIRs have risen from 8.4 in 1979/1983 to 
35.6/100,000 per year in 2009/2013, corresponding to an average annual 
increase of +4.6% (95% CI=3.8, 5.4), Table 17a and 18. In women, CIRs 
increased from 11.8 in 1979/1983 to 40.1/100,000 per year in 2009/2013, 
corresponding to an average annual increase of +4.1% (95% CI=3.6, 4.7), 
Table 17b and 18. For males the strongest increase in CIRs was found between 
2004 and 2009 (+9.7% p.a.), followed by a slower increase thereafter (+2.9% 
p.a.). A continuous increase of CIRs by +6.1% p. a. from 2002 onwards was 
observed for females. Over a decade of 7 years (1944/1948-2009/2013), the 
estimated average annual increase in CIRs was +5.3% (95% CI=5.1, 5.4) for 
males, and +5.1% (95% CI=4.8, 5.3) for females, Figure 20a/b. 
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Until the mid-1970s (females) and the mid-1980s (males), respectively, ASIRs 
were generally higher than CIRs, in the following periods the crude rates 
exceeded the age-standardized rates, Table 17a/b. 
Ongoing increases in age-standardized incidence rates until 2029/2033 are 
projected for both sexes, somewhat stronger growth can be expected among 
women. For men, ASIRs will rise from 29.8/100,000 per year in 2009/2013 to 
53.6/100,000 per year in 2029/2033 (+80%) and for women from 34.3/100,000 
per year to 74.6/100,000 per year (+117%), Figure 22a/b, Table 17a/b. 
Higher increases are projected for CIRs, with slightly stronger increases among 
men. CIRs will climb by +122% from 35.6/100,000 per year in 2009/2013 up to 
79.1/100,000 per year in 2029/2033 in men, and by +120% from 40.1 in 
2009/2013 up to 88.3/100,000 per year in 2029/2033 in women, Figure 23a/b, 
Table 17a/b. 
While changes in crude and age-standardized incidence rates (CIRs: +122% 
vs. ASIRs: +80%) vary widely among men, the difference among women is 
rather small (CIRs: +120% vs. ASIRs: +117%). On the other hand, changes in 
ASIRs are much stronger among women (+117%) than among men (+80%). 
Age-specific incidence rates 
Age-specific incidence rates increased with age and were generally highest in 
the elderly (>80 years), most evident among males, Table 17a/b. At start of the 
registration period (1944/1948), melanoma incidence was very rare in young 
adults (<40 years), with IRs of less than 1.0/100,000 per year for both sexes. 
IRs peaked in the elderly (80+ yrs) with IRs of about 5.4 for females and 
6.0/100,000 per year for males, respectively. In the age groups <60 years, 
melanoma was more common in females, while IRs in the elderly (80+ yrs) 
were generally higher in males. In 1944/1948 the difference in IRs between men 
and women aged 80+ years was rather small, in the further course however IRs 
differed significantly and were almost 60% higher in men than in women 
(2009/2013: 138.2/100,000 per year vs. 87.4/100,000 per year), Table 17a/b. 
Between 1980 and 2013, the average annual increase in melanoma incidence 
was highest in men and women aged ≥60 years. IRs increased by an average 
of +5.7% p.a. (95% CI=4.4; 7.1) and of +4.1% p.a. (95% CI=2.7; 5.6) for males 
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and females aged 80+ years. The corresponding increase was +5.1% p.a. (95% 
CI=3.7; 6.4) and +3.8% p.a. (95% CI=3.1; 4.4) for men and women in the age 
group 60-79 years, Figure 18a/b, Table 18. Significant increases in melanoma 
incidence were also observed in younger age groups, where the average 
increases ranged between +2.9% p.a. (0-39 yrs) and +3.1% p.a. (40-59 yrs) for 
males and between +3.3% p.a. (40-59 yrs) and +3.7% p.a. (0-39 yrs) for 
females, respectively Table 18. 
Changes in trends between 1980 and 2013, varied across the age groups. For 
both sexes, melanoma incidence in the age group <40 years, transitioned 
through three distinct phases, characterized by a modest increase in the first 
period (males: 1980-2004, APC=+2.3% and females: 1980-2002: APC=+3.4%), 
followed by steeper increases (males: 2004-2009, APC=+13.4% and females: 
2002-2008: APC=+11.0%), and a decline in the last interval, however without 
being statistically significant (males: 2009-2013, APC=-5.5% and females: 
2008-2013: APC=-2.9%), Table 18. No signs of declining incidence rates were 
found for men and women in the age groups ≥40 years. Trends in these age 
groups were characterized by moderate increases at the beginning and an 
acceleration of the increase thereafter. The strongest increase was observed for 
males aged 60-79 years (2002-2006, APC=+12.6%), followed by a slower 
increase in more recent years (2006-2013, APC=+4.4%), Table 18. 
Over the entire period of observation (1944/1948-2009/2013), uniformly 
increasing incidence rates have been seen in all age groups, Table 17a/b, 
Figure 21a/b. Among men, the steepest increase was found in age groups >60 
years, rising by an average of +5.2% p.a. (95% CI=5.0, 5.5) for those aged 60-
79 years, and of +5.4% p.a. (95% CI=4.5, 6.2) for the elderly (80+ yrs), 
respectively, Figure 21a. Similarly high increases (+6.0% p.a., 95% CI=4.7, 7.2) 
were also found in women aged 80+ years and even in women under 40 years 
(+5.1% p.a., 95% CI=4.8, 5.3), Figure 21b.  
Trends of increasing incidence rates are anticipated for all age groups, Table 
17a/b, Figure 24a/b. Among men, the strongest increase is expected for the age 
group 80+ years, IRs will increase by +126% from 138.2/100,000 per year in 
2009/2013 to 312.0/100,000 per year in 2029/2033. For men aged 60-79 years, 
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IRs will rise from 89.9/100,000 per year in 2009/2013 to 142.3/100,000 per year 
in 2029/2033. Steep increases in melanoma incidence rates are also projected 
for young men (<60 years). IRs will rise from 8.1/100,000 per year in 2009/2013 
to 17.4/100,000 per year in 2029/2033 for men aged <40 years and from 
37.0/100,000 per year to 70.9/100,000 per year for those between 40 and 59 
years of age. A leveling off in increase is not expected for the foreseeable 
future, Table 17a, Figure 24a.  
Steadily increasing IRs without any signs of stabilization or leveling off in 
increase, are also supposed for women of all age groups. In contrast to the 
male population, the strongest growth in incidence is expected for age groups 
<60 years, rising by +125% from 17.0/100,000 per year in 2009/2013 to 
38.3/100,000 per years in 2029/2033 in the age group <40 years and by +138% 
from 52.0/100,000 per year in 2009/2013 to 123.8/100,000 per year in 
2029/2033 for women aged 40-59 years, Table 17b, Figure 24b. Moderate 
increases until 2029/2033, ranging between +74% (80+ yrs) and +81% (60-70 
yrs), are expected for women in higher age groups. While the difference in IRs 
between men and women will be rather small in the age group 60-79 years 
(142.4 in men vs. 120.7/100,000 per year in women), IRs in elderly men (80+ 
yrs) are estimated to be twice as high (312.0/100,000 per year) as in women of 
same age (151.9/100,000 per year) in 2029/2033, Table 17a/b, Figure 24a/b. 
For age groups <60 years, higher incidence rates are proposed for women, with 
significant differences in the age group <40 years (38.3/100,000 per year in 






Abbreviations: APC, annual percentage change: AAPC, average annual percentage change 
* APC, AAPC are significantly different from zero at α=0.05 
Figure 16: Trends of age-standardized incidence rates (European Standard 
Population, WHO 1976) of cutaneous melanoma, Denmark (1980-2013): 






Abbreviations: APC, annual percentage change: AAPC, average annual percentage change 
* APC, AAPC are significantly different from zero at α=0.05 
Figure 17:  Trends of crude incidence rates of cutaneous melanoma, Denmark 






Abbreviations: APC, annual percentage change: AAPC, average annual percentage change 
* APC, AAPC are significantly different from zero at α=0.05 
Figure 18: Trends of age-specific incidence rates of cutaneous melanoma, 






Abbreviations: APC, annual percentage change: AAPC, average annual percentage change 
* APC, AAPC are significantly different from zero at α=0.05 
Figure 19: Trends of age-standardized incidence rates (European Standard 
Population, WHO 1976) of cutaneous melanoma, Denmark (1944-2013): 






Abbreviations: APC, annual percentage change: AAPC, average annual percentage change 
* APC, AAPC are significantly different from zero at α=0.05 
Figure 20: Trends of crude incidence rates of cutaneous melanoma, Denmark 






Abbreviations: APC, annual percentage change: AAPC, average annual percentage change 
* APC, AAPC are significantly different from zero at α=0.05 
Figure 21: Trends of age-specific incidence rates of cutaneous melanoma, 






Figure 22: Projections of age-standardized incidence rates (European 
Standard Population, WHO 1976) of cutaneous melanoma, Denmark 






Figure 23: Projections of crude incidence rates of cutaneous melanoma, 






Figure 24: Projections of age-specific incidence rates of cutaneous melanoma, 
Denmark (2014/2018-2029/2033): (a) Males; (b) Females. 
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Table 17a: Observed (1944/1948-2009/2013) and projected (2014/2018-
2029/2033) age-standardized, crude and age-specific incidence rates of 
cutaneous melanoma, Denmark, Males* 
Time 
period 
ASIR CIR Age-specific IRs 
   0-39 yrs 40-59 yrs 60-79 yrs 80+ yrs 
Observed Data 
1944-1948 1.4 1.2 0.4 1.6 4.3 6.0 
1949-1953 1.9 1.6 0.5 2.7 4.4 11.6 
1954-1958 2.1 1.9 0.6 3.4 4.9 8.1 
1959-1963 2.9 2.6 0.9 4.4 5.9 11.6 
1964-1968 4.1 3.7 1.1 6.3 8.9 17.8 
1969-1973 4.9 4.6 1.6 7.5 11.0 15.0 
1974-1978 7.2 6.8 2.2 12.7 15.3 20.9 
1979-1983 8.6 8.4 2.9 13.6 19.8 26.0 
1984-1988 10.6 10.7 3.1 17.0 27.0 25.6 
1989-1993 12.6 13.2 3.3 19.5 34.7 38.0 
1994-1998 14.8 15.7 3.9 22.1 43.2 44.1 
1999-2003 17.0 18.6 4.6 25.6 46.3 68.7 
2004-2008 21.7 24.9 5.9 26.5 68.7 94.0 




2014-2018 41.3 53.8 11.1 51.9 124.4 204.1 
2019-2023 48.1 66.5 13.5 63.2 141.2 265.7 
2024-2028 52.6 75.9 16.1 69.2 145.0 314.0 
2029-2033 53.6 79.1 17.4 70.9 142.3 312.0 
Abbreviations: ASIR, age-standardized incidence rate (European Standard Population, WHO 
1976); CIR, crude incidence rate; IR, incidence rate 
* All rates are expressed as number per 100,000 per year  
** Based on age-period-cohort models (Moller et al, 2002) 
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Table 17b: Observed (1944/1948-2009/2013) and projected (2014/2018-
2029/2033) age-standardized, crude and age-specific incidence rates of 
cutaneous melanoma, Denmark, Females* 
Time 
period 
ASIR CIR Age-specific IRs 
   0-39 yrs 40-59 yrs 60-79 yrs 80+ yrs 
Observed Data 
1944-1948 1.6 1.4 0.6 2.2 3.6 5.4 
1949-1953 2.4 2.2 1.0 3.5 4.6 8.7 
1954-1958 2.6 2.4 1.3 3.4 5.1 6.3 
1959-1963 4.2 4.1 1.4 7.7 7.4 10.5 
1964-1968 6.4 6.3 2.6 10.5 12.2 10.3 
1969-1973 7.0 6.9 2.6 11.7 13.4 15.7 
1974-1978 9.3 9.4 3.7 16.3 18.0 14.0 
1979-1983 11.3 11.8 5.1 19.1 20.9 24.0 
1984-1988 12.9 14.0 5.4 21.9 26.1 26.9 
1989-1993 15.2 17.0 6.8 25.1 31.7 29.5 
1994-1998 17.3 19.5 8.4 28.0 34.7 35.1 
1999-2003 19.4 22.4 9.5 30.3 39.7 49.5 
2004-2008 26.5 30.4 14.9 38.1 50.9 63.6 




2014-2018 49.9 59.5 25.9 77.5 89.1 105.1 
2019-2023 60.7 72.3 31.2 97.9 103.9 125.8 
2024-2028 69.4 81.3 34.7 115.0 112.8 147.5 
2029-2033 74.6 88.3 38.3 123.8 120.7 151.9 
Abbreviations: ASIR, age-standardized incidence rate (European Standard Population, WHO 
1976); CIR, crude incidence rate; IR, incidence rate 
* All rates are expressed as number per 100,000 per year  






Table 18: Trends and annual percentage change of age-standardized, crude and age-specific incidence rates of cutaneous 
melanoma by sex, Denmark (1980-2013)** 
  Line segment 1 Line segment 2 Line segment 3 Line segment 4  
  








1980-2004 3.34* 2004-2009 8.49* 2009-2013 1.90 
  
1980-2013 3.9* (2.9; 4.9) 
  
 
       
  
CIR   1980-2004 3.84* 2004-2009 9.74* 2009-2013 2.93 
  
1980-2013 4.6* (3.8; 5.4) 
         
0-39 yrs 1980-2004 2.31* 2004-2009 13.41* 2009-2013 -5.48 
  
1980-2013 2.9* (1.8: 5.1) 
40-59 yrs 1980-2013 3.06* 
      
1980-2013 3.1* (2.7; 3.5) 
60-79 yrs 1980-1995 5.64* 1995-2002 0.42 2002-2006 12.57* 2006-2013 4.38* 1980-2013 5.1* (3.7; 6.4) 
80+ yrs 1980-1993 3.26* 1993-2013 7.36* 
 
   1980-2013 5.7* (4.4; 7.1) 
           
Females            
ASIR  1980-2002 2.76* 2002-2013 6.11*     1980-2013 3.9* (3.3; 4.5) 
            
CIR  1980-2002 3.17* 2002-2013 6.06*     1980-2013 4.1* (3.6; 4.7) 
            
0-39 yrs 1980-2002 3.39* 2002-2008 10.97* 2008-2013 -2.85 
  
1980-2013 3.7* (2.3; 5.2) 
40-59 yrs 1980-2002 1.98* 2002-2013 5.85* 
  
  1980-2013 3.3* (2.6; 3.9) 
60-79 yrs 1980-2003 3.00* 2003-2013 5.52* 
    
1980-2013 3.8* (3.1; 4.4) 
80+ yrs 1980-1993 1.55 1993-2013 5.86* 
    
1980-2013 4.1* (2.7; 5.6) 
Abbreviations: ASIR, age-standardized incidence rate (European Standard Population, WHO 1976); CIR, crude incidence rate 
* Annual percentage change (APC) and average annual percentage change (AAPC) are significantly different from zero at α=0.05 
** All rates are expressed as number per 100,000 per year 
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3.2.2 Trends in incident melanoma cases 
The numbers of observed (1980/1983) and projected (2014/2018-2029/2033) 
melanoma cases are provided in Table 19a/b. The percentage change from 
baseline (1980/1983) by age group is illustrated in Figure 25a/b. 
Trends in the total population 
For both sexes, the number of persons diagnosed with melanoma increased 
between 1980/1983 and 2009/2013, for males from 214 to 981 cases p.a. 
(+358.4%), Table 19a and for females from 318 to 1,124 cases p.a. (+253.5%), 
respectively, Table 19b. During the forecast period (2014/2018-2029/2033), an 
ongoing increase is expected. The number of melanoma cases will rise to 2,015 
new cases p.a. for males (+841.6% from 1980/1983-2029/2033) and to 2,484 
new melanomas p.a. for females (+681.1% from 1980/1983-2029/2033). 
Trends by age group 
Between 1980/1983 and 2009/2013, the number of melanoma cases increased 
in all age groups. The growth increased with age and was highest in the age 
groups ≥60 years. The increase ranged between +148.9% (<40 years) and 
+666.7% (80+ years) in males and between +211% (<40 years) and +396.2% 
(80+ years) in females, respectively, Table 19a/b, Figure 25a/b. 
Until 2019/2023, a further increase in melanoma cases is expected for all age 
groups and both sexes. Again, the largest increase is projected for subjects 
aged ≥60 years, particularly among males. For men ≥80 years, the number of 
melanoma cases will rise from 115 cases p.a. in 2009/2013 to 559 cases p.a. in 
2029/2033. Relative to baseline (1980/1983), this corresponds to an increase of 
+3,626.7%, while only a quarter of that (+952.5%) is expected for men aged 60-
79 years, climbing from 80 cases p.a. in 1980/1983 up to 842 cases p.a. in 
2029/2033. For women, corresponding estimates are +635% (60-79 yrs) and 
+1,711.5% (80+ yrs), respectively, Table 19a/b, Figure 25a/b. 
Significant increases in incidence are also projected for subjects aged <60 
years, particularly for women. For women younger than 40 years, the number of 
melanoma cases will increase by +553.4% from 73 cases p.a. in 1980/1983 up 
to 477 cases p.a. in 2029/2033. A lower increase is expected for men 
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(+366.7%), rising from 45 melanoma cases p.a. in 1980/1983 to 210 cases p.a. 
in 2029/2033. An ongoing increase in the number of melanoma cases is also 
supposed for middle-aged women (40-59 yrs), climbing by +571.6% from 116 
cases p.a. in 1980/1983 to 779 cases p.a. in 2029/2033. For men aged 40-59 
years, a leveling off in increase might be seen from the 2020s onwards. The 
increase in melanoma cases will peak in 2019/2023 (+470.3%), followed by 
slightly lower increases (+458.1% and +445.9%) thereafter, Table 19a. First 
signs of stabilization might also become apparent among men aged 60-79 
years from 2024/2028 onwards (with relative increases of +953.8% compared 
to baseline). No leveling off in increase, however, might be seen in the youngest 







Table 19a: Number of melanoma cases and percentage change from baseline (1980/1983) by age and sex, Denmark, Males, 





1984-1988 1989-1993 1994-1998 1999-2003 2004-2008 
            
Total 214 271 (+26.6%) 334 (+56.1%) 408 (+90.7%) 492 (+129.9%) 671 (+213.6%) 
0-39 yrs 45 46 (+2.2%) 47 (+4.4%) 55 (+22.2%) 66 (+46.7%) 82 (+82.2%) 
40-59 yrs 74 104 (+40.5%) 130 (+75.7%) 159 (+114.9%) 193 (+160.8%) 203 (+174.3%) 
60-79 yrs 80 106 (+32.5%) 133 (+66.3%) 164 (+105.0%) 184 (+130.0%) 314 (+292.5%) 




 Projected Data* 
2009-2013 2014-2018 2019-2023 2024-2028 2029-2033 
            
Total 214 981 (+358.4%) 1335 (+523.8%) 1663 (+677.1%) 1907 (+791.1%) 2015 (+841.6%) 
0-39 yrs 45 112 (+148.9%) 130 (+188.9%) 156 (+246.7%) 191 (+324.4%) 210 (+366.7%) 
40-59 yrs 74 286 (+286.5%) 359 (+385.1%) 422 (+470.3%) 413 (+458.1%) 404 (+445.9%) 
60-79 yrs 80 468 (+485.0%) 662 (+727.5%) 793 (+891.3%) 843 (+953.8%) 842 (+952.5%) 
80+ yrs 15 115 (+666.7%) 184 (+1126.7%) 292 (+1846.7%) 460 (+2966.7%) 559 (+3626.7%) 





Table 19b: Number of melanoma cases and percentage change from baseline (1980/1983) by age and sex, Denmark, 





1984-1988 1989-1993 1994-1998 1999-2003 2004-2008 
            
Total 318 364 (+14.5%) 444 (+39.6%) 518 (+62.9%) 605 (+90.3%) 835 (+162.6%) 
0-39 yrs 73 75 (+2.7%) 92 (+26.0%) 115 (+57.5%) 129 (+76.7%) 200 (+174.0%) 
40-59 yrs 116 133 (+14.7%) 166 (+43.1%) 197 (+69.8%) 224 (+93.1%) 287 (+147.4%) 
60-79 yrs 103 125 (+21.4%) 148 (+43.7%) 158 (+53.4%) 181 (+75.7%) 255 (+147.6%) 




 Projected Data* 
2009-2013 2014-2018 2019-2023 2024-2028 2029-2033 
            
Total 318 1124 (+253.5%) 1509 (+374.5%) 1835 (+477.0%) 2102 (+561.0%) 2484 (+681.1%) 
0-39 yrs 73 227 (+211.0%) 288 (+294.5%) 356 (+387.7%) 410 (+461.6%) 477 (+553.4%) 
40-59 yrs 116 396 (+241.4%) 521 (+349.1%) 544 (+369.0%) 654 (+463.8%) 779 (+571.6%) 
60-79 yrs 103 372 (+261.2%) 514 (+399.0%) 580 (+463.1%) 628 (+509.7%) 757 (+635.0%) 
80+ yrs 26 129 (+396.2%) 186 (+615.4%) 355 (+1265.4%) 410 (+1476.9%) 471 (+1711.5%) 







Abbreviation: MM, malignant melanoma 
Figure 25: Relative change of melanoma cases from baseline (1980/1983) by 








































































3.2.3 Shift in the age distribution of melanoma patients 
Relative and absolute changes in the age distribution of melanoma patients 
between baseline (1980/1983) and following periods (1984/1988-2029/2033) 
are shown in Figure 26a/b, and in Figure 27a/b. 
Both, males and females are expected to see a shift in the age distribution of 
melanoma patients towards an increasing proportion of older patients (≥60 
years), most obvious among males, Figure 26a and 27a. Between 1980/1983 
and 2029/2033, the proportion of male melanoma patients aged 60 years and 
older is expected to increase from 44.4% to 69.5%, Figure 27a. The growth in 
this age group will mainly be attributed to strong increases in the elderly (80+ 
yrs), climbing from 7.0% in 1980/1983 to 27.7% in 2029/2033. On the other 
hand, steeply decreasing numbers of melanoma patients aged 40-59 years 
(from 34.6% in 1980/1983 to 20.1% in 2029/2033) will lead to a significant 
decline of male melanoma patients younger than 60 years (from 55.6% in 
1980/1983 to 30.5% in 2029/2033), Figure 26a and 27a. 
Similar trends, although to a lesser extent, are projected for women. The 
proportion of melanoma patients aged ≥60 years will rise from 40.6% in 
1980/1983 to 49.5% in 2029/2033, Figure 26b and 27b. As in men, a large 
proportion of the projected increase will be due to strong increases among 
elderly patients (≥80 years), climbing from 8.2% in 1980/1983 up to 19.0% in 
2029/2033. At the same time, the proportion of younger patients (<60 years) will 






Abbreviation: MM, malignant melanoma 
Figure 26: Number of melanoma cases by age group and sex, Denmark 














































Abbreviation: MM, malignant melanoma 
Figure 27: Age distribution (%) of melanoma cases by sex, Denmark 
(1980/1983-2029/2033): (a) Males, (b) Females 
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3.2.4 Numbers of new melanoma attributed to changes in UVR exposure 
and demographics 
Results of the estimated increase in melanoma patients attributed to changes in 
risk and demographics between baseline and future periods, applying the 
method developed by Moller et al., are given in Table 20a/b and in Figure 
28a/b. 
Increasing numbers of melanoma cases since 1980/1983 have been observed 
in both sexes. For men, 767 additional melanoma cases were diagnosed in 
2009/2013 compared to baseline, representing a total increase of +358.4% 
(+338.3% due to changes in risk and +20.1% due to changes in population 
structure), Table 20a, Figure 28a. For women, 806 additional melanoma cases 
were diagnosed in 2009/2013, which corresponds to an increase of +253.5% 
(+239.7% due to changes in risk and +13.8% due to changes in population 
structure), Table 20b, Figure 28b. For both sexes, the increase in melanoma 
cases was mainly attributed to changes in age-specific melanoma risk rather 
than in population size and aging (+94.4% for males and +94.5% for females), 
Table 20a/b, Figure 28a/b. 
The observed trends are proposed to continue for the next 20 years. Until 
2029/2033, 1,801 new melanoma cases will be diagnosed among men, which 
corresponds to a relative increase of +841.6% (+803.3% due to changes in risk 
and +38.3% due to changes in population structure). Among women, 2,166 
additional melanomas are expected by 2029/2033, representing an increase of 
+681.1% (+666% due to changes in risk and +21.1% due to changes in 
population structure) compared to baseline. Again, most of the expected 
increase in numbers of persons diagnosed with melanoma will be attributable to 
increasing risk (+95.4% for men and +96.9% for women) rather than to changes 
in population size and age distribution, Table 20a/b, Figure 28a/b. 
For both sexes, the number and proportion of additional melanoma cases 
diagnosed since baseline due to changes in UVR exposure has increased and 
is expected to increase in the future, most evident in women. For women, the 
proportion of new melanomas caused by UVR exposure will increase from 
76.1% in 1984/1988 to 96.9% in 2029/2033, for men from 89.5% to 95.4%. The 
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Table 20a: Excess number of melanoma cases (1984/1988-2029/2033) attributed to changes in population risk and 
population structure (size and age distribution) from baseline (1980/1983), Denmark, Males 




1984-1988 1989-1993 1994-1998 1999-2003 2004-2008 2009-2013 
MM cases 214 271 334 408  492 671 981 
Population 2447534 2431364 2420545 2432443 2442834 2454078 2473777 
Excess MM  
(total): 
- 57 (100.0%) 120 (100.0%) 194 (100.0%) 278 (100.0%) 457 (100.0%) 767 (100.0%) 
due to UVR 
exposure 
 51 (89.5%) 109 (90.8%) 177 (91.2%) 253 (91.0%) 424 (92.8%) 724 (94.4%) 
due to 
demographics 
 6 (10.5%) 11 (9.2%) 17 (8.8%) 25 (9.0%) 33 (7.2%) 43 (5.6%) 
(size)  -1 (-1.8%) -3 (-2.5%) -1 (-0.5%) 0 (0.0%) 1 (0.2%) 2 (0.3%) 
(age)  7 (12.3%) 14 (11.7%) 18 (9.3%) 25 (9.0%) 32 (7.0%) 41(5.3%) 




- -0.66% -1.10% -0.62% -0.19% 0.27% 1.07% 
Excess MM from 
baseline (total) 
- 26.6% 56.1% 90.7% 129.9% 213.6% 358.4% 
due to risk   23.8% 51.0% 82.7% 118.2% 198.2% 338.3% 
due to 
population  
 2.8% 5.1% 8.0% 11.7% 15.4% 20.1% 
(size)  -0.47% -1.4% -0.47%  0.0% 0.5% 1.0% 
        
(age)  3.27% 6.5% 8.47% 11.7% 14.9% 19.1% 









2014-2018 2019-2023 2024-2028 2029-2033 
MM cases 214 1335 1663 1907 2015 
Population 2447534 2482496 2500379 2524712 2548540 
Excess MM  
(total): 
- 1121 (100.0%) 1449 (100.0%) 1693 (100.0%) 1801 (100.0%) 
due to UVR 
exposure 
 1067 (95.2%) 1385 (95.6%) 1621 (95.7%) 1719 (95.4%) 
due to 
demographics 
 54 (4.8%) 64 (4.4%) 72 (4.3%) 82 (4.6%) 
(size)  3 (0.3%) 5 (0.3%) 7 (0.4%) 9 (0.5%) 
(age)  51 (4.5%) 59 (4.1%) 65 (3.9%) 73 (4.1%) 




- 1.43% 2.16% 3.15% 4.13% 
Excess MM from 
baseline (total) 
- 523.8% 677.1% 791.1% 841.6% 
due to risk   498.6% 647.2% 757.5% 803.3% 
due to 
population  
 25.2% 29.9% 33.6% 38.3% 
(size)  1.4% 2.3% 3.2%  4.2% 
(age)  23.8% 27.6% 30.4% 34.1% 
Abbreviation: MM, malignant melanoma 





Table 20b: Excess number of melanoma cases (1984/1988-2029/2033) attributed to changes in population risk and 
population structure (size and age distribution) from baseline (1980/1983), Denmark, Females 




1984-1988 1989-1993 1994-1998 1999-2003 2004-2008 2009-2013 
MM cases 318 364 444 518 605 835 1124 
Population 2507109 2502238 2494392 2499785 2501366 2503949 2514913 
Excess MM 
(total): 
- 46 (100.0%) 126 (100.0%) 200 (100.0%) 287 (100.0%) 517 (100.0%) 806 (100.0%) 
due to UVR 
exposure 
 35 (76.1%) 105 (83.3%) 172 (86.0%) 253 (88.2%) 478 (92.5%) 762 (94.5%) 
due to 
demographics 
 11 (23.9%) 21 (16.7%) 28 (14.0%) 34 (11.8%) 39 (7.5%) 44 (5.5%) 
(size)  -1 (-2.2%) -2 (-1.6%) -1 (-0.5%) -1 (-0.4%) 0 (0.0%) 1 (0.1%) 
(age)  12 (26.1%) 23 (18.3%) 29 (14.5%) 35 (12.2%) 39 (7.5%) 43(5.4%) 




- -0.19% -0.51% -0.29% -0.23% -0.13% 0.31% 
Excess MM from 
baseline (total) 
- 14.5% 39.6% 62.9% 90.3% 162.6% 253.5% 
due to risk   11.0% 33.0% 54.1% 79.6% 150.3% 239.7% 
due to  
population 
 3.5% 6.6% 8.8% 10.7% 12.3% 13.8% 
(size)  -0.3% -0.6% -0.3%  -0.3% 0.0% 0.3% 
(age)  3.8% 7.2% 9.1% 11.0% 12.3% 13.5% 









2014-2018 2019-2023 2024-2028 2029-2033 
MM cases 318 1509 1835 2102 2484 
Population 2507109 2517344 2530835 2552927 2574121 
Excess MM  
(total): 
- 1191 (100.0%) 1517 (100.0%) 1784(100.0%) 2166 (100.0%) 
due to UVR 
exposure 
 1141 (95.8%) 1460 (96.2%) 1721 (96.5%) 2099 (96.9%) 
due to 
demographics 
 50 (4.2%) 57 (3.8%) 63 (3.5%) 67 (3.1%) 
(size)  1 (0.1%) 3 (0.2%) 6 (0.3%) 8 (0.4%) 
(age)  49 (4.1%) 54 (3.6%) 57 (3.2%) 59 (2.7%) 




- 0.41% 0.94% 1.83% 2.67% 
Excess MM from 
baseline (total) 
- 374.5% 477.0% 561.0% 681.1% 
due to risk  358.8% 459.1% 541.2% 660.0% 
due to 
population 
 15.7% 17.9% 19.8% 21.1% 
(size)  0.3% 0.9% 1.9%  2.5% 
(age)  15.4% 17.0% 17.9% 18.6% 
Abbreviation: MM, malignant melanoma 







Abbreviation: MM, malignant melanoma 
Figure 28: Number of excess melanoma cases from baseline (1980/1983), 
attributed to changes in population risk and demographics, Denmark 












































































3.2.5 Proportions of melanoma attributable to UVR exposure 
(background level) 
The number and proportion of melanoma cases caused by sun exposure at 
baseline, using incidence rates of a historical Danish cohort from 1943/1947 as 
reference population, are summarized in Table 21. 
At baseline, an estimated 458 melanoma cases p.a. (182 in males and 276 in 
females) were attributable to ambient UVR exposure, representing 86.1% of all 
melanomas diagnosed in 1980/1983. The proportion attributable fraction 
(PAF%) was slightly higher in women (276 attributable cases; 86.8% of all 
melanomas) than in men (182; 85%) This trend is visible in all age groups 
(PAF% in females vs. PAF% in males: <40 yrs: 87.7% vs. 84.4%, 40-59 yrs: 






Table 21: Number and proportion of melanoma cases attributed to UVR exposure at baseline (1980/1983) by age and sex, 
Denmark 

















         
0-4  0 0 0  0 0 0  
5-9 0 0 0  0 0 0  
10-14 1 1 0 0.0 1 0 -1  
15-19 0 1 1 100.0 0 4 4 100.0 
20--24 0 4 4 100.0 2 6 4 66.7 
25-29 1 8 7 87.5 2 14 12 85.7 
30-34 3 12 9 75.0 1 21 20 95.2 
35-39  2 19 17 89.5 3 28 25 89.3 
40-44 2 16 14 87.5 2 28 26 92.9 
45-49 3 16 13 81.3 2 29 27 93.1 
50-54 2 20 18 90.0 3 28 25 89.3 
55-59 2 22 20 90.9 6 31 25 80.6 
60-64 2 22 20 90.9 3 29 26 89.7 
65-69 3 23 20 87.0 4 25 21 84.0 
70-74 4 21 17 81.0 6 28 22 78.6 
75-79 4 14 10 71.4 2 21 19 90.5 
80-84 2 6 4 66.7 3 15 12 80.0 
85+ 1 9 8 88.9 2 11 9 81.8 
Total 32 214 182 85.0 42 318 276 86.8 
Abbreviations: UVR, ultraviolet radiation; PAF, population attributable fraction 
* Incidence rates of a historical Danish cohort (1943/1947) were used as reference population 
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3.2.6 Proportions of melanoma attributable to UVR exposure and 
demographics at baseline and in the further course  
Table 22a/b and Figure 29a/b show the estimated numbers and proportions of 
melanomas that can be attributed to UVR exposure and demographics at 
baseline (1980/1983) and in the further course (1984/1988-2029/2033). 
Trends of increasing numbers and proportions of melanomas caused by UVR 
exposure have been observed in both sexes. At baseline (1980/1983), the 
proportion of melanomas caused by UVR exposure was slightly higher in 
women (86.8%) than in men (85%). Projections indicate an ongoing increase of 
UVR-induced melanoma cases. By 2029/2033 up to 95% (94.3% in men and 
95.6% in women) of all diagnosed melanoma cases are expected to be caused 
by high ambient levels of UVR exposure. At the same time, the proportion of 
melanomas attributable to demographic changes is expected to decline, in 
males from 15% in 1980/1983 to 5.7% in 2029/2023, and in females by a third 




Table 22a: Number and proportion of melanoma cases attributed to UVR and demographic changes at baseline (1980/1983) 
and following time periods (1984/1988-2029/33), Denmark, Males 
Time Period Number of 
cases 
Changes in cases (from baseline)** Number of cases  
attributed to 




due to change 
in UVR 
due to change  
in demographics 
UVR demographics UVR demographics 
1980/1983 
(baseline)* 
214 - - - 182 32 85.0% 15.0% 
1984/1988 271 57 51 6 233 38 86.0% 14.0% 
1989/1993 334 120 109 11 291 43 87.1% 12.9% 
1994/1998 408 194 177 17 359 49 88.0% 12.0% 
1999/2003 492 278 253 25 435 57 88.4% 11.6% 
2004/2008 671 457 424 33 606 65 90.3% 9.7% 
2009/2013 981 767 724 43 906 75 92.4% 7.6% 
2014/2018 1335 1121 1067 54 1249 86 93.6% 6.4% 
2019/2023 1663 1449 1385 64 1567 96 94.2% 5.8% 
2024/2028 1907 1693 1621 72 1803 104 94.5% 5.5% 
2029/2033 2015 1801 1719 82 1901 114 94.3% 5.7% 
Abbreviation: UVR, ultraviolet radiation 
* The number of melanoma cases attributable to UVR exposure and demographics at baseline (1980/1983) is given in Table 21  
** The excess number of melanoma cases attributed to changes in population risk (UVR) and demographics (population size and age distribution) in 







Table 22b: Number and proportion of melanoma cases attributed to UVR and demographic changes at baseline (1980/1983) 
and following time periods (1984/1988-2029/33), Denmark, Females 
Time Period Number of 
cases 
Changes in cases (from baseline)** Number of cases  
attributed to 




due to change 
in UVR 
due to change  
in demographics 
UVR demographics UVR demographics 
1980/1983 
(baseline)* 
318 - - - 276 42 86.8% 13.2% 
1984/1988 364 46 35 11 311 53 85.4% 14.6% 
1989/1993 444 126 105 21 381 63 85.8% 14.2% 
1994/1998 518 200 172 28 448 70 86.5% 13.5% 
1999/2003 605 287 253 34 529 76 87.4% 12.6% 
2004/2008 835 517 478 39 754 81 90.3% 9.7% 
2009/2013 1124 806 762 44 1038 86 92.3% 7.7% 
2014/2018 1509 1191 1141 50 1417 92 93.9% 6.1% 
2019/2023 1835 1517 1460 57 1736 99 94.6% 5.4% 
2024/2028 2102 1784 1721 63 1997 105 95.0% 5.0% 
2029/2033 2484 2166 2099 67 2375 109 95.6% 4.4% 
Abbreviation: UVR, ultraviolet radiation 
* The number of melanoma cases attributable to UVR exposure and demographics at baseline (1980/1983) is given in Table 21  
** The excess number of melanoma cases attributed to changes in population risk (UVR) and demographics (population size and age distribution) in 













Abbreviation: MM, malignant melanoma 
Figure 29: Baseline and excess number of melanoma cases attributed to 
changes in UV exposure and demographics by sex, Denmark (1980/1983-




































































The aim of the present research project was to investigate the impact of 
changes in UVR exposure and demographics on past and present incidence 
trends of cutaneous melanoma in Germany and Denmark and to estimate the 
future melanoma burden according to these changes.  
For this purpose, melanoma incidence data were extracted from population-
based cancer registries in Germany and Denmark. Data for Germany were 
obtained from the Center for Cancer Registry Data at the Robert Koch-Institute 
in Berlin (Robert Koch Institut Berlin, 2016), which describes the incidence of 
melanoma for entire Germany from 1995 to 2013. Data for Denmark, covering 
the period from 1943 to 2013, were sourced from the Danish Cancer Registry, 
which is part of the NORDCAN database (NORDCAN, 2018). 
Joinpoint regression analysis was used to identify significant changes in 
incidence rates over the observation period. Based on observed incidence data, 
age-period-cohort models were applied to predict future incidence rates from 
2014 through 2033. Analyses were carried out for age-standardized, crude and 
age-specific incidence rates, as well as for absolute numbers of melanoma 
cases. Age-standardized incidence rates were used to describe changes in 
UVR exposure over time (risk component), and crude rates were analyzed to 
account for the additional impact of age (demographic component) on observed 
and projected incidence trends. Absolute numbers of melanoma cases were 
calculated to quantify the proportion of melanoma cases attributable to changes 
in UVR exposure and demographics. 
Observed incidence trends 
In Germany, age-standardized incidence rates displayed an increase between 
1995/1998 and 2009/2013 for both sexes. Specifically, an increase from 10.1 to 
19.7/100,000 per year was observed for men and an increase from 9.9 to 
19.4/100,000 per year was observed for women. This corresponds to an 
average annual increase of +4.4% for men and of +4.3% for women. A 
particularly strong increase in incidence rates (+11% p.a. for men and women) 
was seen between 2006 and 2009, which has largely been attributed to the 
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introduction of skin cancer screening and the resulting increase in diagnoses 
(Breitbart et al., 2012, Waldmann et al., 2012). In the years after 2009, this 
increase has leveled off for both sexes. 
In Denmark, the age-standardized incidence rates for men increased from 
1.4/100,000 per year in 1944/1948 to 29.8/100,000 per year in 2009/2013 and 
for women from 1.6 /100,000 per year to 34.3/100,000 per year. During this time 
period, the average annual increase was estimated at +4.6% for women and 
+4.7% for men. Between 1950 and 1970, incidence rates in Denmark increased 
slightly. From the 1970s onwards the increase becomes somewhat steeper. 
Particularly strong increases can be observed from the 2000s onwards.  
In both countries, the increase in melanoma incidence was more pronounced in 
crude incidence rates, most notably among men. In Germany. the crude rates 
rose by an average of +4.9% p.a. for women and of +6.0% p.a. for men 
between 1995/1998 and 2009/2013, and in Denmark by an average of +5.1% 
p.a. (women) and +5.3% p.a. (men) between 1944/1948 and 2009/2013. 
The overall incidence trends observed in this study are largely consistent with 
those reported from other countries with predominantly fair-skinned populations. 
The reported annual increase varied between different populations but has 
been estimated to be between 3-7% (de Vries et al., 2003, Erdmann et al., 
2013, Garbe and Leiter, 2009). Between 1990 and 2007, incidence rates in 
Europe increased by an average of +3.8% pea for women and by an average of 
+4.2% p.a. for men (Arnold et al., 2014). 
Long-term trends are reported from Scandinavia, where cancer registration has 
already been established since the early 1940s. Osterlind et al. was one of the 
first researchers who described incidence trends in Denmark (Osterlind et al., 
1988a, Osterlind et al., 1988b). Between 1943 and 1982, a five- to six-fold 
increase in age-standardized incidence rates was reported for both sexes. 
During this period, incidence rates in females were consistently higher than in 
males. This increase continued in the following years (Bay et al., 2015, Fuglede 
et al., 2011, Helvind et al., 2015). Between 1985 and 2012, incidence rates 
increased by an average of +4.5% p.a. for men and by an average of +4.3% 
p.a. for women, reaching rates of 29.5 and 31.7/100,000 per year in 2012, 
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respectively. An even stronger increase was observed from 2004 onwards (Bay 
et al., 2015), which was also seen in the present study.  
The general trend towards increasing melanoma incidence rates is largely due 
to changes in lifestyle and social behavior, involving an increasing amount of 
UVR exposure. Since the middle of the 20th century, a new ideal of beauty has 
developed which embodied tanned skin as a symbol of health and prosperity, 
resulting in a radical change from sun avoidance to sun-seeking behavior. 
Increasing number of holidays spent in (sub)tropical, sunny locations, more 
outdoor leisure activities or changes in fashion that favour less clothing, have 
led to an increasing amount of sun exposure (de Vries and Coebergh, 2004, 
Erdmann et al., 2013). Since the 1960s, the use of artificial sources of UVR (i.e. 
tanning beds, sun lamps) became increasingly popular, particularly in Northern 
European countries, which also contributed to an increase in UVR exposure 
(Bataille et al., 2005, Gandini S. et al., 2011, Hery et al., 2010).  
In the present study, increasing incidence rates of melanoma were seen across 
all age groups. In both countries, the strongest increase was observed in the 
age groups ≥60 years, most obvious in men. In Germany, between 1995/1998 
and 2009/2013, incidence rates in the elderly (80+ years) increased by an 
average of +4.3% p.a. for men and by an average of 3.4% p.a. for women. 
Even higher were the increases for those aged 60-79 years, incidence rates 
increased by +6.2% p.a. among men and by +4.8% p.a. among women. Steeply 
rising incidence rates were also found for younger age groups, especially for 
females, where the estimated annual increase ranged between +3.9% (<40 
years) and +4.2% (40-59 years), respectively. 
In Denmark, the strongest rise in incidence between 1944/1948 and 2009/2013 
was also found for subjects aged ≥60 years, ranging between +5.2-5.4% pea for 
men and between +4.6-6.0% p.a. for women, respectively. Remarkable 
increases were also observed in younger age groups (<60 years). This was 
most pronounced among young women (<40 years: +5.1% pea), but was also 
apparent among men (+4.6% p.a.). 
Strong increases in incidence rates in older age groups (≥60 years) is an 
ubiquitous observation that is frequently reported (Arnold et al., 2014, Bay et al., 
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2015, Fuglede et al., 2011, Hoejberg et al., 2016). Declining rates, as already 
observed in Australia, New Zealand (Baade et al., 2011, Iannacone et al., 
2015), North America (Gaudette and Gao, 1998) or in some Northern European 
countries (Arnold et al., 2014, de Vries et al., 2003, Erdmann et al., 2013), 
among younger cohorts, as result of successful primary prevention (de Haas et 
al., 2010, Iannacone and Green, 2014, Montague et al., 2001), are not 
discernible in Germany and Denmark.  
Still rising incidence rates in younger age groups, most notably among women, 
have also been reported from other countries, such as the Netherlands (de 
Vries et al., 2005), England, Slovenia (Erdmann et al., 2013), the US (Weir et 
al., 2011), and from Denmark (Bay et al., 2015, Fuglede et al., 2011, Helvind et 
al., 2015). Findings from different European studies indicate that the increase 
among young people might be in part attributable to an increasing number of 
thin melanomas (Downing et al., 2006, MacKie et al., 2007, Montella et al., 
2009). Especially women are known to participate more often in screenings 
programs, that in turn may lead to earlier diagnosis, and thus to higher 
proportions of thin and less invasive melanoma. Nevertheless, increasing 
proportions of melanomas located on body sites (i.e.trunk or the limbs), that are 
subject to intermittent sun exposure (Bataille et al., 2005, Bradford et al., 2010, 
Hery et al., 2010), and rapidly growing proportions of superficially spreading 
melanoma, are indications for a true increase in melanoma incidence due to 
increasing sun exposure (Anderson et al., 2009, de Vries and Coebergh, 2004, 
Holterhues et al., 2010, MacKie et al., 2007). Frequent use of artificial sources 
of UVR (i.e. tanning beds), known to be very popular among young 
Scandinavian women (Gandini S. et al., 2011, Hery et al., 2010), might also 
have contributed to rising incidence rates in these cohorts. 
Trends towards stabilization of melanoma incidence in Denmark since 2011, in 
particular for those younger than 40 years, have currently been reported from a 
study investigating incidence trends in eight susceptible population groups 
between 1982 and 2015 (Olsen et al., 2018). The authors however stated, that 
it is still too early to say whether the current melanoma incidence trends in 
Denmark will be sustained over time. 
 135 
 
Projected incidence trends 
Future incidence trends have been calculated for both countries from 
2014/2018 until 2029/2033. Incidence predictions are usually based on 
extrapolation of past trends in three time-related variables, age, period and 
cohort (Bray and Moller, 2006, Moller et al., 2002) and their continuation into 
future. The statistical model that is most commonly used in incidence 
predictions is the age-period-cohort model, in which period and cohort effects 
are proxies for events such as risk factors, which often cannot be measured 
directly. Age, the third component included in the model, is the most important 
time-related variable that influences risk of cancer.  
In the present analyses, a modified age-period-cohort model with a power link 
function was used. Assuming that current trends have less impact on later 
prediction periods, the model allowed for a gradual reduction (0% in the first, 
25% in the second, 50% in the third and 75% in the fourth prediction period) of 
the drift parameter in later periods. As incidence trends showed a significant 
deviation from the linear trend in more recent periods for males and females in 
Germany and for females in Denmark, only the trend of the last 10 years was 
used as drift component to be projected, while for Danish males the average 
trend over the entire period of observation was used. 
Incidence projections for Germany suggest a further increase in age-
standardized incidence, signs of a slight leveling off can be expected for males 
from the mid-2020s onwards. By 2029/2033, the age-standardized incidence 
rates will rise to a 29.9 in men and to 33.6 /100,000 per year in women. A 
steeper increase, without any signs of a leveling off is projected for the crude 
incidence rates. By 2029/2033, crude incidence rates are expected to reach 
values of 50.1/100,000 per year for men and of 47.4/100,000 per year for 
women. The predicted increase will initially affect all age groups. Continuously 
increasing rates are expected for age groups ≥60 years, while men and women 
younger than 60 years might see a leveling off or even a decrease in incidence 
rates from 2024/2028 onwards. 
Higher incidence increases are expected in Denmark. By 2029/2033, age-
standardized incidence rates will increase to 53.6/100,000 per year for men and 
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to 74.6/100,000 per year for women. Even steeper increases are expected for 
the crude incidence rates, reaching values of 79.1/100,000 per year for men 
and of 88.3/100,000 per year for women. A flattening off is not to be expected in 
the foreseeable future. Rising incidence rates are proposed for all age groups. 
In contrast to Germany, there are no signs of a leveling off in younger cohorts, 
neither for men, nor for women.  
The projected ongoing increase in crude incidence rates in Germany and 
Denmark is largely caused by high incidence rates among the elderly and and 
their growing representation in the population (Statistics Denmark, 2018b, 
Statistisches Bundesamt Wiesbaden, 2016).  
In both countries, incidence rates for age groups ≥60 years will continue to rise. 
Different trends are supposed for younger cohorts (<60 years). In Germany, it 
seems likely that screening and prevention campaigns (Breitbart et al., 2012, 
Waldmann et al., 2012) might cause changes in risk behavior, particularly 
among younger cohorts, that might be reflected in stable or even declining 
incidence rates from the mid-2020s onwards. In Denmark, incidence rates in 
younger cohorts are expected to increase further, signs of stabilization are not 
to be expected until 2029/2033. Although a large skin cancer prevention 
campaign, called ‘Reduce your sun’, was introduced about the same time (in 
2007) as in Germany, this does not seem to have a significant effect in the near 
future. The proportion of sunbed user could be reduced by 50% since 2007 
(from 22% to 11% in 2012), but using artificial sources of UVR, particularly 
among young women, is still very common in Denmark (Bay et al., 2015). 
During the summer of 2010, 41% of the Danish population, reported at least 
one episode of sunburn, among children and young adults (15-19 years) even 
73% were sunburned (Helvind et al., 2015). Prevention campaigns to reduce 
UVR exposure do not yet appear to be fully implemented, thus more favorable 
projections for younger cohorts in Denmark are not to be expected in the 
foreseeable future. 
The predicted incidence trends for Germany and Denmark broadly parallel 
others. (Guy et al., 2015, Mistry et al., 2011, Moller et al., 2002, Weir et al., 
2015, Whiteman et al., 2016). The most comprehensive study predicting future 
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melanoma incidence rates and which most closely resembled the own 
approach, was carried out by Whiteman et al. (Whiteman et al., 2016). This 
study predicted incidence rates and numbers of melanoma for six susceptible 
populations with different patterns of UVR exposure and varying approaches for 
melanoma control from 2012/2016 until 2027/2031: Australia, New Zealand, the 
US (Whites), the UK, and for two Scandinavian countries (Norway and 
Sweden). Except of Australia and New Zealand, where age-standardized 
incidence rates have already peaked in 2005 or predicted to peak in near future 
(2012/2016), age-standardized rates in the US and in all European countries 
are expected to rise at least until 2022/2026, followed by stabilizing or even 
declining rates thereafter. Age-standardized incidence rates will peak at 
25/100,000 per year in the UK, at 32/100,000 per year in the US population, 
and at around 36/100,000 per year in the Scandinavian countries (Norway and 
Sweden). However, for all populations, no declines are anticipated in crude 
incidence rates and for subjects aged 60 years or older in the foreseeable 
future. Incidence rates among younger cohorts (<60 years) in Australia and 
New Zealand have already peaked in 2002/2006 and then declined. Similar 
trends are not to be expected until 2021 for the US and until 2026 for Europe 
(UK, Norway and Sweden).  
In Norway and Sweden, campaigns to reduce the burden of melanoma were 
already established in the 1990s (Nilsen et al., 2011, Nilsen et al., 2008). They 
appear to be showing the first signs of success in the near future (Whiteman et 
al., 2016) or have already done so (de Vries et al., 2003, Erdmann et al., 2013). 
In Denmark, the first large skin cancer prevention program was not launched 
until 2007 (Koster et al., 2011). This might explain the expected ongoing 




Impact of changes in exposure to UVR on melanoma incidence trends 
Exposure to UVR is a well-established risk factor for melanoma development 
(Gandini et al., 2005b, Gilchrest et al., 1999). In 2009, the IARC confirmed that 
there is sufficient evidence that solar radiation causes CM, SCC, and BCC, and 
declared UVR as carcinogenic for humans (IARC Working Group on the 
Evaluation of Carcinogenic Risks to Humans, 2012) . 
The mechanisms by which UVR causes cutaneous melanoma are well 
understood. The main intracellular target for UVR is DNA (Gilchrest et al., 
1999). Ultraviolet B radiation is responsible for the formation of the principal 
DNA lesions, cyclobutane pyrimidine dimers (CPD) and pyrimidine (6-4) 
pyrimidone photoproducts (Freeman et al., 1989, Mitchell et al., 1991), whose 
incorrect repair leads to base mutations of cytidine to thymidine (C>T or 
CC>TT), which are considered as ‘UV signature mutations’ (Matsumura and 
Ananthaswamy, 2002). Ultraviolet A radiation causes oxidative DNA damage 
that is also potentially mutagenic, or it leads to immunosuppression that 
prevents the immunologic rejection of nascent ultraviolet induced skin cancers 
(Ichihashi et al., 2003).  
UVR exposure during childhood seems to be the main factor to induce 
mutations in the melanocytic system associated with an increased induction of 
melanocytic nevi and later on an increased risk for the development of 
malignant melanoma (Leiter and Garbe, 2008, Whiteman et al., 2001). A 
longitudinal study of 1,232 German children (2-7 years of age) has shown that 
higher numbers of incident nevi were associated with host factors like light skin 
complexion (skin Type II vs. IV, p=0.022) and freckling of the face (p<0.001), 
with environmental factors like intermittent-high sun exposure during holidays 
(p<0.001) and chronic-moderate ultraviolet radiation at home (p=0.007), and 
with sunburns (p=0.005) (Bauer et al., 2005). Whether nevi, especially clinically 
atypical nevi, are precursors for melanoma however remains a matter of 
debate. Pathology-based studies have found that only 20-30% of melanoma 
contain nevus cells, suggesting a direct transformation of a nevus into 
melanoma. The majority of melanomas (70-80%), arise de novo, with no 
 139 
 
associated nevus (Cymerman et al., 2016, Haenssle et al., 2016, Shain et al., 
2015). 
Quantifying the numbers and proportion of melanoma cases attributable to UVR 
exposure and which could be prevented by reducing UVR exposure plays an 
important role in cancer control planning.  
The central research question of the present project was ‘How many cases of 
melanoma are caused by UVR exposure?’ This question addressed two 
different aspects. First, the proportion of melanoma cases that can be attributed 
to high background levels of UVR in the population, the so-called ‘baseline risk’, 
and second the increase of melanoma cases attributable to changes in risk 
behavior, namely increase in UVR exposure, over time. 
In a first step, an approach described in previous studies (Parkin et al., 2011a) 
was used to calculate the population attributable fraction and numbers of 
melanoma cases due to ambient UVR (at baseline). For this purpose, observed 
melanoma incidence rates at baseline were compared with those of a 
‘minimally-exposed’ or low-incidence reference population, attributing 
differences in melanoma cases to corresponding differences in UVR exposure 
between the reference and study population.  
In the literature, there are a series of different reference populations described. 
Detailed information of commonly used reference populations, including their 
criteria for selection is given in the method section (2.2.4). Frequently used 
reference populations are, for example, historical cohorts that are believed to 
have been minimally exposed to the sun, or dark skinned populations whose 
risk of melanoma is naturally lower. Melanoma incidence rates for these 
reference populations are usually in the range between 1-5 cases per 
100,000/year. 
In the present analysis the incidence rates from a historical Danish cohort of the 
years 1943-1947 was used as reference population. In this period the (age-
standardized) incidence rates were 1.3/100,000 for men and 1.5/100,000 per 
year for women. 
For Germany, the proportion of UVR-induced melanomas at baseline 
(1995/1998) was estimated at 84.4% for women and at 87.3% for men. In 
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Denmark, the proportion of melanomas diagnosed at baseline (1980/1983) was 
slightly higher in women (86.8%) compared to men (85%). Estimates for the 
PAF, retrieved from this study, are in line with those published from other 
studies (Armstrong and Kricker, 1993, Arnold et al., 2018a, Olsen et al., 1997, 
Winther et al., 1997). The estimated PAFs for white-skinned Caucasian 
populations were between 80% and 90%, depending on the reference 
population used to calculate the PAF. 
First estimates for the global melanoma burden caused by UVR was provided 
by Armstrong and Kricker in the early 1980s (Armstrong and Kricker, 1993). To 
calculate the PAF, they compared rates of melanoma in US Blacks (for 1985) 
with incidence rates of 24 standard regions of the world. Although the estimates 
varied by region, they concluded that approximately 65% of all melanomas 
worldwide have been caused by UVR. The highest proportion of melanomas 
attributable to UVR were found in Oceania (94%) and North America (90%). 
Similar high proportions (92-94%) were also calculated for the Scandinavian 
countries (Finland and Denmark) and Switzerland. Lower proportions were 
estimated for South and Eastern Europe, ranging between 78% and 87%. Very 
low proportions of melanoma attributable to UVR, in the range between 3-8%, 
were described for Africa and Asia (Armstrong and Kricker, 1993). 
A higher PAF for the global burden of melanoma due to UVR was described by 
Arnold et al. in a recent study from 2018. Using the Birth Cohort of 1903 from 
the UK, he estimated that globally around 168,000 new melanoma cases 
diagnosed in 2012 were attributable to excess UVR, corresponding to a 
population attributable fraction of 76%. The proportion of melanoma cases 
attributable to UVR exposure varied widely across regions, ranging between 
less than 1% to 96%, with the lowest and highest PAF observed in East Asia 
and Oceania, respectively. PAFs between 80% and 90% were also estimated 
for Europe and North America. Within Europe, the values for the PAF showed 
great variation. The highest PAFs were reported from the Northern (90%) and 
Western (86%) European countries, lower PAFs were estimated for South 
(78%) and East (68%) Europe (Arnold et al., 2018a). 
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First efforts to estimate the melanoma burden attributable to UVR for the 
Scandinavian countries, have been made by Winther et al. at the end of the 
1990s. Following the suggestion of Armstrong and Kricker, they used the 
incidence rates of melanoma on parts of the body usually not exposed to the 
sun (i.e. scalp/buttocks) as estimates for an ‘unexposed’ population and 
compared these rates with observed (1980-1990) and projected (2000) 
incidence rates of melanoma for the Nordic countries (Denmark, Finland, 
Iceland, Norway, and Sweden). In 1980 the proportion of melanoma caused by 
UVR for all Nordic countries together, was estimated at 88% for men, and at 
90% for women. Higher proportions (94% for men and 95% for women) were 
assumed for the year 2000. In Denmark, exposure to UVR accounted for 85% 
of all diagnosed melanomas among men and for 91% among women in 1980. 
Corresponding estimates for the year 2000, ranged between 93% for men and 
95% for women (Winther et al., 1997).  
In a further analysis, Winther et al. have chosen a similar approach as in the 
present research project. They used incidence rates of malignant melanoma of 
a Danish cohort from 1940 as an estimate for the incidence rates of melanoma 
of an ‘unexposed’ reference population and compared these with incidence 
rates observed in all Nordic countries together for 1980. Using the latter 
approach, he found a PAF of 83% for men and of 87% for women, which are 
close to those found by applying the approach suggested by Armstrong and 
Kricker (Armstrong and Kricker, 1993).  
The second part of the research question on the effects of UVR on melanoma 
incidence trends was devoted to the increase in melanoma cases due to 
changes in UVR exposure after the baseline period. For this purpose, current or 
projected melanoma incidence rates were compared with those that would be 
expected when the population would have been exposed to ambient levels of 
UVR experienced by the study population at baseline. The difference in 
observed/projected and expected number of melanoma cases were then be 
attributed to changes in UVR exposure. Calculations were based on the method 
described by Moller et al. in the early 2000s (Moller et al., 2002). 
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For the estimation in Germany, the period between 1995 to 1998 was defined 
as baseline period, the following time periods (1999/2003-2029/2033) were 
considered in 5-year time intervals. During this period, between 83% and 95% 
of new melanomas were caused by an increase in UVR exposure. This was 
most evident among women, where between 91% and 95% of all newly 
diagnosed melanoma cases were attributable to increasing UVR exposure. 
Slightly lower were the estimates for men, ranging between 83-89%.  
In Denmark, the period 1980-1983 was defined as baseline and the increase, 
following baseline period, was also analyzed in 5-year periods up to 2029/2033. 
For men, the increase caused by UVR was between 90% and 96%, and for 
women between 76% and 97%.  
These findings are consistent with estimates published by Whiteman et al. 
(Whiteman et al., 2016). He estimated the numbers and proportion of newly 
diagnosed melanoma cases attributable to changes in risk and demographics 
for six populations between 1987/1991 and 2027/2031, using the years 1982-
1986 as baseline period. Within the European countries, the highest increase 
due to UVR was calculated for the United Kingdom (around 92%), somewhat 
lower were the corresponding estimates for the Scandinavian countries, ranging 
between 76-87% for Norway and between 79-89% for Sweden, respectively. In 
the white US population, the increase in melanoma caused by UVR was 
estimated to range between 73-81%. In Australia and New Zealand, 
successfully implemented prevention programs could reduce the proportion of 
new melanoma cases attributable to UVR from 72% in 1987/1991 to 49% in 
2027/2031 and from 76% to 67%, respectively. 
Finally, to illustrate temporal trends of the melanoma burden attributable to UVR 
in Germany and Denmark, the population attributable fraction of melanomas 
due to UVR at baseline and their increase in the further course were 
summarized, Tables 16a/b and Tables 22a/b. In Germany, the proportion of 
melanoma attributable to UVR is proposed to increase from 87% in 1995/1998 
to 89% in 2029/2033 in men and from 84% to 92% in women. In Denmark, the 
PAFs for males will rise from 85% in 1980/1983 to 94% in 2029/2033 and in 
females from 87% to 96%, respectively. 
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Impact of demographic changes on melanoma incidence trends 
Age plays an important role in the pathogenesis of melanoma. Although 
occurring at an earlier age (median age at diagnosis is 55 years) than most 
other malignant tumors, the risk of being diagnosed with melanoma increases 
with age (Garbe and Leiter, 2009, Robert Koch Institut Berlin, 2017). Aging 
characterizes the cumulative exposure of the body to carcinogens over time, 
and the accumulation of series of mutations that are necessary for unregulated 
cell proliferation that leads to cancer. Further, it influences the host response to 
injury and there is an age associated decrease in the capacity to repair DNA 
and to remove UVR-induced photoproducts from UVR-irradiated skin, resulting 
in an increase in the rate of mutations (Goukassian et al., 2000, Moriwaki et al., 
1996).  
In most western countries life expectancy has significantly increased over the 
last decades. In 1950 life expectancy in Germany was 64 years for men and 
68.5 years for women, in Denmark life expectancy was 68 years for men and 70 
years for women. For 2010, life expectancy in both countries was 77 years for 
men and about 82 years for women. Increasing life expectancy and declining 
birth rates, have caused a significant shift in the age distribution of the 
population towards higher proportions of older people. In Germany, in 
1995/1998 the proportion of the people older than 60 years was 18% for men 
and 25% for women. Until 2029/2033 their proportion will rise to 33% for men 
and to 38% for women. In Denmark, in 1980/1983 the proportion of the those 
aged >60 years was 18% for men and 22% for women, by 2029/2033 the 
proportion will rise to 30% for men and to 34% for women (Statistics Denmark, 
2018b, Statistisches Bundesamt Wiesbaden, 2015b, 2016).  
The second research question was devoted to the impact of demographic 
changes on past, present and future incidence rates of melanoma in Germany 
and Denmark.  
The influence of age on the increase in the incidence of melanoma becomes 
most apparent when comparing the percentage increase in crude incidence 
rates, which accounts for the additional effect of demographic aging, with the 
corresponding increase in the age-standardized incidence rates. For this 
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purpose, the percentage increase between baseline rates (Germany: 
1995/1998 and Denmark: 1979/1983) and end of observation (2009/2013) was 
determined for crude and age-standardized incidence rates.  
In Germany, between 1995/1998 and 2009/2013 the crude incidence rates 
increased by +145% for men and by +111% for women. Age-standardized rates 
increased in the same period by +95% for men and by +96% for women, 
respectively. In Denmark, the increase in crude incidence rates between 
1979/1983 and 2009/2013 was about +324% in men and about +240% in 
women. In the same period, age-standardized incidence rates have risen by 
+247% among men and by +204% among women. The additional effect of age 
incorporated in the crude incidence rates explain their stronger relative increase 
(between baseline and end of observation) compared to those observed in age-
standardized rates.  
To gain more insight into the melanoma burden across different age groups, the 
relative increase in numbers of melanomas between baseline and subsequent 
periods has been calculated for four different age groups (<40 yrs, 40-59 yrs, 
60-79 yrs, and 80+ yrs). 
In both countries, the strongest increase until 2029/2033 will be seen for 
patients aged ≥60 years, particularly among elderly (80+ years) men. In 
Germany, the number of melanoma cases in this age group will rise by 
+1,140%, significantly lower (around +100%) will be the increase in men 
younger than 60 years. Among females, the proposed increase will be less 
pronounced, ranging between +116% in the age group <40 years and +390% 
for the age group 60-79 years. The same trends are anticipated for Denmark for 
the time period between 1980/1983 and 2029/2033. In this period, the expected 
number of melanoma cases in men will rise by +367% for those younger than 
40 years and by +3,630% for the elderly (80+ years). In women, the steepest 
growth will also be seen in the age group 80+ years (+1,710%), significantly 
rising numbers of melanoma cases however are also expected for young and 




The sharp increases in the age groups ≥60 years will lead to a significant shift in 
the age structure of melanoma patients in future, most notably among men. In 
Germany, the proportion of melanoma patients aged ≥60 years will increase 
from 47% in 1995/1998 to 77% in 2029/2033 in men, and from 48% to 61% in 
women. In Denmark, their proportion will rise from 44% in 1980/1983 to 70% for 
men and from 41% to 50% for women.  
To quantify the impact of demographic changes on melanoma incidence trends, 
the increase in the number and proportion of melanoma cases attributable to 
changes in population structure (changes in age distribution and size) have 
been calculated. For this purpose, the number of melanoma cases observed at 
baseline were compared with those that one would expect when baseline rates 
would be applied to future population size and age distribution. The difference 
between expected and observed melanoma cases were then be attributed to 
demographic changes. Calculations were based on the method described by 
Moller et al. (Moller et al., 2002).  
For Germany, the years 1995-1998 were defined as baseline period. The 
following time periods between 1999/2003 and 2029/2033 were considered in 
5-year periods. In men, demographic changes accounted for 11-17% of the 
increase in melanoma cases between 1999/2003 and 2029/2033, and in 
women for 5-9%, Tables 14a/b. 
In Denmark, the period 1980-1983 was defined as baseline and the increase, 
following baseline period, was also analyzed in 5-year periods up to 2029/2033. 
Among men, 4-11% of all newly diagnosed melanoma cases between 
1984/1988 and 2029/2033 could be attributed to demographic changes. Among 
women, the increase in melanoma cases caused by demographic aging, 
significantly decreased from 24% in 1984/1988 to 3% in 2029/2033, Tables 
20a/b. 
Similar results were reported by Whiteman et al. (Whiteman et al., 2016). In 
Europe, demographic changes accounted for 8-24% of the observed or 
projected increase in melanoma cases between 1987/1991 and 2027/2031 (UK: 
8%, Sweden: 11-21%, Norway: 13-24%). Slightly higher proportions were 
estimated for the US (19-27%). Exceptions were Oceania. In New Zealand, 
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demographic changes contributed to 33% and in Australia to 51% of all newly 
diagnosed melanoma cases between 1987/1991 and 2027/2031. 
These findings suggest that demographic changes have less impact on 
melanoma incidence trends than UVR exposure. The impact of demographic 
changes on cancer incidence trends depends largely on the age at tumor 
diagnosis. In general, the higher the median age of onset, the stronger the 
influence of demographic changes on incidence trends. Unlike epithelial skin 
tumors (BCC and SCC), which predominantly occur at an advanced age, 
melanoma can already be diagnosed early in life (Leiter et al., 2014, Weir et al., 
2011). This relationship is well illustrated in a study from the Netherlands (de 
Vries et al., 2005). This study investigated the incidence trends of three different 
types of skin cancer with different disease ages (CM, BCC, SCC) and estimated 
the contribution of risk and demographic changes to the increase in incidence. 
While demographic changes accounted for 51% of the expected increase in 
BCC and for 61% in SCC incidence, only 17% of the projected increase in 
melanoma incidence could be attributed to demographic changes. 
The different age at which melanomas and epithelial tumors are diagnosed, 
results from different responses of melanocytes and keratinocytes to damaging 
UVR (Gilchrest et al., 1999). After sun exposure, the severely damaged 
keratinocytes undergo apoptosis, leaving the less damaged keratinocytes to 
upregulate their DNA-repair capacity and to undergo nearly perfect repair 
(Norris et al., 1997, Polakowska et al., 1994). The skin tans, providing protective 
melanin to surrounding keratinocytes. Frequent subsequent exposure to UVR 
within the SOS-response period will enhance the increases in repair capacity 
and melanin content, and minimizing, but not eliminating the cumulative 
mutational damage in the keratinocytes. In contrast, first high dose of UVR will 
cause substantial damage to melanocytes, but no apoptosis. Their high content 
of anti-apoptotic proteins (i.e. Bcl-2) prevents them from apoptosis (Rodriguez-
Villanueva et al., 1995). The melanocytes will survive and accumulate UVR-
induced DNA mutations, so that even in childhood or adolescence melanomas 
can develop (Gilchrest et al., 1999). 
 147 
 
Finally, the numbers and proportion of melanoma caused by demographic aging 
at baseline and in the further course were summarized, Tables 16a/b and 
Tables 22a/b. In Germany for the time period 1995/1998-2029/2033, the 
proportion of melanoma cases attributable to demographic changes ranged 
between 11-15% among men and between 8-16% among women, Tables 
16a/b. In Denmark, demographic changes accounted for 6-15% of all 
melanomas diagnosed between 1980/1983 and 2029/2033 among men, and for 
4-13% among women, Tables 22a/b. 
In both countries, most of the increase (≥80%) in the numbers of persons 
diagnosed with melanoma were attributable to increasing UVR exposure rather 
than to demographic aging (<20%). 
Outlook 
Incidence predictions suggest an ongoing increase of melanoma incidence 
rates at least until the mid 2020s. In Germany, first signs of a leveling off in 
increase can be expected from 2024/2028 onwards among men. In Denmark, a 
further strong increase is anticipated for both sexes. The expected increase will 
initially be noticeable in all age groups. In Germany, the increase in younger 
age groups (<60 years) is expected to level off from the mid-2020s onwards. In 
both populations, a strong increase is expected in the older age groups (60+ 
years) without any signs of stabilization. The long latency period from exposure 
to carcinogenic risk factors (such as UVR) and clinical presentation (20-30 
years) may explain the ongoing increase in incidence for those aged 60+ years. 
This increase reflects a part of the population who have already accumulated 
enough amounts of UVR during their life time, which is necessary for malignant 
transformation.  
Incidence predictions for a longer period (≥20 years) are difficult, as they would 
need to incorporate any changes in risk behavior (reduced exposure to UVR) 
into their calculations. In most European countries and in the US, however, 
prevention campaigns aimed to combat skin cancer, do not yet appear to be 
universally effective. They show only modest improvements in attitudes and 
behavior regarding tanning, sunburn, use of protective clothing or sunscreen so 
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far (de Haas et al., 2010, Ettridge et al., 2011, Health and Human, 2014, 
Lazovich et al., 2012, Montague et al., 2001). Surveys of European young in 
recent years revealed that many Europeans go on holidays in sunny 
destinations with the expressed aim of sunbathing and getting a tanned skin. 
Among vacationers returning from their holidays, a relatively high proportion 
reported sunburn, indicating frequent intermittent sun exposure. Moreover, 
there seems to exist a widespread misconception about how to protect the skin 
from sun exposure. While sunscreen products were frequently used, wearing 
protective clothing and seeking for shade were less practiced (Petersen et al., 
2013, Petersen et al., 2015, Reinau et al., 2014). Even if prevention campaigns 
will lead to behavioral changes in some population groups, the time span 
between changes in risk behavior and their reflection on declining incidence 
rates is long. Therefore we may not see the full impact of primary measures in 
the near future. 
Nevertheless, examples from Australia and New Zealand have shown that sun 
protection campaigns can be successful if they last long enough and are widely 
spread in the population (Erdmann et al., 2013, Whiteman et al., 2016). In both 
countries, first skin cancer prevention programs, including children and 
adolescents as an important target group, have been introduced in the early 
1980s (Iannacone and Green, 2014, Montague et al., 2001). These programs 
involved a number of important sun protection measures such as wearing hats 
and sun protective clothing, using sunscreen, minimizing the time children 
spend outdoors during peak hours or providing shadow zones (Ettridge et al., 
2011, Montague et al., 2001). As a result, a flattening of incidence growth is 
already becoming apparent in Australia and New Zealand, most notably among 
younger cohorts (Iannacone and Green, 2014, Iannacone et al., 2015, 
Whiteman et al., 2016). 
Similar trends are not discernible neither in Germany nor in Denmark. For this 
reason, it seems to be likely that the incidence of melanoma in both countries 
will continue to rise for the foreseeable future, and probably beyond 2030. To 
combat UVR-induced melanoma burden, we should learn from the public health 
campaigns in Australia and New Zealand geared toward reducing UVR 
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exposure. In Germany and Denmark continuing efforts to promote skin cancer 
prevention and risk modification are needed. Only a more prudent attitude 
towards tanned skin and a sustainable change in UVR exposure might result in 
more promising trends after 2030s.  
Strengths and limitations: 
This study is the first to quantify the melanoma burden due to changes in UVR 
exposure and demographics in Germany by calculating the corresponding 
population attributable fractions (PAF). Previous estimates for Denmark, carried 
out by Winther et al. in 1997 (Winther et al., 1997), have been updated using 
the most recent incidence data for melanoma. To estimate the melanoma 
burden due to UVR, melanoma incidence data from a historical Danish cohort 
(1943/1947), was used as reference population. This has the advantage that 
both the study and reference population represent identical ethnic groups with 
the same genetic risk for melanoma. This minimizes any bias resulting from 
confounders unrelated to UVR.  
Main strengths of the present study are the comprehensive nature with detailed 
data analyses based on high quality data from two population-based cancer 
registries (Engholm et al., 2010, Robert Koch Institut Berlin, 2016). A high 
completeness in the data can be assumed for both Germany and Denmark. The 
coverage rate in Denmark is close to 100% due to mandatory cancer 
notification. In Germany, the coverage rate was 90% in 11 federal states for the 
year 2012. Less than 2% of the melanoma cases, reported to the registries, 
were notified by death certificate only (DCO). Both, high coverage rate and low 
proportion of cases reported by DCO, guarantee a high quality of the data. 
Cancer incidence data for Denmark are provided over a long period of time. In 
Scandinavia, cancer registration began in the early 1940s, so that melanoma 
incidence data for Denmark have been available since 1943, covering a period 
of seven decades (Engholm et al., 2010, Gjerstorff, 2011). 
Incidence trend analyses have been preformed for a series of different 
measures, including age-standardized and crude incidence rates as well as 
absolute numbers of melanoma cases. This has allowed to analyze incidence 
trends from both epidemiological (impact of UVR as the main risk factor for 
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melanoma) and demographic (impact of population aging) perspectives. The 
impact of risk exposure was assessed by applying age-standardized incidence 
rates. Crude incidence rates and absolute numbers of melanoma cases were 
used to account for the impact of aging on incidence trends. 
The present study has several limitations. First, as for every statistical model, 
joinpoint regression relies on some assumptions (Kim et al., 2000), whose 
violation may result in biased estimates. Linear regression, used to fit the data, 
assume a linear relationship between the outcome variable (incidence rates) 
and the considered time variable. Further, different parameter settings may lead 
to differences in model selection (location and number of joinpoints), producing 
different incidence trends. Second, incidence predictions always carry some 
uncertainty with them. They are a mathematical extrapolation of past trends 
assuming that the same trend will continue into the future, and are intended to 
illustrate future changes that might be expected to occur if the assumptions 
were to apply over the prediction period. Projections do not attempt to allow for 
future changes in detection methods (such as the introduction of new screening 
programs) or changes in risk factors beyond the base years of the model which 
may affect future cancer incidence rates (Bray and Moller, 2006). Present 
incidence predictions are based on a modified age-period-cohort model, which 
was developed by Moller et al. (Moller et al., 2002). This model has been tested 
and validated in the Nordic countries, in Canada, in the UK and other countries, 
and a series of conditions that lead to the most accurate predictions has been 
applied (Mistry et al., 2011, Moller et al., 2002, Nowatzki et al., 2011). 
Supposing that future cancer incidence cannot continue to rise exponentially, 
the assumption of unchanged trends was modified by attenuating the drift 
component of the changes in rates by 25%, 50% and 75% for the second, third 
and fourth projection period. Further, it was assumed that future incidence rates 
are more likely to be influenced by recent than historical trends. Thus, when 
joinpoint analyses have shown a significant change in crude incidence rates in 
the most recently time period, the trend in the last 10 years was used as drift 
component D to be projected, instead of the average trend of the whole period. 
The estimates here were presented without standard errors or confidence 
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intervals, as these would be extremely low due to the large population. The 
uncertainty associated with incidence predictions concerns the unquantifiable 
bias when trends in incidence rates behave differently from the underlying 
assumptions about past rates. Third, forecasted population data used to 
calculate the absolute numbers of expected melanoma cases in future, are by 
their nature predictions themselves, based on forecasted birth/death rates and 
on assumptions about future immigration and emigration levels. Thus, any bias 
caused by population forecasts cannot completely be ruled out. Fourth, UVR is 
emitted naturally from the sun, but can also emerge from artificial sources of 
UVR (i.e. tanning beds or sun lamps), which has also been causally linked to 
increasing risk for melanoma (IARC Working Group on the Evaluation of 
Carcinogenic Risks to Humans, 2012). The present analysis did not calculate 
the PAF associated with artificial sources of UVR. Findings from different 
studies and systematic reviews/meta-analyses suggested that the PAF for this 
association is negligible on population level, ranging between 2.6% for Australia 
and 9.4% for Europe (Arnold et al., 2018b, Gandini et al., 2014, Wehner et al., 
2014). In some high-risk countries such as the U.S. or Northern and Western 
Europe, however, where the prevalence of indoor tanning in young adults has 
been increasing, exposure to tanning devices may account for up to 10-15% of 
all diagnosed melanoma cases (Boniol et al., 2012). This should not be 
disregarded when quantifying the melanoma burden caused by UVR. In 
addition, as most sunbed users have also a tendency to show greater exposure 
to natural sunlight (Grange et al., 2015), it is difficult to disentangle the 
melanoma burden caused by artificial UVR exposure from that of natural 
sunlight. Finally, underreporting of melanoma diagnosis to cancer registries 
might be a further limitation of the present analyses. A comprehensive cancer 
registration in Germany does not exist until 2011. Although the majority of 
registries now have a coverage rate of ≥90% and can thus be considered 
almost complete, there were still some registries in 2012 with a lower coverage 
rate for which the incidence rates had to be estimated on the basis of the 
complete registries. A certain degree of underreporting cannot be excluded also 
for Denmark, especially in the early 1940s. But this shortcoming may be 
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compensated by overreporting and increasing detection of thin melanoma, 
related to screening or improved diagnostics. 
The literature review revealed a lack of research investigating the impact of 
UVR exposure and demographic changes on previous and future melanoma 
incidence trends in Germany and Denmark. 
This study observed trends of increasing melanoma incidence in Germany 
(1995-2013) and Denmark (1943-2013). Rising incidence rates were obvious in 
all age groups, most pronounced in men and women aged 60 years or older. In 
both countries, overall melanoma incidence is destined to increase for the next 
two decades (2014-2033). In Germany, rates appear to stabilizise or to decline 
among young men and women (<60 yrs) from the mid-2020s onwards. Strongly 
rising incidence rates in older people and their growing representation in the 
population will further increase the burden of melanoma in the future. 
Nevertheless, the proportion of melanomas attributable to demographic 
changes is rather small (PAF≤15%). Melanoma seems to be less influenced by 
demographic aging than other malignant skin tumors, such as BCC or SCC, 
due to its earlier age of onset. UVR remains the most important causal risk 
factor for melanoma and is responsible for the majority of melanomas 
diagnosed in the past or in the future (PAF: 85-96%). 
In conclusion, this study provides further evidence for the predominant role of 
UVR exposure in the causation of melanoma. Although demographic change 
will continue to push forward the future burden of melanoma, it will play a rather 
subordinate role. Since UVR is a modifiable risk factor, a large number of 
melanoma cases could in principle be prevented by eliminating or reducing the 
causative factor. This harbors a high potential for primary skin cancer 
prevention. Key interventions must include educational campaigns that promote 
an enhanced awareness for melanoma and emphasize the importance of 
changing the behavior to reduce the exposure to UVR. As childhood and 
adolescence is the most critical window for melanoma development, younger 
cohorts are an important target group for primary melanoma prevention. Since 
the increase in melanoma incidence in older populations is likely be caused by 
previous sun exposure, primary prevention seems to be less effective in this 
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group. In order to counter the effects of an aging population, efforts in 
secondary prevention (screening and early detection) should therefore be 





The incidence of cutaneous melanoma (CM) has steadily increased over the 
past 50 years in predominantly fair-skinned populations. The observed increase 
is largely attributed to increasing risk exposure (UV radiation) and to 
demographic changes. While rates in Northern America and Oceania seem to 
have leveled off in recent years, particularly in younger cohorts, melanoma 
rates in most European countries continue to rise. The continual increase in 
incidence rates in higher age groups and their growing presence in the 
population will lead to a further sharp increase in the number of melanoma 
cases in the future. Estimating melanoma incidence trends and identifying the 
main forces (risk exposure and demographic changes) that might drive these 
trends are crucial for targeted cancer control measures aimed to reduce future 
melanoma burden.  
Objectives:  
To investigate the impact of UVR exposure and demographic changes on 
past/present incidence trends of CM and to estimate the future melanoma 
burden according to these changes for Germany and Denmark. 
Material and Methods:  
Melanoma incidence data (ICD-10, C43) for Germany (1995-2013) and 
Denmark (1943-2013) were retrieved from the Center for Cancer Registry Data 
(CCRD) at the Robert Koch-Institute and from the NORDCAN database. 
Historical (1980-2013) and projected population data (2014-2033) were sourced 
from national statistics agencies. Incidence trends (Germany: 1995-2013; 
Denmark: 1944-2013 and 1980-2013) were analyzed using joinpoint regression 
and quantified by calculating the estimated annual percentage change (EAPC) 
and its 95% confidence intervals. The number of future melanoma cases and 
incidence rates (2014/2018-2029/2033) were projected using modified age-
period-cohort models. The increase in the number of melanoma cases was 
apportioned into contribution from change in population risk (UVR exposure) 
and changes in population size and age structure (demographic component). 
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The numbers of melanomas attributable to high ambient levels of UV radiation 
at baseline (Germany: 1995/1998; Denmark: 1980/1983) were calculated by 
comparing baseline incidence rates (IRs) with those of a historical Danish 
cohort (1943/1947), minimally exposed to UVR. The analyses were carried out 
for age-standardized (ASIR) (European Standard Population, WHO 1976), 
crude (CIR) and age-specific (<40 yrs, 40-59 yrs, 60-79 yrs, 80+ yrs) incidence 
rates, recorded as 100,000 persons per year and stratified by sex. 
Results:  
The incidence of CM in Germany and Denmark has steadily increased during 
the past and will continue to do so for the foreseeable future. Between 
1995/1998 and 2009/2013, the ASIRs in Germany almost doubled to 
19.7/100,000 for men and to 19.4/100,000 for women. In Denmark, ASIRs 
increased for both sexes from less than 2 cases per 100,000 in 1944/1948 to 
29.8 for men and to 34.3/100,000 per year for women in 2009/2013. IRs 
increased in all age groups. Sharp increases were noted for those aged 60+, 
particularly among men. Until 2029/2033, ASIRs in Germany will climb to ≥30 
cases/100,000 (men: 29.9; women: 33.6). ASIRs in men will probably stabilize 
from 2024/2028 onwards. In Denmark, the ASIRs will reach 53.6 cases for 
males and 74.6 cases/100,000 for females. Stronger increases, without a 
leveling off, are expected for the CIRs and for those aged 60+ yrs, particularly 
for men. While IRs in people under 60 will stabilize or decline from the mid 
2020s onwards in Germany, IRs in age groups ≤60 yrs will continue to rise in 
Denmark. Steeply rising IRs in higher age groups and population aging will 
significantly increase the number of melanoma cases in future. Until 2029/2033, 
their number will reach about 40,000 (men: 20,161; women: 19,397) in 
Germany and about 4,500 (men: 2,015; women: 2,484) in Denmark. Strong 
increases among those aged 60+ yrs, most evident among men (80+ yrs: 
Germany, 1995/1998-2029/2033: +1,140%; Denmark, 1980/1983-2029/2033: 
+3,627%) will change the age distribution of melanoma patients towards higher 
proportion of old and very old patients. In Germany, the number of patients 
aged 60+ yrs will rise from less than 50% (for both sexes) in 1995/1998 to 77% 
for men and to 61% for women in 2029/2033. In Denmark, their proportion will 
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increase to around 70% for males and to 50% for females. Nevertheless, the 
contribution of demographic aging to the increase in melanoma cases at 
population level will be rather small (5-11% for men and about 5% for women 
for the period 2009/2013-2029/2033). In both populations, most of the increase 
in number of melanoma cases will be attributable to increasing UVR exposure, 
particularly among women (Germany: 90-95%, Denmark: 76-97%). Overall, 
including the number of melanomas attributable to high ambient UVR level at 
baseline, the population attributable fraction (PAF) of melanomas caused by 
UVR exposure in Germany will range between 84-92% for women and between 
87-89% for men. Corresponding estimates for Denmark are: 85-96% (women) 
and 85-95% (men). 
Conclusion:  
In both populations, melanoma burden will increase in future. Most of the 
expected increase (80-97%) in melanoma diagnoses will be attributable to 
increasing exposure to UVR rather than to demographic aging. Since UVR is 
the only known modifiable risk factor for melanoma, a large number of 
melanoma cases could be prevented by reducing exposure to UVR. In order to 
steam the future melanoma burden, primary prevention should remain the 
cornerstone of melanoma control efforts. To counter the effects of an aging 






Die Inzidenz des kutanen Melanoms hat in den letzten 50 Jahren stetig 
zugenommen, insbesondere in hellhäutigen Populationen. Der beobachtete 
Anstieg ist weitgehend auf die zunehmende Risikoexposition (UV-Strahlung) 
und den demografischen Wandel zurückzuführen. Während sich die Raten in 
Nordamerika und Ozeanien in den letzten Jahren, insbesondere in jüngeren 
Kohorten, offenbar stabilisiert haben, steigen die Melanomraten in den meisten 
europäischen Ländern weiter an. Der kontinuierliche Anstieg der Inzidenzraten 
in höheren Altersgruppen und deren wachsende Präsenz in der Bevölkerung 
wird die Zahl der Melanomfälle in Zukunft deutlich erhöhen. Eine 
Abschätzungen zukünftiger Inzidenztrends, insbesondere wie stark diese 
Entwicklungen von der Sonnenexposition und dem demografischen Wandel 
getrieben werden, sind für gezielte Kontrollmaßnahmen zur Verringerung der 
Melanombelastung von entschiedender Bedeutung.  
Zielsetzung:  
Untersuchungen zur Auswirkungen von UV Exposition und demografischem 
Wandels auf vergangene/gegenwärtige Inzidenztrends des kutanen Melanoms 
und Abschätzung wie stark diese Faktoren die zukünftige Melanombelastung in 
Deutschland und Dänemark beeinflussen werden. 
Material und Methoden:  
Melanom-Inzidenzdaten (ICD-10, C43) für Deutschland (1995-2013) und 
Dänemark (1943-2013) wurden aus dem Zentrum für Krebsregisterdaten (ZfKD) 
des Robert Koch-Instituts sowie aus der NORDCAN-Datenbank extrahiert. 
Historische (1980-2013) und projizierte Bevölkerungsdaten (2014-2033) wurden 
von den nationalen statistischen Bundesämtern bezogen. Die Inzidenztrends 
(Deutschland: 1995-2013; Dänemark: 1944-2013 und 1980-2013) wurden 
mittels Joinpoint-Regression analysiert und quantifiziert, indem die geschätzte 





Die Anzahl der zukünftigen Melanomfälle und Inzidenzraten (2014/2018-
2029/2033) wurden mit Hilfe modifizierter Alter-Perioden-Kohorten-Modelle 
prognostiziert. Der Anstieg der Melanomfälle wurde in zwei Anteile unterteilt: (1) 
Veränderungen im Risikoverhalten der Bevölkerung (erhöhte UV Exposition), 
(2) demografischer Wandel. Um die Anzahl der Melanome zu bestimmen, die 
auf die geografisch bedingte UV Strahlung zurückzuführen ist, wurden die 
Inzidenzraten zu Beobachtungsbeginn (Deutschland: 1995/1998; Dänemark: 
1980/1983) mit denen einer historischen Kohorte aus Dänemark (1943/1947) 
verglichen, die einer minimalen Sonnenexposition ausgesetzt war. Die 
Analysen wurden für altersstandardisierte (ASIR) (Europäische 
Standardbevölkerung, WHO 1976), rohe (CIR) und altersspezifische (<40 
Jahre, 40-59 Jahre, 60-79 Jahre, 80+ Jahre) Inzidenzraten durchgeführt, die als 
100.000 Personen pro Jahr erfasst und nach Geschlecht geschichtet wurden. 
Ergebnisse:  
In Deutschland und in Dänemark sind die Inzidenzraten des kutanen Melanoms 
in den vergangenen Jahren stetig angestiegen. Dieser Anstieg wird sich in den 
nächsten Jahren weiter fortsetzen. Zwischen 1995/1998 und 2009/2013 haben 
sich die alterstandardisierten Inzidenzraten in Deutschland nahezu verdoppelt, 
bei Männern auf 19,7/100.000 und bei Frauen auf 19,4/100.000. In Dänemark 
stiegen die ASIRs für beide Geschlechter von weniger als 2 Fällen pro 100.000 
in den Jahren 1944/1948 auf 29,8 für Männer und auf 34,3/100.000 für Frauen 
in den Jahren 2009/2013. Die Inzidenzraten sind in allen Altersgruppen 
gestiegen. Starke Zuwächse wurden bei Personen über 60 Jahre verzeichnet, 
insbesondere bei den Männern. Bis 2029/2033 werden in Deutschland die 
ASIRs auf ≥30 Fälle/100.000 (Männer: 29,9; Frauen: 33,6) ansteigen. Bei den 
Männern ist ab 2024/2028 mit einer Stabilisierung der ASIRs zu rechnen. In 
Dänemark werden die ASIRs 53,6 bei den Männern und 74,6 Fälle/100.000 bei 
den Frauen erreichen. Stärkere Anstiege, ohne Anzeichen einer Abflachung, 
werden für die rohen Raten, sowie für die Inzidenzraten bei den ≥60-Jährigen 
erwartet, insbesondere bei den Männer. Während sich die IRs in Deutschland 
bei den unter 60-Jährigen ab Mitte der 2020er Jahre stabilisieren oder sogar 
zurückgehen werden, werden diese in Dänemark (in den Altersgruppen ≤60 
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Jahre) weiter ansteigen. Stark zunehmende IRs in höheren Altersgruppen und 
ihr wachsender Anteil in der Bevölkerung werden zu einem deutlichen Anstieg 
der Melanomfälle in Zukunft führen. Bis 2029/2033 wird die Anzahl der 
Melanomfälle in Deutschland auf ca. 40.000 (Männer: 20.161; Frauen: 19.397) 
und in Dänemark auf ca. 4.500 (Männer: 2.015; Frauen: 2.484) steigen. Starke 
Zunahmen bei den über 60-Jährigen, am deutlichsten bei den Männern (80+ 
Jahre: Deutschland, 1995/1998-2029/2033: +1.140%; Dänemark, 1980/1983-
2029/2033: +3.627%) wird die Altersstruktur der Melanompatienten verschieben 
und den Anteil an alten und sehr alten Patienten deutlich erhöhen. In 
Deutschland wird die Anzahl der Patienten ≥60 Jahre von weniger als 50% (für 
beide Geschlechter) in den Jahren 1995/1998 auf 77% für Männer und auf 61% 
für Frauen in den Jahren 2029/2033 ansteigen. In Dänemark wird sich ihr Anteil 
auf rund 70% für Männern und auf 50% für Frauen erhöhen. Dennoch ist der 
Anteil der demografischen Alterung am Anstieg der Melanomerkrankungen auf 
Bevölkerungsebene eher gering sein (5-11% für Männer und etwa 5% für 
Frauen im Zeitraum 2009/2013-2029/2033). In beiden Bevölkerungen wird der 
Hauptanteil des Melanomanstiegs auf zunehmende UV-Exposition 
zurückzuführen sein, insbesondere bei den Frauen (Deutschland: 90-95%, 
Dänemark: 76-97%). Insgesamt, einschließlich der durch die geografische Lage 
bedingten UV Strahlung, wird der Anteil an Melanomen, der durch 
Sonnenexposition verursacht wird, in Deutschland zwischen 84-92% bei den 
Frauen und zwischen 87-89% bei den Männern liegen. Die entsprechenden 
Schätzungen für Dänemark liegen bei 85-96% (Frauen) bzw. bei 85-95% 
(Männer). 
Schlussfolgerung:  
In beiden Populationen wird die Melanombelastung in Zukunft zunehmen. Der 
größte Anteil des zu erwartenden Anstiegs (80-97%) wird auf zunehmende 
Sonnenexposition zurückzuführen sein und nur zu einem geringen Anteil auf die 
demografische Alterung. Da UV Strahlung der einzige bekannte modifizierbare 
Risikofaktor für das Melanom ist, könnte eine große Anzahl an Melanomfällen 
durch eine geringere UV-Exposition verhindert werden. Um die zukünftige 
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Melanombelastung zu begrenzen, sollte die Primärprävention der Eckpfeiler der 
Melanomkontrolle bleiben. Um den Auswirkungen einer alternden Bevölkerung 
entgegenzuwirken, wird die Sekundärprävention ein weiterer wichtiger 
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Table S1: Excess number of melanoma cases in 1999/2003 compared to baseline (1995/1998) due to UVR exposure and 
demographic changes (population size and age), Germany (Males) 
  MM baseline Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1995/1998 1995/1998 1999/2003 1999/2003 1999/2003 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 2046225 0 1982560 0 0 0 0 
 
  
5–9 0 2349718 0 2086492 0 0 0 0 
 
  
10–14 1 2340545 0 2383616 0 -1 0 -1 
 
  
15–19 18 2316669 25 2390970 18 7 7 0 
 
  
20–24 52 2336576 61 2405408 54 9 7 2 
 
  
25–29 122 3189766 136 2479631 95 14 41 -27 
 
  
30–34 205 3748127 289 3269496 179 84 110 -26 
 
  
35–39 248 3455911 314 3705341 265 66 49 17 
 
  
40–44 282 3007156 375 3370889 317 93 58 35 
 
  
45–49 312 2719786 408 2936877 337 96 71 25 
 
  
50–54 405 2368182 481 2587641 442 76 39 37 
 
  
55–59 690 2954504 693 2360784 551 3 142 -139 
 
  
60–64 577 2369859 936 2765154 673 359 263 96 
 
  
65–69 526 1841619 819 2096115 599 293 220 73 
 
  
70–74 350 1296554 713 1556564 420 363 293 70 
 
  
75–79 207 782064 553 1002413 266 346 287 59 
 
  
80–84 214 457218 227 499219 234 13 -7 20 
 
  










NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 











Table S1: Excess number of melanoma cases in 2004/2008 compared to baseline (1995/1998) due to UVR exposure and 
demographic changes (population size and age), Germany (Males) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1995/1998 1995/1998 2004/2008 2004/2008 2004/2008 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 2046225 0 1810339 0 0 0 0 
 
  
5–9 0 2349718 0 1986194 0 0 0 0 
 
  
10–14 1 2340545 1 2096456 0 0 1 -1 
 
  
15–19 18 2316669 31 2410381 18 13 13 0 
 
  
20–24 52 2336576 84 2473676 56 32 28 4 
 
  
25–29 122 3189766 131 2480195 95 9 36 -27 
 
  
30–34 205 3748127 194 2487923 136 -11 58 -69 
 
  
35–39 248 3455911 344 3240927 232 96 112 -16 
 
  
40–44 282 3007156 469 3663265 344 187 125 62 
 
  
45–49 312 2719786 493 3320087 381 181 112 69 
 
  
50–54 405 2368182 576 2867340 490 171 86 85 
 
  
55–59 690 2954504 680 2495360 583 -10 97 -107 
 
  
60–64 577 2369859 911 2226415 542 334 369 -35 
 
  
65–69 526 1841619 1273 2535596 724 747 549 198 
 
  
70–74 350 1296554 1073 1832111 494 723 579 144 
 
  
75–79 207 782064 783 1249080 331 576 452 124 
 
  
80–84 214 457218 456 703321 330 242 126 116 
 
  
85+ 163 363552 261 411999 185 98 76 22 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
0,774967122 
   
0.008678095 






Table S1: Excess number of melanoma cases in 2009/2013 compared to baseline (1995/1998) due to UVR exposure and 
demographic changes (population size and age), Germany (Males) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1995/1998 1995/1998 2009/2013 2009/2013 2009/2013 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 2046225 1 1744409 0 1 1 0 
 
  
5–9 0 2349718 1 1814385 0 1 1 0 
 
  
10–14 1 2340545 2 1987934 0 1 2 -1 
 
  
15–19 18 2316669 31 2110193 16 13 15 -2 
 
  
20–24 52 2336576 85 2468863 56 33 29 4 
 
  
25–29 122 3189766 163 2517038 97 41 66 -25 
 
  
30–34 205 3748127 210 2452802 135 5 75 -70 
 
  
35–39 248 3455911 319 2435647 175 71 144 -73 
 
  
40–44 282 3007156 524 3144764 295 242 229 13 
 
  
45–49 312 2719786 740 3552334 407 428 333 95 
 
  
50–54 405 2368182 806 3205016 548 401 258 143 
 
  
55–59 690 2954504 876 2732872 638 186 238 -52 
 
  
60–64 577 2369859 1078 2334710 569 501 509 -8 
 
  
65–69 526 1841619 1418 2026934 579 892 839 53 
 
  
70–74 350 1296554 1809 2231526 601 1459 1208 251 
 
  
75–79 207 782064 1265 1498818 397 1058 868 190 
 
  
80–84 214 457218 792 886191 416 578 376 202 
 
  
85+ 163 363552 447 532341 238 284 209 75 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
1.41669621 
   
-0.00669067 






Table S1: Excess number of melanoma cases in 2014/2018 compared to baseline (1995/1998) due to UVR exposure and 
demographic changes (population size and age), Germany (Males) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1995/1998 1995/1998 2014/2018 2014/2018 2014/2018 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 2046225 1 1794400 0 1 1 0 
 
  
5–9 0 2349718 1 1793000 0 1 1 0 
 
  
10–14 1 2340545 1 1852800 0 0 1 -1 
 
  
15–19 18 2316669 28 2047600 16 10 12 -2 
 
  
20–24 52 2336576 120 2295800 52 68 68 0 
 
  
25–29 122 3189766 205 2684600 103 83 102 -19 
 
  
30–34 205 3748127 302 2657000 146 97 156 -59 
 
  
35–39 248 3455911 330 2538600 182 82 148 -66 
 
  
40–44 282 3007156 491 2480600 233 209 258 -49 
 
  
45–49 312 2719786 852 3135200 359 540 493 47 
 
  
50–54 405 2368182 1142 3499800 599 737 543 194 
 
  
55–59 690 2954504 1249 3110600 726 559 523 36 
 
  
60–64 577 2369859 1374 2591400 631 797 743 54 
 
  
65–69 526 1841619 1606 2153600 615 1080 991 89 
 
  
70–74 350 1296554 1956 1800600 485 1606 1471 135 
 
  
75–79 207 782064 2190 1862000 493 1983 1697 286 
 
  
80–84 214 457218 1267 1101200 517 1053 750 303 
 
  
85+ 163 363552 790 695000 311 627 479 148 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
2.180385385 
   
0.00374955 






Table S1: Excess number of melanoma cases in 2019/2023 compared to baseline (1995/1998) due to UVR exposure and 
demographic changes (population size and age), Germany (Males) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1995/1998 1995/1998 2019/2023 2019/2023 2019/2023 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 2046225 1 1832200 0 1 1 0 
 
  
5–9 0 2349718 1 1833000 0 1 1 0 
 
  
10–14 1 2340545 1 1824000 0 0 1 -1 
 
  
15–19 18 2316669 26 1901000 14 8 12 -4 
 
  
20–24 52 2336576 149 2195600 49 97 100 -3 
 
  
25–29 122 3189766 242 2480000 95 120 147 -27 
 
  
30–34 205 3748127 335 2808800 154 130 181 -51 
 
  
35–39 248 3455911 423 2739600 196 175 227 -52 
 
  
40–44 282 3007156 502 2594600 244 220 258 -38 
 
  
45–49 312 2719786 726 2507000 287 414 439 -25 
 
  
50–54 405 2368182 1240 3114000 533 835 707 128 
 
  
55–59 690 2954504 1651 3420400 799 961 852 109 
 
  
60–64 577 2369859 1816 2982200 727 1239 1089 150 
 
  
65–69 526 1841619 1972 2421000 692 1446 1280 166 
 
  
70–74 350 1296554 2152 1948600 525 1802 1627 175 
 
  
75–79 207 782064 2248 1526000 404 2041 1844 197 
 
  
80–84 214 457218 2079 1400800 657 1865 1422 443 
 
  
85+ 163 363552 1329 935000 419 1166 910 256 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
2.863768083 
   
0.01301251 






Table S1: Excess number of melanoma cases in 2024/2028 compared to baseline (1995/1998) due to UVR exposure and 
demographic changes (population size and age), Germany (Males) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1995/1998 1995/1998 2024/2028 2024/2028 2024/2028 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 2046225 1 1789800 0 1 1 0 
 
  
5–9 0 2349718 1 1858800 0 1 1 0 
 
  
10–14 1 2340545 1 1855400 0 0 1 -1 
 
  
15–19 18 2316669 26 1861400 14 8 12 -4 
 
  
20–24 52 2336576 162 2012200 45 110 117 -7 
 
  
25–29 122 3189766 264 2321200 89 142 175 -33 
 
  
30–34 205 3748127 354 2556800 140 149 214 -65 
 
  
35–39 248 3455911 429 2853800 204 181 225 -44 
 
  
40–44 282 3007156 586 2765600 260 304 326 -22 
 
  
45–49 312 2719786 690 2599200 298 378 392 -14 
 
  
50–54 405 2368182 989 2484200 425 584 564 20 
 
  
55–59 690 2954504 1671 3042400 710 981 961 20 
 
  
60–64 577 2369859 2248 3287200 801 1671 1447 224 
 
  
65–69 526 1841619 2466 2803800 800 1940 1666 274 
 
  
70–74 350 1296554 2522 2209600 596 2172 1926 246 
 
  
75–79 207 782064 2404 1681800 446 2197 1958 239 
 
  
80–84 214 457218 2060 1169600 549 1846 1511 335 
 
  
85+ 163 363552 2180 1254600 562 2017 1618 399 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
3.358003316 
   
0.01160054 






Table S1: Excess number of melanoma cases in 2029/2033 compared to baseline (1995/1998) due to UVR exposure and 
demographic changes (population size and age), Germany (Males) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1995/1998 1995/1998 2029/2033 2029/2033 2029/2033 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 2046225 1 1686600 0 1 1 0 
 
  
5–9 0 2349718 1 1816200 0 1 1 0 
 
  
10–14 1 2340545 1 1881000 0 0 1 -1 
 
  
15–19 18 2316669 26 1892600 14 8 12 -4 
 
  
20–24 52 2336576 172 1972800 44 120 128 -8 
 
  
25–29 122 3189766 262 2137400 82 140 180 -40 
 
  
30–34 205 3748127 358 2397800 131 153 227 -74 
 
  
35–39 248 3455911 421 2603000 186 173 235 -62 
 
  
40–44 282 3007156 557 2880000 271 275 286 -11 
 
  
45–49 312 2719786 753 2771000 318 441 435 6 
 
  
50–54 405 2368182 891 2579200 441 486 450 36 
 
  
55–59 690 2954504 1264 2435000 569 574 695 -121 
 
  
60–64 577 2369859 2147 2933600 715 1570 1432 138 
 
  
65–69 526 1841619 2896 3107600 888 2370 2008 362 
 
  
70–74 350 1296554 3017 2581000 696 2667 2321 346 
 
  
75–79 207 782064 2718 1929400 511 2511 2207 304 
 
  
80–84 214 457218 2166 1324600 621 1952 1545 407 
 
  
85+ 163 363552 2510 1277600 572 2347 1938 409 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
3.6110904 
   
0.0065685 






Table S1: Excess number of melanoma cases in 1999/2003 compared to baseline (1995/1998) due to UVR exposure and 
demographic changes (population size and age), Germany (Females) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1995/1998 1995/1998 1999/2003 1999/2003 1999/2003 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 1940357 0 1880100 0 0 0 0 
 
  
5–9 0 2229795 0 1979934 0 0 0 0 
 
  
10–14 0 2219407 1 2261455 0 1 1 0 
 
  
15–19 27 2194211 49 2269391 30 22 19 3 
 
  
20–24 98 2229393 181 2323644 102 83 79 4 
 
  
25–29 281 2988806 241 2377130 223 -40 18 -58 
 
  
30–34 343 3488358 480 3090385 304 137 176 -39 
 
  
35–39 291 3259618 530 3491994 311 239 219 20 
 
  
40–44 330 2894738 514 3221085 367 184 147 37 
 
  
45–49 402 2654033 473 2875262 435 71 38 33 
 
  
50–54 397 2325116 505 2565661 438 108 67 41 
 
  
55–59 472 2960431 595 2369889 378 123 217 -94 
 
  
60–64 451 2487954 785 2873584 521 334 264 70 
 
  
65–69 441 2155853 607 2333365 477 166 130 36 
 
  
70–74 494 2117549 685 2013974 470 191 215 -24 
 
  
75–79 372 1612946 633 1863796 430 261 203 58 
 
  
80–84 382 1139603 416 1193616 400 34 16 18 
 
  
85+ 304 1138817 402 1157493 309 98 93 5 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
0.395584837 
   
0.00249242 






Table S1: Excess number of melanoma cases in 2004/2008 compared to baseline (1995/1998) due to UVR exposure and 
demographic changes (population size and age), Germany (Females) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1995/1998 1995/1998 2004/2008 2004/2008 2004/2008 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 1940357 0 1718769 0 0 0 0 
 
  
5–9 0 2229795 0 1886130 0 0 0 0 
 
  
10–14 0 2219407 1 1989451 0 1 1 0 
 
  
15–19 27 2194211 49 2291341 28 22 21 1 
 
  
20–24 98 2229393 192 2395851 105 94 87 7 
 
  
25–29 281 2988806 292 2415280 227 11 65 -54 
 
  
30–34 343 3488358 382 2409811 237 39 145 -106 
 
  
35–39 291 3259618 572 3095011 276 281 296 -15 
 
  
40–44 330 2894738 755 3486394 398 425 357 68 
 
  
45–49 402 2654033 676 3209930 486 274 190 84 
 
  
50–54 397 2325116 590 2852324 487 193 103 90 
 
  
55–59 472 2960431 650 2525157 403 178 247 -69 
 
  
60–64 451 2487954 705 2303866 418 254 287 -33 
 
  
65–69 441 2155853 897 2763120 565 456 332 124 
 
  
70–74 494 2117549 706 2184791 510 212 196 16 
 
  
75–79 372 1612946 629 1786038 412 257 217 40 
 
  
80–84 382 1139603 574 1480619 497 192 77 115 
 
  
85+ 304 1138817 476 1210240 322 172 154 18 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
0.602123998 
   
-0.00078175 






Table S1: Excess number of melanoma cases in 2009/2013 compared to baseline (1995/1998) due to UVR exposure and 
demographic changes (population size and age), Germany (Females) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1995/1998 1995/1998 2009/2013 2009/2013 2009/2013 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 1940357 1 1657001 0 1 1 0 
 
  
5–9 0 2229795 1 1722468 0 1 1 0 
 
  
10–14 0 2219407 1 1886238 0 1 1 0 
 
  
15–19 27 2194211 47 2002610 25 20 22 -2 
 
  
20–24 98 2229393 220 2364984 104 122 116 6 
 
  
25–29 281 2988806 370 2433905 229 89 141 -52 
 
  
30–34 343 3488358 419 2406173 237 76 182 -106 
 
  
35–39 291 3259618 535 2392650 214 244 321 -77 
 
  
40–44 330 2894738 895 3052677 348 565 547 18 
 
  
45–49 402 2654033 1053 3443584 521 651 532 119 
 
  
50–54 397 2325116 920 3159595 539 523 381 142 
 
  
55–59 472 2960431 850 2788334 445 378 405 -27 
 
  
60–64 451 2487954 842 2439921 442 391 400 -9 
 
  
65–69 441 2155853 954 2195400 449 513 505 8 
 
  
70–74 494 2117549 1158 2588211 603 664 555 109 
 
  
75–79 372 1612946 855 1952875 451 483 404 79 
 
  
80–84 382 1139603 678 1438776 483 296 195 101 
 
  
85+ 304 1138817 676 1432415 381 372 295 77 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
1.06008162 
   
-0.01615641 






Table S1: Excess number of melanoma cases in 2014/2018 compared to baseline (1995/1998) due to UVR exposure and 
demographic changes (population size and age), Germany (Females) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1995/1998 1995/1998 2014/2018 2014/2018 2014/2018 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 1940357 1 1704000 0 1 1 0 
 
  
5–9 0 2229795 1 1703600 0 1 1 0 
 
  
10–14 0 2219407 1 1757800 0 1 1 0 
 
  
15–19 27 2194211 43 1937200 24 16 19 -3 
 
  
20–24 98 2229393 266 2173800 95 168 171 -3 
 
  
25–29 281 2988806 418 2527800 238 137 180 -43 
 
  
30–34 343 3488358 585 2527400 249 242 336 -94 
 
  
35–39 291 3259618 639 2466600 220 348 419 -71 
 
  
40–44 330 2894738 822 2427800 277 492 545 -53 
 
  
45–49 402 2654033 1273 3059400 463 871 810 61 
 
  
50–54 397 2325116 1450 3428400 585 1053 865 188 
 
  
55–59 472 2960431 1309 3118000 497 837 812 25 
 
  
60–64 451 2487954 1124 2717600 493 673 631 42 
 
  
65–69 441 2155853 1117 2342200 479 676 638 38 
 
  
70–74 494 2117549 1200 2064400 481 706 719 -13 
 
  
75–79 372 1612946 1338 2340000 540 966 798 168 
 
  
80–84 382 1139603 860 1608800 540 478 320 158 
 
  
85+ 304 1138817 894 1545600 412 590 482 108 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
1.623751414 
   
-0.013954 






Table S1: Excess number of melanoma cases in 2019/2023 compared to baseline (1995/1998) due to UVR exposure and 
demographic changes (population size and age), Germany (Females) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1995/1998 1995/1998 2019/2023 2019/2023 2019/2023 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 1940357 1 1739200 0 1 1 0 
 
  
5–9 0 2229795 1 1741800 0 1 1 0 
 
  
10–14 0 2219407 1 1733400 0 1 1 0 
 
  
15–19 27 2194211 40 1798200 22 13 18 -5 
 
  
20–24 98 2229393 306 2073400 91 208 215 -7 
 
  
25–29 281 2988806 458 2317200 218 177 240 -63 
 
  
30–34 343 3488358 634 2612600 257 291 377 -86 
 
  
35–39 291 3259618 786 2583400 231 495 555 -60 
 
  
40–44 330 2894738 943 2504600 286 613 657 -44 
 
  
45–49 402 2654033 1104 2449200 371 702 733 -31 
 
  
50–54 397 2325116 1635 3054600 521 1238 1114 124 
 
  
55–59 472 2960431 1917 3392600 541 1445 1376 69 
 
  
60–64 451 2487954 1633 3054000 554 1182 1079 103 
 
  
65–69 441 2155853 1399 2625600 537 958 862 96 
 
  
70–74 494 2117549 1375 2225200 519 881 856 25 
 
  
75–79 372 1612946 1304 1883200 434 932 870 62 
 
  
80–84 382 1139603 1337 1958800 657 955 680 275 
 
  
85+ 304 1138817 1113 1782800 475 809 638 171 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
2.14414278 
   
-0.0120652 






Table S1: Excess number of melanoma cases in 2024/2028 compared to baseline (1995/1998) due to UVR exposure and 
demographic changes (population size and age), Germany (Females) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1995/1998 1995/1998 2024/2028 2024/2028 2024/2028 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 1940357 1 1699000 0 1 1 0 
 
  
5–9 0 2229795 1 1765400 0 1 1 0 
 
  
10–14 0 2219407 1 1763000 0 1 1 0 
 
  
15–19 27 2194211 39 1764400 22 12 17 -5 
 
  
20–24 98 2229393 317 1900800 84 219 233 -14 
 
  
25–29 281 2988806 483 2171400 204 202 279 -77 
 
  
30–34 343 3488358 643 2372000 233 300 410 -110 
 
  
35–39 291 3259618 797 2647200 236 506 561 -55 
 
  
40–44 330 2894738 1083 2605600 297 753 786 -33 
 
  
45–49 402 2654033 1193 2514400 381 791 812 -21 
 
  
50–54 397 2325116 1346 2442800 417 949 929 20 
 
  
55–59 472 2960431 2039 3021800 482 1567 1557 10 
 
  
60–64 451 2487954 2256 3325400 603 1805 1653 152 
 
  
65–69 441 2155853 1922 2959000 605 1481 1317 164 
 
  
70–74 494 2117549 1642 2505000 584 1148 1058 90 
 
  
75–79 372 1612946 1442 2052200 474 1070 968 102 
 
  
80–84 382 1139603 1255 1596000 535 873 720 153 
 
  
85+ 304 1138817 1674 2213400 590 1370 1084 286 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
2.566248095 
   
-0.0170846 






Table S1: Excess number of melanoma cases in 2029/2033 compared to baseline (1995/1998) due to UVR exposure and 
demographic changes (population size and age), Germany (Females) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1995/1998 1995/1998 2029/2033 2029/2033 2029/2033 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 1940357 0 1600600 0 0 0 0 
 
  
5–9 0 2229795 1 1725000 0 1 1 0 
 
  
10–14 0 2219407 1 1786600 0 1 1 0 
 
  
15–19 27 2194211 40 1794000 22 13 18 -5 
 
  
20–24 98 2229393 331 1867200 82 233 249 -16 
 
  
25–29 281 2988806 470 1997800 188 189 282 -93 
 
  
30–34 343 3488358 637 2225800 219 294 418 -124 
 
  
35–39 291 3259618 765 2407200 215 474 550 -76 
 
  
40–44 330 2894738 1045 2670200 305 715 740 -25 
 
  
45–49 402 2654033 1300 2616000 396 898 904 -6 
 
  
50–54 397 2325116 1385 2509400 428 988 957 31 
 
  
55–59 472 2960431 1605 2421200 386 1133 1219 -86 
 
  
60–64 451 2487954 2285 2966800 538 1834 1747 87 
 
  
65–69 441 2155853 2525 3231000 661 2084 1864 220 
 
  
70–74 494 2117549 2151 2836200 661 1657 1490 167 
 
  
75–79 372 1612946 1655 2325400 537 1283 1118 165 
 
  
80–84 382 1139603 1351 1772400 595 969 756 213 
 
  
85+ 304 1138817 1850 2224600 592 1546 1258 288 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
2.81472049 
   
-0.025206 






TableS2: Number and proportion of melanoma cases at baseline (1995/1998) attributable to UVR exposure, applying 





 MM expected MM observed
2
 MM excess PAF% 
  1943/1947 1995/1998 1995/1998 1995/1998 1995/1998 1995/1998 
Age (years) A B C = (A*B)/100,000 D E = D - C F = (E/D) *100 
0–4 0.1 2046225 2 0 -2 
 5–9 0.2 2349718 5 0 -5 
 10–14 0.3 2340545 7 1 -6 
 15–19 0 2316669 0 18 18 100.0 
20–24 0.2 2336576 5 52 47 90.4 
25–29 0.8 3189766 26 122 96 78.7 
30–34 1.4 3748127 52 205 153 74.6 
35–39 0.9 3455911 31 248 217 87.5 
40–44 1.4 3007156 42 282 240 85.1 
45–49 2.1 2719786 57 312 255 81.7 
50–54 1.3 2368182 31 405 374 92.3 
55–59 1.9 2954504 56 690 634 91.9 
60–64 2 2369859 47 577 530 91.9 
65–69 2.4 1841619 44 526 482 91.6 
70–74 4.8 1296554 62 350 288 82.3 
75–79 6.4 782064 50 207 157 75.8 
80–84 5.9 457218 27 214 187 87.4 
85+ 3.3 363552 12 163 151 92.6 
Total  1.1 39944028 556 4372 3816 87.3 
1
 Incidence rates (per 100,000/year) of a historical Danish cohort of 1943/1947 (reference population) 
2






Table S2: Number and proportion of melanoma cases at baseline (1995/1998) attributable to UVR exposure, applying 





 MM expected MM observed
2
 MM excess PAF% 
  1943/1947 1995/1998 1995/1998 1995/1998 1995/1998 1995/1998 
Age (years) A B C = (A*B)/100,000 D E = D - C F = (E/D) *100 
0–4 0.2 1940357 4 0 -4   
5–9 0.1 2229795 2 0 -2   
10–14 0.5 2219407 11 0 -11   
15–19 0 2194211 0 27 27 100.0 
20–24 1 2229393 22 98 76 77.6 
25–29 1 2988806 30 281 251 89.3 
30–34 0.7 3488358 24 343 319 93.0 
35–39 1.5 3259618 49 291 242 83.2 
40–44 1.2 2894738 35 330 295 89.4 
45–49 1.8 2654033 48 402 354 88.1 
50–54 1.9 2325116 44 397 353 88.9 
55–59 4.1 2960431 121 472 351 74.4 
60–64 2.1 2487954 52 451 399 88.5 
65–69 3.4 2155853 73 441 368 83.4 
70–74 5.5 2117549 116 494 378 76.5 
75–79 2.5 1612946 40 372 332 89.2 
80–84 5.9 1139603 67 382 315 82.5 
85+ 5 1138817 57 304 247 81.3 
Total  1.4 42036985 795 5085 4290 84.4 
1
 Incidence rates (per 100,000/year) of a historical Danish cohort of 1943/1947 (reference population) 
2






Table S3: Excess number of melanoma cases in 1984/1988 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Males) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 1984/1988 1984/1988 1984/1988 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 148385 0 131143 0 0 0 0 
 
  
5–9 0 176316 0 151676 0 0 0 0 
 
  
10–14 1 189795 1 177519 1 0 0 0 
 
  
15–19 1 202622 2 193009 1 1 1 0 
 
  
20–24 4 184010 4 198261 5 0 -1 1 
 
  
25–29 8 182838 8 181363 8 0 0 0 
 
  
30–34 12 194899 12 180898 11 0 1 -1 
 
  
35–39 19 192144 19 195794 20 0 -1 1 
 
  
40–44 16 148848 26 184592 20 10 6 4 
 
  
45–49 16 132933 23 144524 17 7 6 1 
 
  
50–54 20 130168 28 128379 20 8 8 0 
 
  
55–59 22 133442 27 124526 20 5 7 -2 
 
  
60–64 22 124087 31 123209 22 9 9 0 
 
  
65–69 23 109607 34 108131 23 11 11 0 
 
  
70–74 21 88539 22 89677 21 1 1 0 
 
  
75–79 14 57762 19 63218 15 5 4 1 
 
  
80–84 6 32225 8 34730 6 2 2 0 
 
  
85+ 9 18916 7 20715 10 -2 -3 1 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
0.26635514 
   
-0.00660657 






Table S3: Excess number of melanoma cases in 1989/1993 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Males) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 1989/1993 1989/1993 1989/1993 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 148385 0 143166 0 0 0 0 
 
  
5–9 0 176316 0 131096 0 0 0 0 
 
  
10–14 1 189795 1 151693 1 0 0 0 
 
  
15–19 1 202622 2 177630 1 1 1 0 
 
  
20–24 4 184010 5 190565 4 1 1 0 
 
  
25–29 8 182838 10 194298 8 2 2 0 
 
  
30–34 12 194899 10 178414 11 -2 -1 -1 
 
  
35–39 19 192144 19 178449 18 0 1 -1 
 
  
40–44 16 148848 30 193044 21 14 9 5 
 
  
45–49 16 132933 40 181048 21 24 19 5 
 
  
50–54 20 130168 31 140225 22 11 9 2 
 
  
55–59 22 133442 29 121960 20 7 9 -2 
 
  
60–64 22 124087 33 114761 21 11 12 -1 
 
  
65–69 23 109607 37 108115 22 14 15 -1 
 
  
70–74 21 88539 35 88455 21 14 14 0 
 
  
75–79 14 57762 28 65804 16 14 12 2 
 
  
80–84 6 32225 15 38915 7 9 8 1 
 
  
85+ 9 18916 9 22904 11 0 -2 2 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
0,560747664 
   
-0.01102718 






Table S3: Excess number of melanoma cases in 1994/1998 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Males) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 1994/1998 1994/1998 1994/1998 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 148385 0 159951 0 0 0 0 
 
  
5–9 0 176316 0 143998 0 0 0 0 
 
  
10–14 1 189795 0 131571 1 -1 -1 0 
 
  
15–19 1 202622 1 152047 1 0 0 0 
 
  
20–24 4 184010 6 176439 4 2 2 0 
 
  
25–29 8 182838 10 188067 8 2 2 0 
 
  
30–34 12 194899 17 192063 12 5 5 0 
 
  
35–39 19 192144 21 176757 18 2 3 -1 
 
  
40–44 16 148848 25 176355 19 9 6 3 
 
  
45–49 16 132933 38 189833 23 22 15 7 
 
  
50–54 20 130168 48 176415 27 28 21 7 
 
  
55–59 22 133442 48 134391 22 26 26 0 
 
  
60–64 22 124087 43 113192 20 21 23 -2 
 
  
65–69 23 109607 42 101646 21 19 21 -2 
 
  
70–74 21 88539 43 88804 21 22 22 0 
 
  
75–79 14 57762 36 65048 16 22 20 2 
 
  
80–84 6 32225 19 40865 7 13 12 1 
 
  
85+ 9 18916 11 25001 11 2 0 2 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
0.906542056 
   
-0.00616596 






Table S3: Excess number of melanoma cases in 1999/2003 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Males) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 1999/2003 1999/2003 1999/2003 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 148385 0 155865 0 0 0 0 
 
  
5–9 0 176316 0 160685 0 0 0 0 
 
  
10–14 1 189795 0 144339 1 -1 -1 0 
 
  
15–19 1 202622 2 131830 1 1 1 0 
 
  
20–24 4 184010 5 150608 3 1 2 -1 
 
  
25–29 8 182838 13 173340 7 5 6 -1 
 
  
30–34 12 194899 22 184988 11 10 11 -1 
 
  
35–39 19 192144 24 189874 19 5 5 0 
 
  
40–44 16 148848 33 174670 19 17 14 3 
 
  
45–49 16 132933 38 173246 21 22 17 5 
 
  
50–54 20 130168 55 185017 29 35 26 9 
 
  
55–59 22 133442 67 169705 28 45 39 6 
 
  
60–64 22 124087 58 126134 23 36 35 1 
 
  
65–69 23 109607 45 101547 21 22 24 -2 
 
  
70–74 21 88539 45 85194 20 24 25 -1 
 
  
75–79 14 57762 36 66787 16 22 20 2 
 
  
80–84 6 32225 27 41451 7 21 20 1 
 
  
85+ 9 18916 22 27554 13 13 9 4 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
1.299065421 
   
-0.00192020 






Table S3: Excess number of melanoma cases in 2004/2008 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Males) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 2004/2008 2004/2008 2004/2008 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 148385 0 150628 0 0 0 0 
 
  
5–9 0 176316 0 156473 0 0 0 0 
 
  
10–14 1 189795 1 160954 1 0 0 0 
 
  
15–19 1 202622 3 144636 1 2 2 0 
 
  
20–24 4 184010 7 130398 3 3 4 -1 
 
  
25–29 8 182838 18 147861 6 10 12 -2 
 
  
30–34 12 194899 23 170257 10 11 13 -2 
 
  
35–39 19 192144 30 182877 19 11 11 0 
 
  
40–44 16 148848 42 187834 20 26 22 4 
 
  
45–49 16 132933 39 171868 20 23 19 4 
 
  
50–54 20 130168 50 168817 26 30 24 6 
 
  
55–59 22 133442 72 178299 29 50 43 7 
 
  
60–64 22 124087 99 160280 29 77 70 7 
 
  
65–69 23 109607 86 115228 24 63 62 1 
 
  
70–74 21 88539 64 87312 21 43 43 0 
 
  
75–79 14 57762 65 66406 16 51 49 2 
 
  
80–84 6 32225 41 44243 8 35 33 2 
 
  
85+ 9 18916 31 29706 14 22 17 5 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
2.135514019 
   
0.002673712 






Table S3: Excess number of melanoma cases in 2009/2013 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Males) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 2009/2013 2009/2013 2009/2013 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 148385 0 148955 0 0 0 0 
 
  
5–9 0 176316 0 151035 0 0 0 0 
 
  
10–14 1 189795 1 156877 1 0 0 0 
 
  
15–19 1 202622 4 161645 1 3 3 0 
 
  
20–24 4 184010 14 143703 3 10 11 -1 
 
  
25–29 8 182838 18 128732 5 10 13 -3 
 
  
30–34 12 194899 31 146127 9 19 22 -3 
 
  
35–39 19 192144 44 168927 17 25 27 -2 
 
  
40–44 16 148848 55 181373 20 39 35 4 
 
  
45–49 16 132933 72 185610 22 56 50 6 
 
  
50–54 20 130168 72 168135 26 52 46 6 
 
  
55–59 22 133442 87 163014 27 65 60 5 
 
  
60–64 22 124087 122 169326 30 100 92 8 
 
  
65–69 23 109607 140 148069 31 117 109 8 
 
  
70–74 21 88539 121 101657 24 100 97 3 
 
  
75–79 14 57762 85 70574 17 71 68 3 
 
  
80–84 6 32225 68 46368 8 62 60 2 
 
  
85+ 9 18916 47 33650 16 38 31 7 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
3.584112150 
   
0.010722139 






Table S3: Excess number of melanoma cases in 2014/2018 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Males) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 2014/2018 2014/2018 2014/2018 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 148385 0 133381 0 0 0 0 
 
  
5–9 0 176316 0 149663 0 0 0 0 
 
  
10–14 1 189795 1 151422 1 0 0 0 
 
  
15–19 1 202622 4 157674 1 3 3 0 
 
  
20–24 4 184010 12 160648 3 8 9 -1 
 
  
25–29 8 182838 30 141871 6 22 24 -2 
 
  
30–34 12 194899 34 127323 8 22 26 -4 
 
  
35–39 19 192144 49 145135 15 30 34 -4 
 
  
40–44 16 148848 71 167876 18 55 53 2 
 
  
45–49 16 132933 82 179605 21 66 61 5 
 
  
50–54 20 130168 103 182430 28 83 75 8 
 
  
55–59 22 133442 103 163207 27 81 76 5 
 
  
60–64 22 124087 127 155582 28 105 99 6 
 
  
65–69 23 109607 171 158013 33 148 138 10 
 
  
70–74 21 88539 201 133140 32 180 169 11 
 
  
75–79 14 57762 163 85449 20 149 143 6 
 
  
80–84 6 32225 98 51814 9 92 89 3 
 
  
85+ 9 18916 86 38264 18 77 68 9 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
5.238317757 
   
0.01428458 






Table S3: Excess number of melanoma cases in 2019/2023 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Males) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 2019/2023 2019/2023 2019/2023 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 148385 0 141392 0 0 0 0 
 
  
5–9 0 176316 0 134019 0 0 0 0 
 
  
10–14 1 189795 1 150250 1 0 0 0 
 
  
15–19 1 202622 4 152332 1 3 3 0 
 
  
20–24 4 184010 12 156685 3 8 9 -1 
 
  
25–29 8 182838 44 158846 6 36 38 -2 
 
  
30–34 12 194899 48 140735 9 36 39 -3 
 
  
35–39 19 192144 47 126859 13 28 34 -6 
 
  
40–44 16 148848 75 144897 16 59 59 0 
 
  
45–49 16 132933 94 167143 20 78 74 4 
 
  
50–54 20 130168 115 177681 28 95 87 8 
 
  
55–59 22 133442 138 178410 29 116 109 7 
 
  
60–64 22 124087 144 157054 28 122 116 6 
 
  
65–69 23 109607 169 146401 30 146 139 7 
 
  
70–74 21 88539 225 143594 34 204 191 13 
 
  
75–79 14 57762 255 114241 27 241 228 13 
 
  
80–84 6 32225 174 65245 12 168 162 6 
 
  
85+ 9 18916 118 44592 21 109 97 12 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
6.771028037 
   
0.02159096 






Table S3: Excess number of melanoma cases in 2024/2028 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Males) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 2024/2028 2024/2028 2024/2028 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 148385 0 156641 0 0 0 0 
 
  
5–9 0 176316 0 141750 0 0 0 0 
 
  
10–14 1 189795 1 134386 5 0 -4 4 
 
  
15–19 1 202622 4 150966 1 3 3 0 
 
  
20–24 4 184010 11 151125 3 7 8 -1 
 
  
25–29 8 182838 51 154756 6 43 45 -2 
 
  
30–34 12 194899 63 157493 9 51 54 -3 
 
  
35–39 19 192144 61 140159 14 42 47 -5 
 
  
40–44 16 148848 67 126534 13 51 54 -3 
 
  
45–49 16 132933 83 144082 17 67 66 1 
 
  
50–54 20 130168 120 165251 25 100 95 5 
 
  
55–59 22 133442 143 173886 28 121 115 6 
 
  
60–64 22 124087 179 172356 31 157 148 9 
 
  
65–69 23 109607 179 148962 31 156 148 8 
 
  
70–74 21 88539 211 134838 32 190 179 11 
 
  
75–79 14 57762 274 125036 29 260 245 15 
 
  
80–84 6 32225 262 89520 16 256 246 10 
 
  
85+ 9 18916 198 56970 26 189 172 17 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
7.911214953 
   
0.031533050 






Table S3: Excess number of melanoma cases in 2029/2033 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Males) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 2029/2033 2029/2033 2029/2033 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 148385 0 163610 0 0 0 0 
 
  
5–9 0 176316 0 157023 0 0 0 0 
 
  
10–14 1 189795 1 142119 1 0 0 0 
 
  
15–19 1 202622 3 135039 1 2 2 0 
 
  
20–24 4 184010 11 149799 3 7 8 -1 
 
  
25–29 8 182838 54 149307 6 46 48 -2 
 
  
30–34 12 194899 67 153499 9 55 58 -3 
 
  
35–39 19 192144 74 156921 16 55 58 -3 
 
  
40–44 16 148848 80 139897 15 64 65 -1 
 
  
45–49 16 132933 76 125960 15 60 61 -1 
 
  
50–54 20 130168 109 142605 22 89 87 2 
 
  
55–59 22 133442 139 162036 27 117 112 5 
 
  
60–64 22 124087 173 168562 30 151 143 8 
 
  
65–69 23 109607 210 164635 34 187 176 11 
 
  
70–74 21 88539 213 138746 33 192 180 12 
 
  
75–79 14 57762 246 119550 29 232 217 15 
 
  
80–84 6 32225 271 99586 18 265 253 12 
 
  
85+ 9 18916 288 79648 37 279 251 28 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
8.41588785 
   
0.04126840 






Table S3: Excess number of melanoma cases in 1984/1988 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Females) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 1984/1988 1984/1988 1984/1988 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 141717 0 125489 0 0 0 0 
 
  
5–9 0 169304 0 145330 0 0 0 0 
 
  
10–14 0 180533 1 170272 0 1 1 0 
 
  
15–19 4 193069 4 183150 3 0 1 -1 
 
  
20–24 6 175640 7 189334 6 1 1 0 
 
  
25–29 14 174270 15 173780 14 1 1 0 
 
  
30–34 21 187032 16 173400 19 -5 -3 -2 
 
  
35–39 28 184875 32 188519 30 4 2 2 
 
  
40–44 28 145700 41 178570 34 13 7 6 
 
  
45–49 29 133157 36 142587 31 7 5 2 
 
  
50–54 28 132394 26 130068 30 -2 -4 2 
 
  
55–59 31 139783 30 129189 29 -1 1 -2 
 
  
60–64 29 133824 33 133863 29 4 4 0 
 
  
65–69 25 125553 33 124302 24 8 9 -1 
 
  
70–74 28 112486 32 113158 28 4 4 0 
 
  
75–79 21 85764 27 93546 23 6 4 2 
 
  
80–84 15 55269 16 62649 17 1 -1 2 
 
  
85+ 11 36741 15 45033 12 4 3 1 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
0.144654088 
   
-0.00194304 






Table S3: Excess number of melanoma cases in 1989/1993 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Females) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 1989/1993 1989/1993 1989/1993 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 141717 0 135680 0 0 0 0 
 
  
5–9 0 169304 0 125605 0 0 0 0 
 
  
10–14 0 180533 0 145421 0 0 0 0 
 
  
15–19 4 193069 3 169501 3 -1 0 -1 
 
  
20–24 6 175640 14 180841 6 8 8 0 
 
  
25–29 14 174270 21 186278 15 7 6 1 
 
  
30–34 21 187032 24 171932 19 3 5 -2 
 
  
35–39 28 184875 30 172293 27 2 3 -1 
 
  
40–44 28 145700 44 187013 36 16 8 8 
 
  
45–49 29 133157 50 176259 37 21 13 8 
 
  
50–54 28 132394 41 139624 30 13 11 2 
 
  
55–59 31 139783 31 125703 28 0 3 -3 
 
  
60–64 29 133824 33 122908 29 4 4 0 
 
  
65–69 25 125553 39 124371 24 14 15 -1 
 
  
70–74 28 112486 44 111366 28 16 16 0 
 
  
75–79 21 85764 32 95187 23 11 9 2 
 
  
80–84 15 55269 22 70014 19 7 3 4 
 
  
85+ 11 36741 16 54395 15 5 1 4 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
0,396226415 
   
-0.00507246 






Table S3: Excess number of melanoma cases in 1994/1998 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Females) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 1994/1998 1994/1998 1994/1998 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 141717 0 151754 0 0 0 0 
 
  
5–9 0 169304 0 136558 0 0 0 0 
 
  
10–14 0 180533 0 126098 0 0 0 0 
 
  
15–19 4 193069 3 145254 3 -1 0 -1 
 
  
20–24 6 175640 13 168426 6 7 7 0 
 
  
25–29 14 174270 31 179117 14 17 17 0 
 
  
30–34 21 187032 34 184986 20 13 14 -1 
 
  
35–39 28 184875 34 171520 27 6 7 -1 
 
  
40–44 28 145700 41 171422 33 13 8 5 
 
  
45–49 29 133157 58 185123 40 29 18 11 
 
  
50–54 28 132394 56 173202 37 28 19 9 
 
  
55–59 31 139783 42 135706 30 11 12 -1 
 
  
60–64 29 133824 39 119797 26 10 13 -3 
 
  
65–69 25 125553 43 113924 22 18 21 -3 
 
  
70–74 28 112486 40 110872 28 12 12 0 
 
  
75–79 21 85764 36 93173 23 15 13 2 
 
  
80–84 15 55269 28 71041 20 13 8 5 
 
  
85+ 11 36741 20 61814 17 9 3 6 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
0.628930818 
   
-0.00292113 






Table S3: Excess number of melanoma cases in 1999/2003 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Females) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 1999/2003 1999/2003 1999/2003 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 141717 0 147918 0 0 0 0 
 
  
5–9 0 169304 0 152507 0 0 0 0 
 
  
10–14 0 180533 1 136936 0 1 1 0 
 
  
15–19 4 193069 4 126177 2 0 2 -2 
 
  
20–24 6 175640 13 144093 5 7 8 -1 
 
  
25–29 14 174270 28 166756 14 14 14 0 
 
  
30–34 21 187032 38 177355 20 17 18 -1 
 
  
35–39 28 184875 45 184303 29 17 16 1 
 
  
40–44 28 145700 48 170635 33 20 15 5 
 
  
45–49 29 133157 47 169696 36 18 11 7 
 
  
50–54 28 132394 63 182127 39 35 24 11 
 
  
55–59 31 139783 66 168904 38 35 28 7 
 
  
60–64 29 133824 49 130125 28 20 21 -1 
 
  
65–69 25 125553 42 111349 22 17 20 -3 
 
  
70–74 28 112486 47 101524 25 19 22 -3 
 
  
75–79 21 85764 43 93037 23 22 20 2 
 
  
80–84 15 55269 35 70468 19 20 16 4 
 
  
85+ 11 36741 36 67457 19 25 17 8 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
0.902515723 
   
-0.0022905 






Table S3: Excess number of melanoma cases in 2004/2008 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Females) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 2004/2008 2004/2008 2004/2008 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 141717 0 143729 0 0 0 0 
 
  
5–9 0 169304 0 148639 0 0 0 0 
 
  
10–14 0 180533 1 152817 0 1 1 0 
 
  
15–19 4 193069 5 137161 2 1 3 -2 
 
  
20–24 6 175640 24 125114 4 18 20 -2 
 
  
25–29 14 174270 43 143049 12 29 31 -2 
 
  
30–34 21 187032 56 165160 18 35 38 -3 
 
  
35–39 28 184875 71 176755 28 43 43 0 
 
  
40–44 28 145700 73 183621 35 45 38 7 
 
  
45–49 29 133157 67 169198 36 38 31 7 
 
  
50–54 28 132394 67 167113 36 39 31 8 
 
  
55–59 31 139783 80 177938 40 49 40 9 
 
  
60–64 29 133824 88 162772 36 59 52 7 
 
  
65–69 25 125553 70 122644 24 45 46 -1 
 
  
70–74 28 112486 51 100482 25 23 26 -3 
 
  
75–79 21 85764 46 86072 21 25 25 0 
 
  
80–84 15 55269 46 71226 20 31 26 5 
 
  
85+ 11 36741 47 70458 20 36 27 9 
 
  






NBFF  NFF F- NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
1.625786164 
   
-0.00126034 






Table S3: Excess number of melanoma cases in 2009/2013 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Females) 
  MM 
baseline 
Population  MM 
observed 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 2009/2013 2009/2013 2009/2013 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 141717 0 141334 0 0 0 0 
 
  
5–9 0 169304 1 144205 0 1 1 0 
 
  
10–14 0 180533 1 149065 0 1 1 0 
 
  
15–19 4 193069 8 153494 3 4 5 -1 
 
  
20–24 6 175640 29 136743 5 23 24 -1 
 
  
25–29 14 174270 44 124589 10 30 34 -4 
 
  
30–34 21 187032 61 142343 16 40 45 -5 
 
  
35–39 28 184875 83 164971 26 55 57 -2 
 
  
40–44 28 145700 105 176489 34 77 71 6 
 
  
45–49 29 133157 110 182722 39 81 71 10 
 
  
50–54 28 132394 93 167293 36 65 57 8 
 
  
55–59 31 139783 88 163643 36 57 52 5 
 
  
60–64 29 133824 114 172225 38 85 76 9 
 
  
65–69 25 125553 111 154757 30 86 81 5 
 
  
70–74 28 112486 82 112920 28 54 54 0 
 
  
75–79 21 85764 65 86807 22 44 43 1 
 
  
80–84 15 55269 60 67010 18 45 42 3 
 
  
85+ 11 36741 69 74304 21 58 48 10 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
2.53459119 
   
0.003112828 






Table S3: Excess number of melanoma cases in 2014/2018 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Females) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 2014/2018 2014/2018 2014/2018 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 141717 0 126507 0 0 0 0 
 
  
5–9 0 169304 1 141819 0 1 1 0 
 
  
10–14 0 180533 1 144575 0 1 1 0 
 
  
15–19 4 193069 6 149750 3 2 3 -1 
 
  
20–24 6 175640 30 152725 5 24 25 -1 
 
  
25–29 14 174270 70 135585 11 56 59 -3 
 
  
30–34 21 187032 78 123807 14 57 64 -7 
 
  
35–39 28 184875 102 142113 22 74 80 -6 
 
  
40–44 28 145700 127 164723 31 99 96 3 
 
  
45–49 29 133157 148 175867 38 119 110 9 
 
  
50–54 28 132394 132 181110 39 104 93 11 
 
  
55–59 31 139783 114 164449 37 83 77 6 
 
  
60–64 29 133824 115 159046 35 86 80 6 
 
  
65–69 25 125553 146 164937 32 121 114 7 
 
  
70–74 28 112486 142 144610 36 114 106 8 
 
  
75–79 21 85764 111 100299 25 90 86 4 
 
  
80–84 15 55269 85 69555 19 70 66 4 
 
  
85+ 11 36741 101 75867 21 90 80 10 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
3.745283019 
   
0.00408239 






Table S3: Excess number of melanoma cases in 2019/2023 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Females) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 2019/2023 2019/2023 2019/2023 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 141717 0 134249 0 0 0 0 
 
  
5–9 0 169304 1 127151 0 1 1 0 
 
  
10–14 0 180533 1 142362 0 1 1 0 
 
  
15–19 4 193069 6 145303 3 2 3 -1 
 
  
20–24 6 175640 29 149047 5 23 24 -1 
 
  
25–29 14 174270 90 151583 12 76 78 -2 
 
  
30–34 21 187032 105 134974 15 84 90 -6 
 
  
35–39 28 184875 124 123892 20 96 104 -8 
 
  
40–44 28 145700 136 142219 27 108 109 -1 
 
  
45–49 29 133157 141 164651 35 112 106 6 
 
  
50–54 28 132394 141 174895 38 113 103 10 
 
  
55–59 31 139783 126 178911 40 95 86 9 
 
  
60–64 29 133824 125 160769 35 96 90 6 
 
  
65–69 25 125553 129 153154 30 104 99 5 
 
  
70–74 28 112486 154 155073 38 126 116 10 
 
  
75–79 21 85764 172 130567 32 151 140 11 
 
  
80–84 15 55269 182 82733 23 167 159 8 
 
  
85+ 11 36741 173 79302 22 162 151 11 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
4.770440252 
   
0.00946349 






Table S3: Excess number of melanoma cases in 2024/2028 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Females) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 2024/2028 2024/2028 2024/2028 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 141717 0 148656 0 0 0 0 
 
  
5–9 0 169304 0 134651 0 0 0 0 
 
  
10–14 0 180533 1 127479 0 1 1 0 
 
  
15–19 4 193069 6 142875 3 2 3 -1 
 
  
20–24 6 175640 30 144453 5 24 25 -1 
 
  
25–29 14 174270 105 147760 12 91 93 -2 
 
  
30–34 21 187032 123 150733 17 102 106 -4 
 
  
35–39 28 184875 145 134968 21 117 124 -7 
 
  
40–44 28 145700 164 123848 24 136 140 -4 
 
  
45–49 29 133157 170 142010 30 141 140 1 
 
  
50–54 28 132394 160 163675 35 132 125 7 
 
  
55–59 31 139783 160 172850 39 129 121 8 
 
  
60–64 29 133824 150 175353 38 121 112 9 
 
  
65–69 25 125553 149 155620 30 124 119 5 
 
  
70–74 28 112486 151 145107 36 123 115 8 
 
  
75–79 21 85764 178 140897 35 157 143 14 
 
  
80–84 15 55269 204 109295 30 189 174 15 
 
  
85+ 11 36741 206 92698 26 195 180 15 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
5.610062893 
   
0.01827523 






Table S3: Excess number of melanoma cases in 2029/2033 compared to baseline (1980/1983) due to UVR exposure and 
demographic changes (population size and age), Denmark (Females) 
  MM 
baseline 
Population  MM 
projected 











to pop. size 
Change 
due to pop 
age 
  1980/1983 1980/1983 2029/2033 2029/2033 2029/2033 
     Age A B C D E = (A/B)*D F = C-A G = C-E H = E-A I = L*NBBB J = H-I 
0–4 0 141717 0 155265 0 0 0 0 
 
  
5–9 0 169304 1 149086 0 1 1 0 
 
  
10–14 0 180533 1 134979 0 1 1 0 
 
  
15–19 4 193069 7 127948 2 3 5 -2 
 
  
20–24 6 175640 32 142053 5 26 27 -1 
 
  
25–29 14 174270 123 143226 12 109 111 -2 
 
  
30–34 21 187032 144 146962 16 123 128 -5 
 
  
35–39 28 184875 169 150757 24 141 145 -4 
 
  
40–44 28 145700 192 134968 26 164 166 -2 
 
  
45–49 29 133157 205 123748 27 176 178 -2 
 
  
50–54 28 132394 196 141295 30 168 166 2 
 
  
55–59 31 139783 186 162007 36 155 150 5 
 
  
60–64 29 133824 198 169784 37 169 161 8 
 
  
65–69 25 125553 188 170442 33 163 155 8 
 
  
70–74 28 112486 185 148363 37 157 148 9 
 
  
75–79 21 85764 186 133011 33 165 153 12 
 
  
80–84 15 55269 226 118761 33 211 193 18 
 
  
85+ 11 36741 245 121465 34 234 211 23 
 
  






NBFF  NFFF - NBBB NFFF - NBFF NBFF - NBBB 
  
           Excess melanomas from 
baseline K = (C-A)/A 
 
Population change from 
baseline* L = (D-B)/B 
    
  
6.81132075 
   
0.02672895 






Table S4: Number and proportion of melanoma cases at baseline (1980/1983) attributable to UVR exposure, applying 





 MM expected MM observed
2
 MM excess PAF% 
  1943/1947 1980/1983 1980/1983 1980/1983 1980/1983 1980/1983 
Age (years) A B C = (A*B)/100,000 D E = D - C F = (E/D) *100 
0–4 0.1 148385 0 0 0 
 5–9 0.2 176316 0 0 0 
 10–14 0.3 189795 1 1 0 0.0 
15–19 0 202622 0 1 1 100.0 
20–24 0.2 184010 0 4 4 100.0 
25–29 0.8 182838 1 8 7 87.5 
30–34 1.4 194899 3 12 9 75.0 
35–39 0.9 192144 2 19 17 89.5 
40–44 1.4 148848 2 16 14 87.5 
45–49 2.1 132933 3 16 13 81.3 
50–54 1.3 130168 2 20 18 90.0 
55–59 1.9 133442 2 22 20 90.9 
60–64 2 124087 2 22 20 90.9 
65–69 2.4 109607 3 23 20 87.0 
70–74 4.8 88539 4 21 17 81.0 
75–79 6.4 57762 4 14 10 71.4 
80–84 5.9 32225 2 6 4 66.7 
85+ 3.3 18916 1 9 8 88.9 
Total  1.1 2447534 32 214 182 85.0 
1
 Incidence rates (per 100,000/year) of a historical Danish cohort of 1943/1947 (reference population) 
2






Table S4: Number and proportion of melanoma cases at baseline (1980/1983) attributable to UVR exposure, applying 





 MM expected MM observed
2
 MM excess PAF% 
  1943/1947 1980/1983 1980/1983 1980/1983 1980/1983 1980/1983 
Age (years) A B C = (A*B)/100,000 D E = D - C F = (E/D) *100 
0–4 0.2 141717 0 0 0   
5–9 0.1 169304 0 0 0   
10–14 0.5 180533 1 0 -1   
15–19 0 193069 0 4 4 100.0 
20–24 1 175640 2 6 4 66.7 
25–29 1 174270 2 14 12 85.7 
30–34 0.7 187032 1 21 20 95.2 
35–39 1.5 184875 3 28 25 89.3 
40–44 1.2 145700 2 28 26 92.9 
45–49 1.8 133157 2 29 27 93.1 
50–54 1.9 132394 3 28 25 89.3 
55–59 4.1 139783 6 31 25 80.6 
60–64 2.1 133824 3 29 26 89.7 
65–69 3.4 125553 4 25 21 84.0 
70–74 5.5 112486 6 28 22 78.6 
75–79 2.5 85764 2 21 19 90.5 
80–84 5.9 55269 3 15 12 80.0 
85+ 5 36741 2 11 9 81.8 
Total  1.4 2507109 42 318 276 86.8 
1
 Incidence rates (per 100,000/year) of a historical Danish cohort of 1943/1947 (reference population) 
2
 Data refer to Danish population (females) in 1980/1983 
 
 
